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ABSTRACT
Introduction
2009 H1N1 Pandemic: The historical 2009 H1N1 Influenza pandemic, which had
a CDC estimated accrued disease burden of 100.5 million illnesses, 936,000
hospitalizations, and 75,000 deaths from 2009 to 2018, resulted in a declared state of
emergency nationally, with ensuing diminished vaccine confidence and amplified fears of
infection, prompting some to pursue flu vaccination, and others to forego. Although the
Centers for Disease Control and Prevention (CDC), and its Advisory Committee on
Immunization Practices (ACIP) recommend an annual flu vaccine for individuals 6
months of age and older as the “first and best” defense against influenza, a low
percentage of children are vaccinated, and parental decisions are not fully understood.
Examining previous literature, a void exists in relation to parental perceptions and
decisions for child immunizations, particularly concerning the U.S. nationally, with most
studies being international. Furthermore, there is evidence of varied results with
inadequate and conflicting conclusions, specifically for children.
2015 LAIV Policy Shift: The 2015 Centers for Disease Control and Prevention’s
(CDC) Advisory Committee on Immunization Practices (ACIP) retraction of its original
preferential recommendations for usage of the live attenuated influenza vaccine (LAIV),
which is the intra-nasal version of the vaccine, has resulted in varied responses, with
fluctuations in ensuing CDC vaccine advisements affecting its implementation and
uptake among children. Although the CDC’s ACIP recommend an annual flu vaccine for
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individuals 6 months of age and older as the “first and best” defense against influenza, a
low percentage of children are vaccinated, and parental decisions are not completely
comprehended, particularly in regards to the LAIV formulation. Reviewing the literature,
in certain studies a decline in flu vaccine uptake was concluded, whereas in other
instances, it conversely increased, or remained static, yielding inconsistent outcomes.
Furthermore, there exists a great void in the number, scale, and scope of studies
published, with none being nationally representative, and examining parental
perspectives, decisions, and responses in regard to child flu vaccine uptake following the
2015 ACIP LAIV policy shift.
Methods
2009 H1N1 Pandemic: To assess impacts of the 2009 H1N1 pandemic on
decisions to uptake influenza vaccines for children age 6 months to 17 years of age, data
from NIS was used as a series of weighted consecutive annual surveys in order to
synthesize a longitudinal panel dataset spanning from 2003 to 2018. Population adjusted
measures of influenza like illness (ILI) by state and season procured from CDC’s
FluView application and ILI Net from 2008 to 2018 was used in order to supplement the
primary NIS dataset. Quasi-experimental (QE) approaches in the form of segmented
interrupted time series (ITS), and fixed effects model (FEM) logistic estimations were
executed on the integrated dataset yielding logistic regression coefficients and postestimation marginal effects signifying the impact of the pandemic on child influenza
vaccine uptake (CIVU). ITS regressions examined both level and trend changes due to
pandemic occurrence via binary and continuous pandemic incidence variables
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respectively. FEM regressions examined fluctuations in CIVU as a function of influenza
disease progression across seasons and geographic jurisdictions.
2015 LAIV Policy Shift: To assess impacts of the 2015 ACIP LAIV preferential
recommendation revocation on decisions to uptake influenza vaccines for children age 6
months to 17 years of age, data from NIS was used as a series of weighted consecutive
annual surveys in order to synthesize a longitudinal panel dataset spanning from 2003 to
2018. Quasi-experimental (QE) approaches in the form of segmented interrupted time
series (ITS), and difference in differences (DID) logistic estimations were executed on
the integrated dataset yielding logistic regression coefficients and post-estimation
marginal effects signifying the impact of the 2015 ACIP LAIV policy shift on child
influenza vaccine uptake (CIVU). ITS regressions examined both level and trend changes
due to policy shift occurrence via binary and continuous policy shift incidence variables
respectively. DID regressions incorporated LAIV eligibility indicators to ascertain the
level and trend differences in CIVU between LAIV eligible (age 2 years and greater), and
LAIV ineligible (age 6 to 23 months) individuals, pre and post policy shift. This
additionally allowed for ascertainment of spillover effects and impacts of the policy shift
on individuals who were only eligible for the injected influenza vaccine (IIV)
formulation. Vaccine specific ITS estimations for individual formulations were executed
applying previous procedures, in addition to regressions assessing heterogeneity effects.
Results
2009 H1N1 Pandemic: The interrupted time series (ITS) regression for the NISChild sample yielded statistically significant coefficients. Post-estimation average
marginal effects (AMEs) were as follows. The H1N1 pandemics occurrence yielded a
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12.57 percentage point (pp), 95% CI [10.28, 14.32], immediate level change increase in
the probability of a child being immunized, on average. It also yielded a 3.77 pp, 95% CI
[-4.32, -2.55], sustained slope change decrease in the probability of a child being
immunized annually, on average. Pre-pandemic, a 1.64 pp, 95% CI [1.47, 1.81],
sustained increase in the probability of a child being immunized annually, on average,
was evident. Restricted scale epidemic (RSE) occurrences of the influenza virus yielded
post-estimation AMEs that were statistically significant for RSEs on 2012, 2013, and
2014. These coefficients were a 1.79 pp, 95% CI [-2.22, 0.38], 5.23 pp, 95% CI [-6.27, 4.77], and 1.92 pp, 95% CI [2.74 1.10], decrease in the probability of a child being
immunized, on average, respectively. The respective trend change increases post RSE
occurrences were 0.85 pp, 95% CI [0.74, 0.96], 0.34 pp, 95% CI [0.28, 0.40], and 1.24
pp, 95% CI [1.12 1.35], on average, in the probability of the same outcome. Sensitivity
analysis fixed effects model (FEM) regressions yielded logit and AME coefficients that
were statistically insignificant with the exception of a single variable in subgroup 5,
which indicated a decrease of 2.29 pp, on average, in immunization rates during peak
season weeks registering at a ILI intensity magnitude of 9 or greater. FEM regressions for
the NIS-Teen sample yielded logit and AME coefficients that were statistically
insignificant with the exception of three variables in subgroup 5. The initial variable
indicated a 1.31 pp increase, and the subsequent variables indicated a 0.135 pp, and a
0.212 pp decrease, on average, in immunization rates respectively.
2015 LAIV Policy Shift: The interrupted time series (ITS) regression for the NISChild sample yielded statistically significant coefficients. Post-estimation average
marginal effects (AMEs) were as follows. The LAIV preferential recommendation
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revocation yielded a 3.01 percentage point (pp), 95% CI [2.54, 4.74], immediate level
change increase in the probability of a child being immunized, on average. It also yielded
a 2.41 pp, 95% CI [-2.62, -2.11], sustained slope change decrease in the probability of a
child being immunized annually, on average. Pre-policy shifts, a 2.06 pp, 95% CI [1.91,
2.22], sustained increase in the probability of a child being immunized annually, on
average, was evident. The LAIV preferential recommendation of 2014, and the
subsequent LAIV recommendation rescindment of 2016, respectively yielded a 5.25 pp
decrease, 95% CI [-7.05, -3.25], and a 1.02 pp increase, 95% CI [0.55, 1.12], in the
probability of a child being immunized, on average. The respective trend changes postpolicy shifts were a 1.21 pp increase, 95% CI [1.11, 1.31], and a 5.30 pp decrease, 95%
CI [-6.22, -4.38], on average. The sensitivity analysis difference in differences (DID)
estimation yielded statistically significant coefficients. Comparing the differences
between LAIV-eligible and LAIV-ineligible individuals, pre and post 2015 policy shift,
yielded a DID of 20.70 pp, 95% CI [19.52, 21.88], indicating an increase occurred in the
probability of a LAIV-eligible child being immunized as compared to an LAIV-ineligible
child, on average, following the 2015 policy shift. Examining the LAIV-eligibility
indicator’s AME, it is evident that an LAIV-eligible child experiences a 1.34 pp, 95% CI
[0.64, 2.03], increase in the probability of being immunized, on average, as compared to
an LAIV-ineligible child. The interrupted time series (ITS) regression for the NIS-Teen
sample yielded statistically significant coefficients. Post-estimation AMEs are as follows.
The LAIV preferential recommendation revocation yielded a 4.25 pp, 95% CI [2.31,
6.22], immediate level change increase in the probability of a teen being immunized, on
average. It also yielded a 3.02 pp, 95% CI [-4.77, -2.33], sustained slope change decrease
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in the probability of a teen being immunized annually, on average. Pre-policy shifts, a
2.70 pp, 95% CI [2.12, 3.16], sustained increase in the probability of a teen being
immunized annually, on average, was evident. The LAIV preferential recommendation of
2014, and the subsequent LAIV recommendation rescindment of 2016, respectively
yielded a 8.41 pp decrease, 95% CI [-10.35, -6.41], and a 6.52 pp decrease, 95% CI [8.21, -4.42], in the probability of a teen being immunized, on average. The respective
trend changes post-policy shifts were a 7.17 pp increase, 95% CI [6.11, 8.58], and a 2.84
pp increase, 95% CI [1.96, 3.71], on average.
Conclusion
2009 H1N1 Pandemic: Preliminary escalations in the probability of child
immunization uptake are evident following the pandemic. This is possibly linked to
immediate vaccination promoting factors connected to the pandemics occurrence, but
cannot be ascertained. These factors are possibly paramount in the initial post-pandemic
phase, and gradually diminish with the progression of time, theoretically yielding
reductions in uptake rates in the long term. Public health immunization professionals
should expect preliminary increases in uptake behavior, followed by gradual decreases in
the same outcome for influenza pandemics such as H1N1. They should anticipate
decreases in uptake behavior following smaller scale epidemics. For pandemic intensity
ILI seasons, uptake behavior is not sensitive to weekly fluctuations in ILI severity for
children, but slightly sensitive for teens during peak and late phases of the influenza
season, with fluctuating uptake behavior associated with peak season phases, and
consistent increases for late season phases. This study contributes to the existing
literature by enhancing the understanding of how vaccine uptake rates change following
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pandemic and epidemic events. However it is limited in determining why these changes
occur, and due to what factors and mechanisms specifically, which future studies should
attempt to discern and ascertain.
2015 LAIV Policy Shift: The 2015 policy shift was associated with preliminary
increases in vaccine uptake, followed by annual declines, for both children and teens.
Reductions in overall immunization uptake following the preceding 2014 policy shift,
and subsequent 2016 policy shift were evident, for both samples for 2014, and teens for
2016. Public health policies concerning influenza immunization for children and
adolescents should concentrate on refraining from issuing preferential advisements for
either vaccine formulation if possible. Immunization policies should focus on consistent
and stable annual advisements, which may promote greater trust in immunization
policies. This study contributes to the existing literature by enhancing the understanding
of how vaccine uptake rates change following policy shifts. However it is limited in
determining why these changes occur, and due to what factors and mechanisms
specifically, which future studies should attempt to discern and ascertain.
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CHAPTER 1
INTRODUCTION
1.1.

Project Background, Significance, and Innovation
Each year millions of children in the U.S. experience influenza-related illness.

Although most children infected with influenza viruses recover within a week, serious
complications can result in hospitalization or death.1 Currently, the Centers for Disease
Control and Prevention (CDC), and its Advisory Committee on Immunization Practices
(ACIP) recommend an annual flu vaccine for individuals 6 months of age and older as
the “first and best” defense against influenza.2,3 Nevertheless, only 45.6% of children 6
months to 17 years of age received the vaccine in 2018 – 2019, and even less at 38.8% in
2017-2018.4 Understanding parental attitudes and barriers associated with uptake of
childhood immunization is a crucial national public health priority. This process is
complex, as numerous socioeconomic, psychological, demographic, and contextual
factors influence vaccine uptake rates.5–9 Doubts regarding vaccine benefits,10 concerns
regarding side-effects and safety,5,11–17 perceived disease seriousness and risk
assessment,11,15,16,18,19 uncertainties about vaccine effectiveness,8,11,12,20,21 and healthcare
access and costs,7,8,14,22,23 are prime influencers and factors affecting immunization
uptake.
The effects of policy shifts and pandemic occurrences on parental perceptions and
decisions to uptake immunizations in the U.S. are not completely understood, with
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conflicting, and inconsistent conclusions, 5,11,19,23–26 specifically for child flu vaccines.
This study overcame these shortcomings and contributes to a better understanding of how
parental perceptions and decisions are affected by these aforementioned factors by
examining the historical 2009 H1N1 pandemic, and the 2015 ACIP live attenuated
influenza vaccine (LAIV) preferential advisement revocation. These events served as
points of analysis to determine how parental decision-making and perceptions regarding
child flu vaccines may shift through mechanisms such as perceived disease risk and
erosion of vaccine confidence. This study has parallels to past research that has examined
the controversies regarding other diseases, health conditions, and vaccine formulation
elements. These include the measles, mumps, rubella and Autism dilemma, and
thimerosal presence in vaccines debate, where child vaccination rates shifted due to false
scares, ensuing spillover effects, incorrect conclusions, and parental inability to critically
analyze and decipher vaccine information.5,13,24,27

1.1.1. 2009 H1N1 Influenza Pandemic
The occurrence of the historical 2009 H1N1 Influenza pandemic, which had a
CDC estimated accrued disease burden of 100.5 million illnesses, 936,000
hospitalizations, and 75,000 deaths from 2009 to 2018,28 resulted in a declared state of
emergency nationally. For the U.S. in 2009 alone, the pandemic resulted in
approximately 270,000 hospitalizations and 12,270 mortalities, with 1,270 of those
deaths being under age 18.29 Examining previous literature, a void exists in relation to
parental perceptions and decisions for their children, particularly concerning influenza for
the U.S. nationally, with most studies having been completed internationally.
Furthermore, there is evidence of varied results with inadequate and conflicting
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conclusions, specifically for children. In certain studies, flu vaccine rates decreased
following the pandemic,11,16,30 while in others it increased,31,32 with the measured
magnitude of change being vastly different, with certain publications reporting
substantial fluctuations,11,31,32 and others stating milder effects, regardless of
directionality. There also exists a lack of a comprehensive nationwide study that is
representative and all encompassing.
Given the aforementioned, the question arises as to what was the impact of the
historical 2009 H1N1 pandemic on overall child influenza vaccination uptake rates in the
U.S.? This study is novel and innovative in that it is the first nationally representative and
comprehensive study that examines the impacts of the 2009 H1N1 pandemic on overall
child flu vaccine rates over a significant time span using an extensive vaccine-focused
data source in the form of the National Immunization Survey (NIS). It is the first to
assess how parental uptake of child influenza immunizations is affected nationally across
diverse segments of the population, while yielding improved results with public health
implications. This is significant, as it allows for a better understanding of parental
cognitive and behavioral responses to pandemics in relation to decision making for
uptake of child flu vaccines within the United States. This is significant, as it ultimately
allows for U.S. public health policymakers to increase future child flu vaccine uptake by
understanding how parental perspectives and decisions shift following a pandemic.

1.1.2. 2015 Retraction of Preferential Recommendations for LAIV
The 2015 CDC ACIP retraction of its original preferential recommendations for
usage of the LAIV, which is the intra-nasal version of the vaccine for children, 21,25,26,33–37
has resulted in varied parental responses, with fluctuations in ensuing CDC vaccine
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advisements affecting its implementation and uptake among children.25,33,38,39 Reviewing
the literature, in certain studies a decline in flu vaccine uptake was concluded,33 whereas
in other instances, it conversely increased,26 or remained static,25 yielding inconsistent
outcomes. There is a void in the number, scale, and scope of studies published with none
being nationally representative and examining parental perspectives, decisions, and
responses in regard to child flu vaccine uptake following the ACIP LAIV withdrawal.
Given the aforementioned, the question arises as to what was the policy impact of
the 2015 ACIP LAIV withdrawal on overall child influenza vaccination uptake rates in
the U.S.? This study is novel and innovative as it is the first nationally extensive study
assessing the potential impacts of the 2015 LAIV withdrawal on overall child flu vaccine
rates over a substantial time range using the National Immunization Survey (NIS)
focusing specifically on children. It is the first to evaluate parental decisions to vaccinate
their children against the flu by considering changes in parental uptake of child influenza
immunizations, following consecutive and evolving ACIP recommendations and
advisements. This study is significant, as it is an improved assessment of the LAIV
withdrawals, and assists in addressing the shortcomings of predecessor publications. It is
significant, as it provides a preliminary understanding of how CDC policy shifts may
impact decision making for uptake of child flu vaccines within the U.S., permitting public
health policymakers to increase future child flu vaccine uptake by anticipating how
parental perspectives and decisions may alter following future ACIP advisements and
recommendations.
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1.2.

Project Specific Aims and Hypotheses
Given the absence of knowledge regarding the broader question of how parental

decisions and perspectives to adopt child influenza vaccines are impacted by macroscopic
phenomenon and events, this study will aim to answer this conundrum, and rectify this
quandary, by specifically examining 2 macro-scale events of diverse origin in relation to
their respective effects on decisions to uptake influenza vaccines among children. The
first of these events is in the form of a pandemic occurrence, such as the historical H1N1
pandemic of 2009, and the second is in the form of a major flu vaccine related policy
shift, such as the CDC ACIP LAIV preferential advisement reversals of 2015. Concepts
involved in decision processes such as hesitancy to complete vaccines, and confidence
erosion regarding vaccine effectiveness will be applied in order to explain why behaviors
relative to parental flu vaccine adoption altered following event occurrences. The
following are the primary goals and objectives of this study and their hypotheses.
Specific Aim 1: To ascertain the effects of the 2009 H1N1 pandemic on overall
child influenza vaccination uptake rates in the U.S. by assessing changes in the likelihood
that a child is vaccinated for influenza following the pandemic event.
H1: The 2009 H1N1 pandemic is expected to increase the likelihood of overall
child influenza vaccine uptake. In accordance with the previous literature, and this studies
conceptual model, vaccine uptake stimulating factors related to disease severity and
susceptibility to infection will drive the expected increases in flu immunization uptake.
Specific Aim 2: To ascertain the policy effects of the 2015 ACIP LAIV
preferential recommendation revocation on overall child influenza vaccination uptake
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rates in the U.S. by assessing changes in the likelihood that a child is vaccinated for
influenza following the policy shift event.
H2: The 2015 ACIP LAIV preferential recommendation revocation is expected to
decrease the likelihood of overall child influenza vaccine uptake. In accordance with the
previous literature, and this studies conceptual model, provider dissemination of
immunization information, based on ACIP advisements, will likely reduce vaccine
uptake, since LAIV will not be recommended as the preferred option to parents by
providers.
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CHAPTER 2
LITERATURE REVIEW
2.1.

U.S. Immunization Program: Public Health Strategy and Mission

2.1.1. Primary Objectives
The United States immunization strategy has consistently been to increase
immunization rates for vaccine preventable diseases, and to minimize the morbidity and
mortality rates resulting from vaccine preventable infectious diseases, through
completion of immunizations for eligible individuals.29 Part of this approach is to allocate
special attention to higher risk populations and susceptible groups such as children and
the elderly.29

2.1.2. Successes and Failures
Overall increases in life expectancy and reductions in infectious disease induced
mortalities have been observed during the 20th century, chiefly due to improvements and
enhancements in vaccines and optimized implementation of immunizations nationally.29
Despite technological advancements in immunizations and vaccine applications, there
still exists a great degree of disease burden attributable to infectious diseases within the
U.S., primarily resulting from diseases such as influenza, tuberculosis, and viral hepatitis,
which are the leading causes of illnesses and mortalities due to infectious diseases in the
United States.29 Among the respiratory vaccine preventable infectious diseases, the
disease burden of influenza nationally amounts to 200,000 hospitalizations, and 36,000
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mortalities overall annually.29 The H1N1 influenza pandemic of 2009 resulted in
approximately 270,000 hospitalizations, and 12,270 mortalities, among which 1,270 were
children in one year’s time following the outbreak.29
In addition to the aforementioned mortality and morbidity rates linked to vaccine
preventable infectious disease burdens, there also exist major accompanying expenditures
and costs which can be avoided if immunizations are administered appropriately.29
Vaccines have been demonstrated to be an exceedingly effective and exceptionally cost
efficient method of clinical prevention of infectious diseases with child immunizations
being influential in this area, since they have been demonstrated to increase survival rates
among the population and diminish disease related expenditures overall.29 For each birth
cohort of routine child immunization series that are administered and completed for the
U.S., child vaccines have been observed to prevent 33,000 mortalities, 14 million
instances of disease, decrease costs directly associated with health care by $9.9 billion,
and by $33.4 billion indirectly.29

2.1.3. Future Prognosis
Through vaccine preventable infectious disease surveillance, monitoring,
screening, and prevention via immunizations, it is possible to circumvent consequences,
such as vaccine preventable disease induced morbidity and mortality, and associated
costs.29 The public health strategy for dealing with vaccine preventable infectious
diseases in the future will be dependent upon the execution and degree of coordination
present between disease detection, control, and prevention via immunizations.29
Expanding pathways to achieve and accomplish these objectives, and attain these results
is dependent upon improving current understanding of vaccine preventable diseases as
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well as determinants and factors that serve as facilitators and barriers to immunization
adoption and vaccine uptake and completion by the population.29

2.2.

Determinants Affecting Immunization Decisions and Uptake
Vaccination for children is a highly effective and prominent disease prevention

and control strategy in the field of public health, yet deficiencies in immunization uptake
and variations in vaccine practices persist with ensuing consequences.37,40 The effects of
policy shifts and pandemic occurrences on vaccination rates, perceptions, and uptake of
immunizations in the U.S. are not completely understood with conflicting, uncertain, and
inconsistent results.5,11,19,23–26 Various determinants have been demonstrated to affect
vaccination decisions by parents both in the U.S. and globally.

2.2.1. General Determinant Classification by Category
These elements include socioeconomic, psychological, demographic, and
contextual factors. These variables have been demonstrated to influence vaccine uptake
rates through different mechanisms, producing complexities in determining policy and
pandemic effects.5–9 Additionally, ascertaining the magnitude of effect of these numerous
factors is difficult as well.

2.2.2. General Vaccine Uptake Decision Influencing Factors
Hesitancy regarding vaccine benefits,10,30,40,41 level of vaccine confidence,30,42,43
degree of vaccine information and knowledge,9,15,42 safety concerns, and apprehensions
regarding side-effects,5,11–17 perceived disease seriousness and risk assessment,11,15,16,18,19
uncertainties in vaccine effectiveness,8,11,12,20,21 and healthcare accessibility, availability,
and costs,7,8,14,22,23,44 are prime influencers and barriers to immunization uptake. These
determinants serve as mechanisms that affect the parental decision to vaccinate their
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children broadly for various immunizations and disease types (refer to Figure 2.1 for
visual illustration).

2.2.3. Specific Vaccine Uptake Predictive Variables
Demographic and socioeconomic predictors that have been demonstrated to
impact vaccination uptake decisions include the mother’s education level,5,13,24,30,45
marital status,46,47 age,30,45 ethnicity or racial background,12,30,31,33,34,44,48 geographic
location,18,36,45 overall income level,5,30,34,45 health care access,14,23 and parental vaccine
knowledge.12,45,49 Specific determinants attributed to the child include gender,30,44 order
of birth,46 age,30,44 ethnicity or racial background,12,30,31,33,34,44,48 and insurance type and
status.7,30,33,34 Immunization specific factors such as perceived vaccine effectiveness,
efficiency, safety, and disease susceptibility and vulnerability impact vaccine completion
rates.50 Contextual predictors, and external non-individualized factors related to regional,
or state specific policies and mandates, their temporal implementation, the social beliefs
and norms of the population, as well as patient and clinician relationships and
interactions, and facility types where these interactions occur, also affect vaccine
decisions.50
Differences and disparities in these characteristics impact vaccine uptake rates to
varying degrees. This is particularly the case in relation to the provider’s and clinician’s
roles in recommending and administering required immunizations, specifically for
minority and marginalized subgroups, who are the most vulnerable to experiencing
differences and disparities in vaccine completions (refer to Figure 2.1 for visual
illustration).
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Parent, Child, and Family Specific Factors:
Child Associated Predictors
Age Subgroup: Child’s age has been demonstrated to influence vaccine uptake
minimally.30,44 It is expected that this studies analyses will yield consistent results. It is
possible that increases in age yield increases in uptake for certain age groups as compared
to others for specific vaccine types, hence this factor is correlated with uptake rates.
Gender: Child’s gender has been demonstrated to influence vaccine uptake
minimally in certain instances for specific immunizations.30,44 It is expected that this
studies analyses will yield consistent results and exhibit minimal disparities. Certain
genders as compared to others, may be more likely to receive vaccines for particular
immunization types and experience disparities in this respect, hence this factor is
correlated with uptake rates.
Ethnic and Racial Background: Child’s ethnicity has been demonstrated to
influence vaccine uptake,12,30,31,33,34,44,48 with Caucasians experiencing greater uptake as
compared to other ethnicities, with African Americans and Hispanics experiencing lower
uptake rates. It is expected that this studies analyses will yield consistent results.
Disparities in vaccine accessibility and availability are linked to ethnicity, among other
differences, hence this factor is correlated with uptake rates.
Birth Order Status: Childs birth order status has been demonstrated to influence
vaccine uptake,46 with first born status children experiencing greater uptake as compared
to non-first born children. It is expected that this studies analyses will yield consistent
results. Mothers may be more risk averse to the first born child and pursue vaccines to a
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greater extent for them, with the degree of attention and concern diminishing for the
subsequent children, hence this factor is correlated with uptake rates.
Mobility and Relocation: Childs relocation status has been demonstrated to
influence vaccine uptake,51 with children who relocated from a different geographic
region generally experiencing lower uptake as compared to those who did not. It is
expected that this studies analyses will yield consistent results. Children who relocate are
more likely to experience disruptions in vaccination completion due to shifting to a
different clinician or facility. This may result in declines in the subsequent access to
vaccines, or availability of immunizations, hence this factor is correlated with uptake
rates.
Insurance Status: Child’s insurance type has been demonstrated to influence
uptake of vaccines,7,30,33,34,48 with children possessing health insurance experiencing
greater uptake rates as compared to those who are uninsured. It is expected that this
studies analyses will yield consistent results. Insurance status permits parents to attain
greater access to vaccines and related immunization resources, hence this factor is
correlated with uptake rates.
Maternal Associated Predictors
Age Subgroup: Maternal age has been demonstrated to influence vaccine
uptake,30,45 with uptake for children generally increasing with mothers age for certain
ranges. It is expected that this studies analyses will yield consistent results. It is possible
that older mothers are more risk averse and more likely to pursue preventive measures
such as vaccination, hence this factor is correlated with uptake rates.
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Education Level: Maternal educational achievement has been demonstrated to
influence vaccine uptake,5,13,24,30,45,48 with uptake generally increasing for children with
more educated mothers beyond university degree completion. It is expected that this
studies analyses will yield consistent results. It is possible that mothers with higher
educational attainment are more knowledgeable or informed about the importance of
vaccines, and more likely to pursue medical information and possess access to it, in
addition to absorbing it more effectively, hence this factor is correlated with uptake
rates.24
Marital Status: Maternal marital status has been demonstrated to influence
vaccine uptake,46–48 with married mothers exhibiting greater uptake for their children. It
is expected that this studies analyses will yield consistent results. Married mothers may
pursue uptake at greater levels due to availability of vaccine related resources, hence this
factor is correlated with uptake rates.
Family Associated Predictors
Total Number of Children Present: Number of children in the family unit has
been linked to variations in uptake,12,47 with greater number of children beyond a certain
number being linked to differences in vaccine uptake. It is expected that this studies
analyses will yield consistent results. Its predicted that a greater number of children
beyond a certain point may reduce parental capability in attaining vaccinations for their
children, due to limitations in resources available to them, hence this factor is correlated
with uptake rates.
Income Level and Economic Status: Income category and as a function of the
Federal Poverty Line (FPL) has been demonstrated to affect vaccine uptake,5,30,34,45,48
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with increases in percentage of the FPL being linked to greater uptake generally for
certain ranges. It is expected that this studies analyses will yield consistent results.
Differences in economic status affect the ability of the parent to obtain access to
immunizations, with greater poverty status reducing this capability, hence this factor is
correlated with uptake rates.
Vaccine Specific Factors:
Characteristics related to the vaccine itself have been demonstrated to be linked
with vaccine uptake rates. Immunization specific aspects such as the perceived
effectiveness of the immunization, the vaccines efficiency, clinical safety, and capability
in reducing disease susceptibility are associated with vaccine uptake decisions.50 The
concerns regarding the side effects and disadvantages of the vaccine as compared to its
benefits have also been linked to vaccine uptake decisions.50 For this study, these vaccine
specific aspects are not measured or accounted for when performing the study, and are a
limitation of this study.
External Factors:
Provider Associated Predictors
Provider Facility Type: Provider and clinician facility classification has been
demonstrated to influence vaccine uptake,50,52 with supply, distribution, and availability
of immunizations influencing uptake rates.50,53 with private practices exhibiting greater
uptake as compared to other facilities. It is expected that this studies analyses will yield
consistent results. Variations in facility type generate variations in availability and
accessibility of vaccines, and potentially their sub-formulations, hence this predictor
influences uptake rates.
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Clinicians and health care providers possess a major role in vaccine uptake
decisions by parents since they are the individual that is explaining vaccine information,
disseminating immunization options based on ACIP advisements and in correspondence
with ACIP protocols and recommendations for the season, as well as influencing parental
vaccination decisions by discussing their suggestions for which immunization
formulation to pursue.50 The degree of vaccine knowledge acquired by the parent from
the clinician affects the decision process as well as whether the information was related to
vaccine policy shifts and to what depth it was discussed.50 The level of trust and
confidence that exists for the provider-patient relationship additionally influences the
decision process, with parents accepting clinician suggestions from providers they have
known and visited for a longer time in the past. This degree of familiarity with the
clinician or provider may decrease hesitancy to uptake vaccines. Provider and clinician
facility type may also determine a particular vaccine types accessibility and availability
which influences the vaccine uptake decision process as well.50
Event Associated Predictors
Pandemic and Epidemic Occurrences: Pandemic and epidemic events have been
demonstrated to affect vaccination rates, with alterations in parental perceptions of
disease risk and benefits of vaccination exhibited in certain studies.11,16,30 Vaccine uptake
decision processes may theoretically alter following these occurrences as well, and can be
influenced by variations in CDC ACIP advisements and guidance, as well as clinician
dissemination of information relative to the risks of the disease, and advantages of
vaccination. These events are anticipated to amplify the concerns and fears associated
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with disease infection and contraction, and are expected to increase vaccine uptake rates
as a consequence.
Vaccine Policy Shifts: Vaccine policy advisements and recommendations have
been demonstrated to affect immunization rates, with ensuing changes in parental
immunization uptake exhibited in certain studies.25,33 Policy shifts could theoretically
induce changes in a physician’s clinical practice and the information they discuss and
disseminate to parents, and their vaccine recommendations following a vaccine policy
shift. This may then induce changes in a parent’s perceptions of the relative risks versus
benefits of immunization. It is expected that vaccine policy shifts could affect
immunization uptake for this studies analysis as well, consistent with the previous
literature.
Factors related to supply and distribution of influenza vaccines and their subtypes
is also associated with immunization uptake rates, with shortages in vaccine supply
during particular time periods or geographic locations affecting vaccine availability and
accessibility.53 This can lead to increases in vaccine costs as well as rationing,
reprioritization, and reallocation of existing dosages to high risk individuals and to cope
with population demands.53 This issue was observed in the 2004 influenza season where
the nation experienced vaccine shortages for the influenza immunization, and is the main
occurrence of this type during this studies time period.53 Vaccine shortage occurrences
would decrease overall immunization uptake rates nationally due to limited vaccine
availability and accessibility eliminating the populations ability to receive the
immunization.
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Figure 2.1 – Vaccine Uptake Conceptual Diagram
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2.3.

Conceptual Rational and Theoretical Underpinnings
Certain vaccine related occurrences have been demonstrated to adversely impact

parental perceptions and decision-making regarding vaccinating their child through
mechanisms of perceived disease risk,54 benefits versus costs,55 hesitancy and doubt,56
safety concerns and risk of side-effects,5 and loss of confidence in vaccine
effectiveness.57 This was exhibited in the Measles, Mumps, Rubella and Autism
controversy where child vaccination rates declined for MMR and overall, due to spillover
effects, based on false conclusions and parental inability to critically analyze and
decipher vaccine information.5,13,24 This was also observed in the case of false claims that
thimerosal being in vaccines could potentially cause harm resulting in declines in overall
vaccine rates due to the inability of parents to delineate the accuracy of these
conclusions.27 In the case of the H1N1 outbreak and LAIV recommendations revocations,
our aforementioned hypotheses are reinforced by these types of studies, and rooted in
previous observational trends and patterns that are parallel to our proposed study (refer to
Figure 2.1 for conceptual framework and hierarchical stratification illustration).

2.3.1. Protection Motivation Theory (PMT)
2.3.1.a. Principal Description and Conceptual Application
Protection Motivation Theory (PMT), as demonstrated in Figure 2.2,58 (refer to
Figure 2.2 for PMT composition diagram), can be subdivided into two core mechanisms
of action and processes, threat appraisal and coping appraisal.59 The threat appraisal
cognitive process emphasizes a source of hazard, and how certain variables would
increase or decrease the probability of maladaptive reactions.59 The subjects’ perceptions
of susceptibility and vulnerability to the hazard source, and the hazards severity dictate
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the level of inhibition of the maladaptive responses.59 In the case of the 2009 H1N1
Pandemic, the threat source is the pandemic occurrence, and the maladaptive reaction
would be avoiding influenza vaccination completion. In this instance, individuals
escalating fear in relation to the pandemic would theoretically inhibit the evasion of
influenza vaccines in order to guarantee self-preservation and protection from the disease,
hence vaccine uptake rates would theoretically increase following the pandemic by this
logic.
The coping appraisal cognitive process emphasizes the coping methods for
reacting to the source of hazard, and variables that would affect the probability of
adaptive responses occurring.59 This process is subdivided into response efficacy and
self-efficacy, which are the degree to which the individual believes a response behavior
will minimize the threat level relative to them, and the degree to which they can achieve
the suggested response behavior successfully, respectively.59 In the case of the 2009
H1N1 Pandemic, the coping response would be receiving the influenza vaccine, the threat
source would be the pandemic occurring and ensuing risk of disease, the response
efficacy portion of the coping mechanism would be the believed potency of the vaccine
in reducing contraction of the influenza virus, and the self-efficacy portion would be the
degree to which the individual believes they can accomplish completion of the vaccine.
Based on this part of the theoretical concept, the occurrence of the pandemic would lead
to increases in the coping response, which is the uptake of influenza vaccines, in order to
maximize survival from the hazard source, and minimize risk of disease contraction. The
degree of coping response exemplified by different individuals may vary in reaction to
the pandemic stimulus source.
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Figure 2.2 - PMT Composition Schematic

2.3.1.b. Extended Scrutiny of PMT Derivation
Dissecting the PMT model and its core components further, and delving into the
sub-elements that contribute to the PMT’s principal appraisal developments, there are
three types of sub-concepts that exist.60 These include intra-personal characteristics, such
as social norms, attitudes, and beliefs.60 Previous experiences with the hazard source and
treatment response, including past infection with the disease in question by the child,
relative, or known individual, and the degree of adversity with side effect production for
these individuals.60 Information sources regarding the hazard or threat, including public
health institution declarations, clinician dissemination, media coverage, and internet
promulgation.60
The PMT model, specifically relative to the threat appraisal core component, is
contributed to through fear appeal pathways, which consist of the magnitude of
noxiousness of the threat, the perceived probability of its occurrence, and the potency of
the protective response in alleviating the threat.61 These fear appeals affect the attitudes
the individual possesses relative to the threat, and decisions they will ultimately
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produce.61 These fear modulating avenues serve as channels through which the degree of
anxiety regarding the threat or hazard source is propagated.61 The intensity of this
transmission dictates the proliferation of concern regarding the hazard source and how
the threat is processed through the threat appraisal mechanism of PMT.61

2.3.2. Diffusion of Innovation (DOI) Theory
The Diffusion of Innovation (DOI) theory is a principle that applies to this study
in terms of the expected trend and anticipated patterns of influenza immunization
adoption, specifically in the case of development and implementation of the LAIV
version of the vaccine that is FluMist. The inception of this vaccine formulation in 2003
serves as the initiation point of the LAIV technological innovation with subsequent years
of its existence theoretically following the DOI adoption curve,62 as illustrated below in
the diagram, with a progression occurring in the stated sequence, at the stated
percentages.62 With the application of this concept, and stages of the curve successively,
it is possible to forecast from 2003 onward the fashion in which FluMist would have been
potentially accepted and adopted by users hypothetically. It is exhibited by the DOI curve
that by the time the 2009 H1N1 Pandemic and the 2015 ACIP recommendations would
have been reached, the vast majority of users would have been aware of FluMist, and
would have theoretically adopted or rejected this vaccine innovation. Furthermore, the
DOI function demonstrates the different subgroups that would theoretically complete
adoption of immunizations with the progression of time. The function emulates the trend
of the normal curve and adheres to a similar appearance and is symmetrical. (refer to
Figure 2.3 for graphical illustration of the DOI function).62
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Figure 2.3 - DOI Adoption Curve

2.4.

The Influenza Virus Pathogen Composition
Influenza is a severely contagious respiratory disease that can be transmitted

directly or indirectly through infected droplets that are contaminated with the virus.63
These are ejected during respiratory activity including coughing and sneezing episodes.63
Individuals of all age ranges can become infected with the virus with certain
subpopulations such as elderly over 65 years of age and infants being the most
vulnerable.63,64 Medically susceptible and immuno-compromised individuals are also at
greater risk of being infected by the pathogen.65
The pathogenic influenza virus can be subdivided into 3 primary subtypes
consisting of influenza type A, B, and C. Influenza type A is observed in both humans
and animal organisms and is highly adaptable.63 Influenza type A can be further divided
into subclasses based on antigen components located on the surface of the pathogens
exterior.63 Hemagglutinin (HA) and neuraminidase (NA) are two such antigens that allow
the virus to attach to and penetrate the target cells respectively.63 The evolutionary and
adaptive vigor of this pathogen is attributable to the minor and major mutations,
designated as antigenic drift and shift respectively, which occur in relation to the
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aforementioned pathogen surface antigens.63 Influenza type B is observed in humans only
and targets mainly children who are the major transmission vectors for the virus, and can
remain contagious for a time period greater than 10 days.63 Influenza type B produces a
moderate degree of illness in infected individuals.63 Influenza type C is a minor cause of
illness in human subjects and less important as a pathogenic agent in relation to human
subjects.63

2.5.

Influenza Immunizations and Vaccines
In response to the inception of the influenza pathogenic agent, and its distinct

ability to mutate and adapt continuously and rapidly, influenza vaccines with varying
compositions were, and have since been continuously developed, and annually adjusted,
modified, and approved for usage in attempts to correspond to the specific annual
strain.63,64 This task has been the joint responsibility of the World Health Organization
(WHO) Collaborating Centre for Reference and Research on Influenza, the Federal Drug
Administration (FDA), and the Centers for Disease Control and Prevention (CDC).63,64
The CDC Advisory Committee on Immunization Practices (ACIP) is the primary agency
at the federal level responsible for vaccine advisements and recommendations, with state
public health agencies being responsible for individual states.

2.5.1. Vaccine Structural Compositions and Functional Mechanisms
Influenza vaccines can be trivalent or quadrivalent in composition, consisting of 2
type A strains and 1 type B strain, or 2 type A and 2 type B strains, respectively.39,63,64,66
The vaccines function through a mechanism of viral surface antigen inhibition, through
the release and subsequent attachment of antibodies that target HA and NA virus surface
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antigens.63 This suppresses the virus’s ability to survive and proliferate.63 The vaccines
effectiveness is characterized primarily by the degree of HA inhibition.63

2.5.2. Vaccine Formulations and Sub-Classes
There are two major formulations of the influenza vaccination, the inactivated
form of the influenza vaccine (IIV), and the live attenuated influenza vaccine
(LAIV).39,63,64,66 IIV class influenza vaccines are the most universally available and have
been produced and implemented historically since the mid-1900’s.39,63,64,66 IIV’s are
intramuscularly injected and abide the standard convention of vaccine
administration.39,63,64,66 LAIV class influenza vaccines are the modern version of the
vaccine, and are administered intra-nasally as opposed to intramuscularly, mimicking the
viruses infiltration and infection pathway.39,63,64,66 IIV’s contain influenza viruses in a
completely inactivated state, whereas LAIV’s contain viruses in a weakened
state.39,63,64,66 IIV’s stimulate both a local and systemic immune response, whereas
LAIV’s trigger a local mucosal immune response.63,64 Neither vaccine type infects the
individual with the virus, but may cause ensuing symptoms and side-effects to
occur.39,63,64,66

2.6.

Influenza Vaccine Recommendations Overview
The Centers for Disease Control and Prevention (CDC) assesses and evaluates

annual influenza infection rates and vaccination rates, as well as vaccine effectiveness
and safety in order to ascertain what immunization recommendations are most
appropriate for the anticipated season.65,67 Specifically, the Advisory Committee on
Immunization Practices (ACIP), located within the CDC, is responsible for these
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recommendations regarding annual influenza vaccinations, and providing advisements
and guidance in relation to influenza immunizations.68,69

2.6.1. Inactivated Influenza Vaccine (IIV) Advisements
The CDC’s ACIP has long recommended flu vaccines for children. Prior to 2002,
it was advised only for those with severe risks for contraction of the disease.31 In 2002,
individuals 6-23 months were advised to receive flu vaccines routinely regardless of
medical predisposition, with ACIP explicitly stating in 2004 that this age range should
universally receive the standard IIV version of the immunization, on a consistent annual
basis.31,39,65–69 The upper limit of the age range was extended to 59 months in 2006, and
18 years in 2008.31 In relation to IIV, this recommendation by ACIP has been sustained,
and IIV has been routinely advised and established as the primary version of the
vaccine.39,65–69 All individuals 6 months and older, for whom it is not contraindicated, are
currently recommended to receive the annual flu vaccine. (refer to Figure 2.4 for a
complete visual illustration of recommendation and advisement chronology)

2.6.2. Live Attenuated Influenza Vaccine (LAIV) Advisements
In 2003, the FDA reviewed and approved the usage of the LAIV formulation of
the immunization, titled as the pharmaceutical product FluMist, which is the quadrivalent
intra-nasally administered version of the flu vaccine.35 From its inception, this subclass of
the vaccine has resulted in fluctuations in the annual ACIP recommendations concerning
its application, particularly as it pertains to the age ranges eligible for it, what medical
conditions qualify or disqualify an individual from receiving it, and whether LAIV’s are
acceptable, or preferential and advantageous as compared to IIV’s, or not recommended
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at all.67,68 (refer to Figure 2.4 for a complete visual illustration of recommendation and
advisement chronology)
In the year after its conception and approval for implementation nationally by the
FDA, ACIP recommended LAIV’s for ages 5-49 years in 2004.67–70 This persisted until
2008, at which point ACIP extended the lower age limit boundary to 2 years of age, and
the age bracket spanned from 2-49 years of age, with indications that children 2-4 years
of age who had wheezing in past 12 months, or in later years asthma or respiratory
medical issues should not receive the formulation.65,68–70 Until 2014, ACIP maintained
the majority of its regulations consistently, except it advised a preferential
recommendation for LAIV as compared to IIV, suggesting it’s the advantageous
formulation of the immunization.26,35,68–70 This was based on initial assessments of its
performance and evaluations of its effectiveness which were deemed superior as
compared to IIV.25,33 In the following year of 2015, ACIP revoked and rescinded the
LAIV preferential recommendations as compared to IIV’s, and the phase of regular
LAIV recommendation resumed.26,35,68–71
This persisted until 2016, when ACIP completely advised against the usage of
LAIV’s, and does not recommend LAIV’s application.25,26,33,35,68–70,72 This was due to
concerns about decreased effectiveness of the vaccine formulation in combating the
A(H1N1)pdm09 strain of the influenza virus, which was circulating in the U.S. during the
two previous seasons. Following these series of advisements, in 2019, ACIP again
recommends LAIV’s as acceptable alternatives to the IIV’s for those 2 to 49 years of age,
with similar medical contraindications as those suggested in 2008.35,68–70 The
aforementioned fluctuations in ACIP LAIV recommendations and advisements since
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2003 indicate a potential lack of consistent consensus on the merits of the LAIV
formulation, and its potency and efficacy in adequately preventing the annually evolving
influenza virus. This alludes to the potential existence of vacillation as to how appropriate
LAIV’s are as alternative influenza vaccine options. It is also important to recognize that
parents who previously used the LAIV formulation for themselves or their children, or
who adhered strictly to LAIV related advisements in the past, may also be more likely to
be impacted directly by subsequent LAIV specific policy shifts, or ACIP
recommendations and decisions.

2.7.

Influenza Pandemics and Restricted Scale Epidemics
Influenza is a cyclical and seasonal disease, with certain periods of the season

exhibiting greater degrees of infection as compared to other time periods.73 It follows that
particular years exhibit greater infection rates throughout the season, due to certain
strains being more potent in their virulence, and the inability of the vaccine to counteract
the strain effectively, resulting in a localized and actively spreading epidemic, or a
national, or global scale pandemic of greater magnitude and intensity occurring.16,73
The most notable influenza pandemic that has occurred in the U.S. is the
historical Spanish flu of 1918, with 675,000 U.S. mortalities confirmed.74 Most recently,
the A(H1N1) virus outbreak of 2009 was highly notable for the United States, as well as
globally.28 The occurrence of the 2009 H1N1 influenza pandemic, with a CDC estimated
accrued disease burden of 100.5 million illnesses, 936,000 hospitalizations, and 75,000
deaths from 2009 to 2018,28 is considered one of the most prominent influenza pandemics
to have affected the United States. The severe repercussions were experienced on a
national scale, and its reverberations are still felt years later in the form of the accrued
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Figure 2.4 - Chronological Sequence of Events
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disease burden aftermath, mortalities, morbidities, and individual level attitudes and
concerns about the flu virus.28
Surrounding the A(H1N1) viral pandemic of 2009, lesser magnitude and intensity,
restricted scale epidemics (RSE’s), where greater than average influenza infection rates,
morbidities, and mortalities were observed and reported by the CDC, occurred in 20122013, 2013-2014, and 2017-2018.75–78 During these miniature epidemics, the influenza
season was labeled as either highly severe, such as in 2017-2018, severe, such as in 20132014, or moderately severe, such as in 2012-2013, with higher than regular mortalities
and morbidities being observed during all three time periods.75–78 These time periods
exhibited severe degrees of influenza like illnesses (ILI’s), and ambulatory clinic and
emergency department visits, as well as hospitalizations.75–78 In these time periods, the
Influenza A virus subtype H3N2 predominated as opposed to the Influenza A virus
subtype H1N1.75–78 These restricted magnitude epidemic occurrences resulted in their
respective consequences similar to the A(H1N1)pdm09 (refer to Figure 2.4 for a
complete diagram of flu pandemic and restricted scale epidemic chronology).

2.8.

Review of Existing and Associated Literature
Reviewing the existing literature broadly as it pertains to vaccine decision making

and determinants, it is evident that numerous publications exist for various immunization
types with a plethora of diverse determinants being assessed in different studies. The
studies span from those evaluating parental attitudes and decisions regarding MMR
vaccines, and related controversies, barriers, and influeners,5,13,24,42,79 to those examining
uptake and decisions surrounding HPV vaccines 7,12,80,81 and associated determinants.
Additional routine child immunization studies are included as well, examining similar
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predictors and factors. The studies are dispersed internationally and domestically with
focuses divided between the studies, which evaluate different age groups, ethnicities and
races, socioeconomic levels, and regional and geographic disparities to name a few. It is
evident by the extensive literature, that the relationship between vaccination decisions
and predictive factors and determinants has been analyzed substantially across numerous
diverse groups, with questions linked to many of the major determinant categories.
Given this, a deeper level of scrutiny of existing publications related to influenza
vaccine uptake decisions for pediatric populations yields a different literary landscape.
This is evident specifically in relation to the H1N1 Influenza pandemic of 2009, and the
CDC ACIP LAIV recommendations revocation of 2015, and their respective impacts on
overall child influenza vaccination rates, and decisions by parents to uptake influenza
immunizations in the United States. It is evident that a void in knowledge exists in the
literature for these particular topics. The quantity of publications available in relation to
these topics specifically is scarce, in particular for the United States.
The majority of existing publications that examine vaccine uptake rates, and
decisions to complete vaccines, are focused on an entirely different vaccine type, for a
different disease class, or they are examining a different phenomenon or event in relation
to a completely different outcome. Furthermore, the vast majority were vaccine studies
conducted internationally in different continents such as Europe, South America, Asia,
Africa, and Australia and excluded North America.

2.8.1. 2009 H1N1 Influenza Pandemic
Examining existing publications related to vaccine uptake following the 2009
H1N1 pandemic, it is evident that the majority of studies evaluated focus on international
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populations and samples, with post pandemic uptake rates analyzed for much of the
central and south American nations broadly for all age groups,82 and seasonal uptake
rates specifically for adults for 12 different European nations including Austria, Czech
Republic, France, England, Finland, Germany, Ireland, Italy, Poland, Portugal, Spain, and
Netherlands.45 A smaller number focused on East Asian nations such as China and
Japan.45 The vast majority of these studies were cross sectional with a minority of
longitudinal studies, and an even greater minority of RCT’s, and CRCT’s. Of the U.S.
based studies in existence, the majority examined the adult population with adequate, but
limited sample sizes, that were less than several thousand, with some being CRCT’s and
RCT’s, and possessing strong methodology and study design.45 The studies in existence
overall examined barriers and uptake factors well with a vast array of predictors that
encompassed nearly all determinant categories. Of studies that examined children
specifically, a study conducted for Western Australia in relation to parental decisions to
uptake for infants,11 and the U.S.,31 which focused primarily on uptake trends, and
percentage coverage over time for IIV eligible infants only.

2.8.2. 2015 LAIV Preferential Advisement Revocation
Examining existing publications related to vaccine uptake following the 2015
LAIV preferential recommendation revocations, a few studies were focused in Europe,
with a study in England assessing LAIV uptake rates in different geographic regions
based on program implementations and analysis of coverage percentages overall.36 Of the
several studies that focus on subpopulations within the U.S., they concentrated on
particular states or regions only, and overall flu vaccine rates. Examples include a study
conducted among children in Pennsylvania, that evaluated the impacts of the complete
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withdrawal of the LAIV, by analyzing 2016-2017 data only, and applying logistic
regression. The study concluded declines in uptake occurred when comparing the initial
and late time periods of the flu season for pediatric flu vaccine uptake within the state.33
Another study examined the same LAIV policy shift and ensuing uptake rates for
children of a broad age group for the state of Oregon, and concluded unchanged uptake
rates overall for pediatric flu vaccines.25
A final example includes a study that examined LAIV uptake following the 2014
ACIP preferential recommendations among the multistate pediatric samples of Michigan,
Minnesota, New York, Wisconsin, Oregon, and North Dakota, and concluded increases
in uptake had occurred for LAIV following the policy implementation.26 These studies
were overall well designed, with application of logistic regressions for the single
statewide analysis studies,25,33 and analysis of percentage fluctuations in coverages for the
multistate study example.26 These studies yielded results that can be extended, and further
expanded upon by future studies in relation to child vaccine uptake rates, particularly in
relation to the 2015 revocations of the ACIP preferential recommendations for LAIV
usage over IIV’s, which was the policy point least evaluated for its consequences as
compared to the 2014 preferential recommendations, and the 2016 complete withdrawal
of recommendations for LAIV usage by ACIP.

2.8.3. Disadvantages of Existing Literature
Of the existing studies that examine influenza vaccines specifically, the majority
are external and exclude the United States, and are evaluating different outcomes,
variables of interest, predictors, or policy shifts and occurrences. Of the existing studies
conducted for the U.S. in relation to influenza vaccination rates, the majority are either

32

assessing different determinants and chief variables of interest, or focus on a different
subpopulation such as adolescents, adults, and the elderly. They are limited in scope and
scale, and are distinct and confined to only a particular city, county, region, or state, and
are not nationally conducted and representative. They employ the use of data sources that
are not designed specifically for influenza vaccine assessment, or are collected by less
robust means. They examine and assess limited time spans that are not substantial,
sufficient, or ample enough to produce decisive conclusions. They implement the use of
methodological approaches that do not establish cause and effect relationships and are
less rigorous in nature. They examine locations that lack diversity in observations and
subjects evaluated, with small sample sizes limiting their statistical power.
Of the literary works that specifically focus on the occurrence of the historical
2009 H1N1 Influenza pandemic, and the 2015 CDC Advisory Committee on
Immunization Practice’s (ACIP) retraction of its original recommendations for
preferential usage of the live attenuated influenza vaccine (LAIV),21,25,26,33–35 the majority
yield conclusions whose explanations of the exact impacts on overall child influenza
vaccine rates and uptake decisions are relatively uncertain, inconsistent, and
contradictory.16,25,26,31,33,34,44,83 Certain studies report a decline in influenza vaccine rates
as a consequence of these occurrences,11,16,30,33 while in other studies, there are reports
that the opposite happened, and state that it conversely increased.26,31,32 Additionally,
certain studies report that the vaccination uptake remained static and did not fluctuate
considerably.25 Assessing the studies in existence overall, it is notable that variations are
exhibited in the range of implications concluded by different studies.
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2.8.4. Prime Publication Examples
2.8.4.a. ACIP LAIV Advisements
There are few existing publications that attempt to examine similar questions to
what this study is proposing. The closest study currently, for examining CDC ACIP
LAIV policy revocations, is the study by Robison et al. that analyzes 5 years of flu
seasons consecutively from 2012 to 2017, for a cohort of individuals located specifically
in Oregon, and focuses on ages 2-17 years excluding those 6 months to just under 2
years. The outcome of IIV receipt was assessed for both IIV and LAIV eligible patients.
The study concluded that the 2016 withdrawal of the recommendations for LAIV usage
had minimal to no impact on the immunization rates overall, with minimal associated
fluctuations observed over the evaluated seasons.
This study is limited in that it examines the state of Oregon alone, which is
limited in diversity and ethnic representation and narrow in this arena, and the study is
not nationally distributed with respect to its sampled subjects. This study only examines
one year following the policy shift point of 2015-2016 and is limited in this aspect. It is
debatable, as to whether it follows the post policy shift time period sufficiently, and
amply enough to produce the most meaningful, decisive, and robust conclusions with
valid implications. This study’s time span of analysis is less symmetric with its
observation years heavily skewed towards pre-policy shift time periods, as compared to
post policy time periods, affecting its post-policy analysis portion and associated
statistical estimations.
This ultimately results in conclusions that were extrapolated from those regression
estimations that may not be optimal. Furthermore, this study uses statewide immunization
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data that lacks the rigor of a nationally representative comprehensive data source, and
may lack the extent of variables that are accessible for analysis. Additionally, the
methodology implemented for this study establishes correlative and associative linkages
as opposed to cause and effect relationships resulting in a connection being established
that possesses lesser connotations. This study does not examine the influences of
intermediary ACIP recommendation alterations in the examined time spans, and only
focuses on the 2016 complete revocation of the recommendations for LAIV usage and
the associated 2016-2017 season. It does not incorporate the 2014 preferential
advisements for LAIV over IIV usage, and the subsequent 2015 rescindment of
preferential advisements. The lack of integration of these critical policy points may have
resulted in unmeasured immediate and lagging impacts that may have occurred and
ensued respectively for the target sample evaluated.

2.8.4.b. H1N1 Influenza Pandemic
The closest study for examining the impact of the H1N1 pandemic is the study by
Santibanez et al. that analyzes 10 consecutive influenza seasons from 2002 to 2012 using
NIS data for 6 to 23 month old children. This study concluded that a significant
escalation in total influenza vaccination coverage occurred from the start of the study
period to its termination using Kaplan-Meier survival analyses. Although this study is
national in its scope, and examines an extensive time span in years, it is limited in several
ways. This study examines only two seasons of post pandemic occurrence years and eight
years pre-pandemic and is heavily asymmetrical and skewed towards pre-pandemic
analysis resulting in a limited number of observations to be available for post pandemic
assessment, and impact estimation.
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This study’s methodology does not establish causative relationships and primarily
reports fluctuations in percentages and descriptive information that is a weaker
foundation for inference generating. Furthermore, this study analyzes a limited range of
child age groups with its boundaries spanning only 17 months and excludes all
individuals two years and older who are prime candidates for other formulations of the
vaccine such as LAIV’s which were introduced and approved in 2003. It follows that the
definition of total vaccine coverage in this study is flawed and incomplete, since its
definition excludes individuals who were eligible for, and were administered LAIV’s, as
opposed to IIV’s, from 2003 onward. The authors of this study justified this age
exemption because this age group was designated as the highest risk subgroup for
influenza related complications, they were the first child subgroup to have routine flu
vaccines recommended for them, and because provider reported immunization histories
were available in NIS specifically for this age group, whereas other ages were parent
reported.
This study is also narrowly focused on ethnic disparities and incorporates a
nominal degree of predictors and covariates potentially weakening the statistical
estimation. It is missing determinants that are present as controls in the regressions of the
majority of other publications, especially for the primary decision maker for vaccine
uptake, and other socioeconomic, psychosocial, and contextual factors. This study also
lacks incorporation of minor scale influenza epidemics that occurred during the time
periods of analysis. This may bias estimates of the impact of the 2009 H1N1 pandemic,
and its ensuing effects on immunization status and influenza vaccination rates.
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Another study examining the relationship between influenza season severity and
vaccine effectiveness in prior and current time periods with influenza immunization rates
in the current season concluded that no statistically significant association was evident,84
with minimal decreases in uptake observed for seasons following low vaccine
effectiveness years.84 This study also concluded that current season severity was not
associated with immunization rates when comparing different age groups. This study
indicated the need for future studies in order to determine and ascertain additional
conclusions.

2.9.

Proposed Study
Given the review of the existing literature, and comparisons of previously

published studies, it is evident that a void in the literature exists in its current state. This
mandates the need for additional studies that will fill current voids and supplement
existing publications.

2.9.1. Primary Goal and Proposed Research Questions
The research questions proposed would be examining the two major pandemic
and policy events, and their respective impacts on overall influenza vaccination rates and
uptake among U.S. children. Specifically, the questions would be assessing how the
occurrence of the 2009 H1N1 influenza pandemic, and the 2015 ACIP LAIV preferential
recommendations revocations, impacted overall child flu vaccine uptake rates in the
United States.

2.9.2. Hypotheses
H1: The 2009 H1N1 pandemic is expected to increase the likelihood of overall
child influenza vaccine uptake. In accordance with the previous literature, and this studies
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conceptual model, vaccine uptake stimulating factors related to disease severity and
susceptibility to infection will drive the expected increases in flu immunization uptake.
H2: The 2015 ACIP LAIV preferential recommendation revocation is expected to
decrease the likelihood of overall child influenza vaccine uptake. In accordance with the
previous literature, and this studies conceptual model, provider dissemination of
immunization information, based on ACIP advisements, will likely reduce vaccine
uptake, since LAIV will not be recommended as the preferred option to parents by
providers.

2.9.3. Advantages and Contributions of this Study
This study is the first nationally representative and comprehensive study that
examines the impacts of the 2009 H1N1 pandemic, and the 2015 ACIP LAIV policy
revocations on overall influenza vaccination rates among children in the United States.
This study is the first to analyze these occurrences over an extensive time continuum, and
examine their impacts respectively, in separate and distinct literary works. Its scope,
comprehensiveness, depth, and representation will supersede that of existing studies.
Previous studies for the U.S. generally focused on a limited region or state. To reiterate,
the majority of previous studies where completed on populations internationally and
abroad and excluded U.S. territories.6,11,20,36,37,82 This study overcame this and is designed
specifically for the United States. Additionally, this study examined a time span that is
greater than existing studies, and ample enough to generate profound results and
conclusions.
Previous studies were focused on children of varying age groups, with some
concentrating on certain ranges, but excluding others, that this study encompasses, and
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analyzes specifically in relation to overall influenza vaccine uptake decisions following
occurrence of the pandemic and policy event points. Furthermore, of the LAIV policy
shifts examined, very few had focused on the 2015 preferential advisement retractions,
and instead evaluated the 2014 preferential advisements, or the complete retractions of
2016. They also did not use a data source such as the National Immunization Survey
(NIS), and its variations (NIS-Child and NIS-Teen), which are designed specifically for
tracking vaccination data for select age subpopulations. This study achieved this, and
combines elements of these NIS data sources to improve its strength and harness its
advantages.
The methodology of this study is more rigorous in terms of its results and
implications. It attempts to establish a strong correlational relationship, as well as
examine marginal effects, as opposed to previous studies that established a weaker
relationship in the form of basic associations, and descriptive results, producing a stage
for less prominent inferences and extrapolations. Furthermore, this study implemented
auxiliary estimations in the form of additional quasi experimental estimations in order to
reinforce primary computations.
On aggregate, the extensive and comprehensive nationally representative dataset
used for this study, its specificity combined with the substantial time range examined, in
conjunction with the rigor of the methodology implemented, allowed for a critical
analysis of the consequences of the historic H1N1 pandemic, and the recent CDC LAIV
policy revocations, on overall child influenza vaccination rates in the United States.
Ultimately this study overcame the lack of consistency in the ascertainment of the
impacts of the H1N1 pandemic, and CDC LAIV recommendations revocation on overall
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child influenza vaccination rates. It supplements the literature, and assisted in
overcoming the deficiency in the number, scale, and scope of studies performed for the
U.S., and addresses the void that is the absence of a comprehensive nationally
representative study focused on children in the United States.

2.9.4. Public Health Implications and Utility of this Study
2.9.4.a. Universally
Conclusions attained by this study would be vital for CDC and public health
policy development and formation as they pertain to child influenza vaccinations in the
future, by ascertaining behavioral responses to policy shifts and pandemics and decision
making for uptake of child influenza vaccines within the United States. This would
ultimately allow for public health policymakers in the U.S. to increase future child
influenza vaccination coverage by understanding how parental perspectives about
influenza vaccines are impacted by influenza epidemics and policy shifts.
In summary, these criteria make this proposed study a necessary addition to the
literature that would reconcile inadequacies that currently exist among the limited child
Influenza vaccine studies, and enhance the child immunization research area of the field
of public health. The results and outcomes of this study essentially provide an in depth
viewpoint on the relationship between adoption of child influenza vaccines and parental
perspectives, allowing for better predictions and forecasts of what is to come, and how to
be ready for it. Examples of potential applications of this study’s results include and are
not limited to the following based on each specific aim.
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2.9.4.b. H1N1 Influenza Pandemic
Results could be used by policymakers to target specific subgroups that were
more vulnerable and susceptible in not completing flu vaccines in post pandemic, such as
children of lower education, lower income parents, or of a certain age group or ethnic
background. Results could be used to develop strategies that would allow for attention to
be directed or diverted accordingly to different subgroups based on how the subgroup
responded in reaction to the pandemic, saving resources, and allowing for more efficient
use of those resources.
Results could be used to improve capabilities to anticipate fluctuations in flu
vaccine uptake for children following pandemics, allowing CDC officials to strengthen
campaigns to encourage flu vaccine uptake, or to inform clinics and medical facilities of
such expected fluctuations, permitting them to reallocate clinical staffing accordingly,
and prepare for surges in patients seeking flu vaccines. Results can be used to yield
improved patient flu vaccine achievement, by implementing the use of health information
technology, and patient-provider health communication pathways. These would include
electronic, and digital correspondences, telemedicine and telehealth interfaces, and flu
vaccine quick-sheets, and fact-sheets, during post pandemic flu seasons. Results can be
integrated into use for flu monitoring apps such as CDC’s Flu View, Flu Near You, and
Flu Defender, which can be enhanced operationally and functionally by this studies
outcomes in order to improve influenza epidemic and pandemic surveillance, prevention,
and control by public health institutions.
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2.9.4.c. ACIP LAIV Advisements
Results could be used by policymakers to target specific subgroups that were
more vulnerable and susceptible in not completing flu vaccines in post policy shift years,
such as children of lower socioeconomic status parents, or of a certain age range, or racial
subgroup. Results could be used to develop tactics that would allow for attention to be
reallocated to more susceptible groups, depending on reactions of those particular groups
to policy decisions, promoting optimal and efficient use of limited resources. Results
could be used to enhance capabilities to anticipate fluctuations in flu vaccine uptake for
children following policy events, permitting public health professionals to increase flu
immunization rates, by notifying health institutions of such projected influxes of vaccine
seekers. Reallocation of clinical personnel would ensue correspondingly in order to
prepare for surges in patients seeking flu vaccines.
Policies could be developed guiding clinicians, such as family doctors and
pediatricians, that would assist them in explaining flu vaccine recommendations and
advisements better, and with more concerted efforts with patients, specifically following
revocation years where greater confusion may be present, in order to improve parental
decision making abilities. Clinicians can be informed to focus more on target parental
groups that are more prone to avoiding flu vaccines, even when flu vaccine rates have
increased overall, or targeting post-policy revocation years with stronger vaccine
interventions, pamphlet distribution, and advertising, in order to counteract the
anticipated decreases in flu vaccines that would occur in post-withdrawal years.
Results can be used to yield improved patient flu vaccine completion rates, and
achievement outcomes, by using patient portal email correspondences, telemedicine and
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telehealth communication pathways and interfaces, and flu vaccine quick-sheets and factsheets during anticipated low uptake seasons following ACIP recommendations. Results
can be used to promote performance of flu vaccine related activities in the education
systems nationally, including implementing and incorporating kindergarten, preschool,
and school based flu vaccine interventions, programs, and memorandum distribution in
order to increase uptake in post policy shift years that may be deficient for immunization
completion.
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CHAPTER 3
METHODOLOGY
3.1.

Description of Project Design and Methodological Approach
The primary purpose of this project is to advance understanding of how influenza

pandemics and policy shifts affect the likelihood of parents getting their children
immunized against the influenza virus. By examining marginal effects for completion of
child flu vaccines following the occurrence of the pandemic and policy shift events
respectively, we plan to evaluate these impacts. Analysis was achieved by executing
logistic regression models, specifically by implementing an interrupted time-series (ITS)
empirical approach, which is a quasi-experimental design strategy for the estimations,
using STATA 16 statistical software. Provider-verified immunization histories from a
state and nationally representative dataset will serve as the basis for performing these
statistical estimations. Vaccine formulation specific measures served as the basis for
execution of a series of auxiliary ITS regressions for the LAIV policy analysis, that
assisted in reinforcing and corroborating the primary ITS estimations evaluating overall
immunization uptake. All ITS regressions are predicated on clinician validated responses.
The 15-year time span from 2003 to 2018 was examined for this study,
encompassing both the 2009 H1N1 pandemic and the 2015 ACIP LAIV withdrawal
completely and sufficiently. The time period of analysis commences in 2003, since that is
the preliminary year the IIV formulation was universally recommended by ACIP.
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It is also the year where the LAIV formulation of the immunization was accepted and
authorized for usage by the ACIP. The time period of analysis terminates in 2018 as that
is the most recent year available for analysis. The data was aggregated, and compiled for
analysis by merging separate annual surveys consecutively into a single dataset. The final
version of the data was a series of repeated cross-sections based on annually completed
NIS surveys. This generated dataset emulates longitudinal and panel data sources, and
allows for minimization of bias, while reinforcing estimation of a correlation relationship
that is representative of a larger scale heterogeneous population.85
Sensitivity analyses, including fixed effects estimations for the H1N1 pandemic
analysis, and difference in differences (DID) estimations for the LAIV policy analysis,
were performed in order to corroborate and validate results yielded by the primary
logistic regressions.
Specific Aim 1: To ascertain the effects of the 2009 H1N1 pandemic on overall
child influenza vaccination uptake rates in the U.S. by assessing changes in the likelihood
that a child is vaccinated for influenza following the pandemic event.
H1: The 2009 H1N1 pandemic is expected to increase the likelihood of overall
child influenza vaccine uptake. In accordance with the previous literature, and this studies
conceptual model, vaccine uptake stimulating factors related to disease severity and
susceptibility to infection will drive the expected increases in flu immunization uptake.
Specific Aim 2: To ascertain the policy effects of the 2015 ACIP LAIV
preferential recommendation revocation on overall child influenza vaccination uptake
rates in the U.S. by assessing changes in the likelihood that a child is vaccinated for
influenza following the policy shift event.
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H2: The 2015 ACIP LAIV preferential recommendation revocation is expected to
decrease the likelihood of overall child influenza vaccine uptake. In accordance with the
previous literature, and this studies conceptual model, provider dissemination of
immunization information, based on ACIP advisements, will likely reduce vaccine
uptake, since LAIV will not be recommended as the preferred option to parents by
providers.

3.1.1. Data Sources
The data source used for this study was the National Immunization Survey (NIS),
which is conducted by the CDC’s National Center for Immunization and Respiratory
Diseases (NCIRD) in order to monitor immunization coverage. It is nationally
representative and comprehensive including flu vaccination data for children 6 months –
17 years of age for all 50 states and additional U.S. territories.86 NIS consists of a
combination of NIS-Child (ages 19-35 months), and NIS-Teen (ages 13-17 years).86 NIS
offers national, state, and local level data, provided directly from the child’s providers
(NIS-Child and NIS-Teen consist of provider-verified immunization measures),
bolstering its accuracy and validity.86 It contains information regarding the types of
vaccines administered to children, their dates and dosages, demographic, socioeconomic,
geographic, and insurance data, as well as administrative data related to providers and
facilities where the procedures were performed.86
The CDC published surveillance reports of influenza disease activity, in the form
of the National Notifiable Diseases Surveillance System (NNDSS), was the data source
used in conjunction with the aforementioned NIS population data, in order to execute
sensitivity analysis estimations for the H1N1 pandemic. CDC’s FluView and generated
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report data from ILI Net was used as well in order to achieve this sensitivity analysis.
This was accomplished by examining measures such as population-adjusted ILI incidence
and prevalence rates, for each state, on an annual basis.

3.1.1.a. NIS Sampling Procedures and Weighting Approach
NIS-Child and NIS-Teen conduct sampling in a two phased and tiered approach.
In phase one, the data collection procedure is to attain immunization information for a
national probability sample of children, by performing random digit dialing (RDD)
within each of the statistical sampling strata in order to identify eligible subjects.86 The
interviewers request permission to contact the vaccination provider of the qualified child,
and subsequently, a mailed survey is sent to the designated clinician. In phase two, the
provider record check (PRC) survey is completed, and allows for confirmation and
verification of the phase one questionnaire responses.86 Overall this allows for
vaccination statistics that are comparable across geographic territories, with the progress
of time, and promotes minimization of bias that may exist.86
NIS-Child and NIS-Teen possess weighting processes and procedures that adjust
for variation in sampling rates, differences and discrepancies in response rates, and
variations in representation in the sample relative to the overall population being
assessed.86 This allows for improved accuracy of estimates at various sampling levels.
The estimates and variance approximations are generated for separate areas, states, and
sampling subdivisions. Weight imputations are performed for the survey as necessary.86

3.1.1.b. NIS Response Rates
The anticipated NIS-Child sample size for completed interviews is approximately
25,000 addresses, on average.86 The annual response rate of NIS-Child is approximately
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65 percent of eligible subjects within the sample, on average, for the parent response
segment.86 The rate of children with adequate provider data available is approximately 70
percent, on average.86
The anticipated NIS-Teen sample size for completed interviews is approximately
35,000 addresses, on average.86 The annual response rate of NIS-Teen is approximately
60 percent of eligible subjects within the sample, on average, for the parent response
segment.86 The rate of children with adequate provider data available is approximately 70
percent, on average.86

3.1.2. Quasi-Experimental Design Overview and Primary Application
Although randomized controlled trials (RCTs) are considered the top echelon or
gold standard for conducting a study, they are not always feasible, possible, or ethical,
and in certain cases, not the optimal design option, as they may focus on a specified
cohort of individuals, and are not generalizable to the population level which is
heterogeneous in composition.85 RCTs are the gold standard for clinical trials concerning
the efficacy of an intervention, treatment, or program, but are not appropriate for many
other types of studies. Instances where overall population level effects of a vaccine
program or related event are being evaluated, and examined, as opposed to individual
level effects, require the implementation of quasi-experimental strategies, as opposed to
RCTs or cluster RCTs (CRCTs), which are incapable of assessing such impacts.
Quasi-experimental designs are optimal to use in instances where assessment is
being performed for a previously used vaccine formulation, or previously implemented
vaccine intervention or program. They also preserve the ethical aspect of the experiment
completely providing protection for participants in this regard. They are also
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advantageous to apply to cases where time constraints and cost limits exist. This aspect
does not directly benefit this study, and is not significantly advantageous for this
instance, hence providing minor value in this capacity. Quasi-experimental approaches
are also optimal when examining the impacts of a vaccine related event, such as a
pandemic, policy, or intervention, in relation to vaccine uptake rates. They allow for
evaluation of the overall impacts of the occurrence on health service outcomes in natural
settings and real world scenarios.87
Quasi-experimental designs, unlike RCTs, do not incorporate randomized
assignment to control and treatment groups in order to enhance their internal validity, and
reinforce the approximation of the true counterfactual phenomenon, which is at the core
of evaluation study designs, and symbolizes what would have been observed if the event
or intervention had not occurred and was absent. The true counterfactual is unknown and
can only be approximated, with more accurate approximations improving the legitimacy
and internal validity of the analysis. Precise mimicry of the true counterfactual is central
and chief to strengthening the statistical approach if the quasi-experimental design.
Quasi-experimental designs, unlike experimental designs, that directly assign
participants to comparison groups, take advantage of exogenous sources to accomplish
this, termed as a natural experiment. This allows the quasi-experimental design to retain
the majority of advantages and superior aspects of the RCT and CRCT designs without
directly allocating subjects to comparison groups, and instead indirectly accomplishing
the same task through exogenous factors. In essence, the quasi-experimental design is a
natural experiment that achieves the objectives of an RCT without being randomized
directly in its assignment process, and instead achieves this quality through other external
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means. They possess similar characteristics, and design attributes as compared to RCTs,
but are distinct and unique.87
These exogenous sources include location differences in event occurrences, where
one location exhibits the event while another was restricted from experiencing it.
Threshold differences, where a marker may limit groups from exposure to a phenomenon,
and serve as natural boundaries. Finally, time point occurrences which divide groups
naturally into pre and post segments, allowing for comparison of the two segments, while
retaining natural assignment to the pre and post groupings due to exposure being divided
by the time point barrier. This latter category is what will be applied as the exogenous
source for this study, with pre-pandemic and pre-policy shift trends being used to
accurately approximate the true counterfactual, or the phenomenon that would have been
observed in the absence of the pandemic or policy shift. Because the subjects examined
in this study are not in control of assignment to the pre and post time point segments of
our analysis, this eliminates volunteer selection bias.87 This type of bias is of minor
concern for this project, with contemporaneous event occurrence being of chief concern.
The major assumption that exists with this study is that the pre-event trend serves
as the comparison control group for non-exposure to the event, and that the post-event
serves as the treatment group for exposure to the event, with differences and fluctuations
in vaccination uptake being attributable distinctly to the event occurrences and exposure
to the event time points. This relies on the pre-event trends, which serve as the true
counterfactual, persisting consistently past the event exposure time point, with minimal
deviation. If the counterfactual is erroneous, then measured increases or decreases in flu
vaccine uptake rates, following the event occurrences, will also inherit flaws that were
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generated from the approximation stage of the true counterfactual. This is because the
assumed baseline for post event comparison is predicated on the assumed counterfactual,
which is the expected trajectory that will be adhered to in the absence of the treatment or
exposure. Hence it follows that changes that are computed in the post event phase that are
attributed to the events impact become inaccurate, since the changes are being compared
to a falsely established baseline trend, and incorrectly presumed anticipated unobservable
trajectory. This assumption is at the crux of this approach, and is its weakest point.87
In order to minimize the potential for violation of this chief assumption,
methodological countermeasures can be strategically employed in order to maintain the
accuracy of the true counterfactual. Tactics include augmenting the regression formula,
and integrating countermeasures in the form of additional control factors, and indicator
variables signifying concomitant incidents, such as simultaneous policy fluctuations or
epidemic occurrences, that may alter the true counterfactuals trend assumption.
Incorporating these aspects assists in maintaining stability with regards to the
counterfactual trends anticipated trajectory past the point of exposure, and allows for
deviations that the unobserved true counterfactual may encounter, to be compensated for
adequately, hence improving the accuracy of the actual effect estimation.
For this studies estimation, the threats that would potentially cause deviations in
the assumed counterfactuals expected unobservable trajectory, from the correct course,
are mitigated by insertion of control variables within the regression function. These
control elements include state level policy and mandate differences, state characteristics
and unique attributes, indicators of time proximal influenza related policy shifts, and
indicators of restricted scale epidemic occurrences of the influenza virus. The hazards to
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this studies counterfactual assumption and potential violation are mainly in the form of
simultaneously or proximally occurring state and national vaccine uptake related policy
shifts and events.
For the 2009 H1N1 pandemic analysis these primarily include the restricted scale
influenza epidemics (RSE’s) that occurred in the aftermath of the H1N1 pandemic, which
will be compensated and adjusted for via augmentation of the regression equation as
described above. This will mitigate the interference of the RSE’s influences on flu
vaccine uptake rates in the post H1N1 pandemic phase of the analysis. The RSE’s could
decrease uptake rates by exacerbating preexisting erosions in vaccine confidence, or by
initiating attritions in vaccine confidence levels. The RSE’s could increase uptake rates
by amplifying preexisting concerns of disease exposure, or by initiating intensified
awareness of disease risk.
For the 2015 LAIV policy shift analysis, these primarily include the following.
First, the lagging effects of the 2014 LAIV preferential advisements, which could
possibly affect the pre 2015 policy shift segment of the analysis, by causing increases in
overall flu vaccine uptake, and delayed effects that are realized proximate to the 2015
policy point of interest. Second, the aftermath of the 2016 LAIV complete rescindment
advisements, which could potentially affect the post 2015 policy shift segment of the
analysis, by causing decreases in overall flu vaccine uptake, and immediate effects that
are realized proximate to the 2015 policy point of interest.
A quasi-experimental design is advantageous for this study due to potential, but
minor, cost and time constraints, which are inherent in epidemic, pandemic, and seasonal
flu vaccination scenarios. Additionally, RCTs would be unethical for this study due to the
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outcome being examined, and the events being assessed for their impacts, hence a quasiexperimental design is most appropriate. Also the fact that both the LAIV and IIV
immunizations have previously been implemented and applied, disqualifying the use of
RCTs or CRCTs as they are not possible to use in these instances. Quasi-experimental
designs are also necessary for our study because we are evaluating an outcome that could
not be examined in initial vaccine trials, such as the uptake of influenza vaccines, among
a specific subpopulation such as children. A quasi-experimental design provides the
advantage of being relatively unaffected by the absence of a direct randomization
process, since allocation to comparison groupings is based on eligibility resulting from
naturally existing barriers, which in this case is the time point that divides subgroups
based on their exposure to the event.87

3.1.3. Interrupted Time-Series (ITS) Overview and Primary Application
The interrupted time-series design is a sub-design category of the quasiexperimental design approach. In the ITS design, the exogenous variable that is
responsible for ensuring assignment is time. With the ITS design, pre and post event
time-point observations are analyzed in order to assess changes in the trends of the
outcome variable that occur over time. This is achieved by comparing the outcomes
trends before and after the time point of interest, and assessing the changes in the
outcome variable that ensue following the occurrence of the time point of interest. The
alteration in the slope of the trend function being analyzed symbolizes the impact of the
event on the outcome variable.
Explicated in regression analysis terms, the slope of the outcome function can be
compared before and after the time point of interest to determine the degree of impact of
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the event in question. If the regression analysis yields an immediate fluctuation in the
outcome variable, it is termed a change in intercept, while if a consistent and sustained
fluctuation is detected, then it is defined as a change in slope.88 The selection and
designation of the ITS model should be accomplished a priori while considering the type
of outcome variable being examined as well as the time point of interest.87
The primary advantage of the ITS design is that it is best implementable in
scenarios where a true unaffected control group is not available, and when the overall
impacts of an event are being assessed in a pre and post time point manner. The ITS
design is advantageous for population level analyses due to the fact that it controls for
preexisting trends, and selection bias due to population level differences, and
heterogeneity that exists.87
The primary disadvantage and limitation of the ITS design is its inability to
eliminate and exclude the effects of simultaneous and coinciding phenomenon such as
pandemics and epidemics, policy shifts, or interventions that are occurring parallel to the
target phenomenon concomitantly. This limitation is termed history bias, and exists with
all ITS design approaches, suppressing its ability and reliability in extrapolation of trends
and patterns. It follows for this study that phenomenon occurring alongside the 2009
H1N1 pandemic and 2015 LAIV policy shifts could be either directly or indirectly
influencing differences in child influenza vaccine uptake rates simultaneously, and
overlapping of effects could potentially be occurring that cannot be isolated with the ITS
design approach.
If the history bias that exists is sufficiently influential, to the degree that it alters
the forecasted counterfactual trend, and violates the presumed counterfactual assumption,
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then the computation of the effect in the post event phase of the estimation becomes
defective. Conceptually stated, if the contemporaneous phenomenon’s expected impact
directionality is the same, and co-aligned with the event in question, then overestimation
of the events impact is yielded. If the contemporaneous phenomenon’s expected impact
directionality opposes and contradicts that of the event in question, then underestimation
of the events impact is yielded.
If the history bias affects the unobserved actual trend in a way that it alters the
functions slope magnitude, and increases it as compared to the assumed counterfactuals
slope magnitude, then the computed event effect is greater in quantity than the actual
impact magnitude, and the approximation is incorrect due to overestimation of the impact
magnitude.
Conversely, if the history bias alters the unobserved actual trend in a way that it
alters the functions slope magnitude, and decreases it as compared to the assumed
counterfactuals slope magnitude, then the computed event effect is lesser in quantity than
the actual impact magnitude, and the approximation is incorrect due to underestimation
of the impact magnitude.
If history bias sufficiently influences the unobserved actual trend, such that the
initial intercept point immediately following the event exposure time point is altered, then
errors can arise as well for the estimation. If the initial intercept, or baseline, point
following the event exposure was actually greater in magnitude than the assumed
counterfactuals, then the effect magnitude computed is flawed, due to overestimation of
the impact magnitude. That is, the estimations computed effect was erroneously greater
than the actual effect, and the events true impact was over-credited.
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If the initial intercept, or baseline, point following the event exposure was
actually lesser in magnitude than the assumed counterfactuals, then the effect magnitude
computed is flawed, due to underestimation of the impact magnitude. That is, the
estimations computed effect was erroneously lesser than the actual effect, and the events
true impact was under-credited.
Table 3.1 - Effect Estimation Fallacies Due to Assumed Counterfactual Violations
Effect (E) Estimation Fallacy

Slope (S) Comparison

Intercept (I) Comparison

Overestimated (EComputed > EActual)

|SActual| > |SCounterfactual|

|IActual| > |ICounterfactual|

Underestimated (EComputed < EActual)

|SActual| < |SCounterfactual|

|IActual| < |ICounterfactual|

The potential for history bias for the 2009 H1N1 pandemic is moderate, prior to
adjusting the regression function accordingly, due to the multiyear distancing of the
preliminary RSE, of the three RSE sequence, relative to the pandemic itself. If the
ensuing two RSEs (2012-2013, 2013-2014) are potent in their immediate effects, then flu
vaccine uptake rates could increase if perceived disease risks are intensified, or
conversely decrease if vaccine confidence is diminished. The former would generate bias
manifested as overestimation of the pandemics effect, and the latter would generate bias
manifested as underestimation of the pandemics effect.
The potential for history bias for the 2015 LAIV policy shift is more prominent,
prior to adjusting the regression function accordingly, due to proximate LAIV linked
advisements in 2014 and 2016, as well as the final RSE in 2017-2018. The hypothetical
biased scenarios that would be exhibited in relation to the LAIV advisements are as
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follows. These particular hypothetical scenarios are predicated on predecessor publication
results that were most significant.
The 2014 preferential advisements for the LAIV may have improved overall flu
vaccine uptake rates, resulting in lagged effects, that may bias the 2015 analysis by
inducing underestimation of 2015 post policy effects. This is due to 2014 post policy
effect directionality opposing the directionality of the 2015 policies, and the
counterfactuals trajectory deviating from the actual trajectory. This subsequently leads to
the post 2015 policy point computed effect being smaller than the actual effect.
The 2016 complete withdrawal advisements for the LAIV may have reduced
overall flu vaccine uptake rates, resulting in immediate effects, that may bias the 2015
analysis by inducing overestimation of 2015 post policy effects. This is due to the
anticipated 2016 post policy effect directionality co-aligning with the directionality of the
2015 policy, and the counterfactual trajectory deviating from the actual trajectory. This
subsequently leads to the post 2015 policy point computed effect being greater than the
actual effect.
The 2017-2018 RSE may have increased or decreased overall flu vaccine uptake
rates. If the RSE increased uptake rates, then the 2015 analysis may be biased, and
underestimation of effects may be yielded. This is due to the presumed counterfactual
trajectory’s slope being different than the actual trajectory’s slope, leading to a computed
effect that is smaller than the actual effect. This is similar to the anticipated biased effects
yielded by the 2014 LAIV policy shift.
If the RSE decreased uptake rates, then the 2015 analysis may be biased, and
overestimation of effects may be yielded. This is due to the presumed counterfactual

57

function’s slope being different than the actual function’s slope, leading to a computed
effect that is greater than the actual effect. This is similar to the anticipated biased effects
yielded by the 2016 LAIV policy shift.
A milder limitation that is inherent with all time and history based design
strategies is the presence of instrumentation fluctuation interferences if the outcome was
measured differently or in a varying manner over the time periods being examined. This
limitation is minimal in this study, as flu vaccine uptake has been measured as an
outcome consistently by the same entity, the CDC, over time with consistent conventions
historically.87
General Empirical Form Regression Model: CIVUtis = β0 + [β1 (Pts)] + [β2 (Xtis)]
+ [β3 (Zts)] + [β4 (Mts)] + [β5 (SFEs)] + [β6 (TFEt)] + [β7 (RSEts)] + etis
Regression models were executed using the formulation described above, with
one corresponding to the pandemic event (2009 H1N1), and one to the policy shift event
(2015 LAIV withdrawal). For each respective event point, the major regression
estimations were performed based on the provider-verified responses. Variations of the
regression equation were applied in the auxiliary estimations.
Outcome (Dependent) Variable: CIVU (Child Influenza Vaccine Uptake) denotes
whether the child was administered and received the influenza vaccine. This is a binary
“Yes” or “No” outcome measure represented by 1 or 0 respectively.
Primary Variable of Interest: P (Event of Interest) denotes the occurrence of the
policy shift or pandemic. This is binary and symbolizes incidence of the H1N1 pandemic
or the LAIV preferential advisement rescindment accordingly.

58

Predictive (Independent) Variables: Child sex, age, birth order, race/ethnicity,
relocation/mobility comparing state of birth and current location, maternal age, education
level, marital status, insurance type, family income level, and provider/clinician facility
type. These covariates are in concordance with previously applied conventions among
predecessor studies, and are standard across previously completed studies published in
the literature. They are represented by the vector “X”.
Additional Control Factors: SFE = State Fixed Effects; TFE = Time Fixed
Effects; Z = State level characteristics that vary with time; M = State level policy and
mandate differences; RSE = Restricted Scale Epidemic Occurrences of the Influenza
Virus. Time-variant state level attributes specifically include: Unemployment rates,
retrieved from the Bureau of Labor Statistics (BLS); Poverty rates, retrieved from the
U.S. Census; Health insurance coverage rates subdivided between percentage private,
public, and uninsured, retrieved from the U.S. Census; Medicaid income eligibility
thresholds as a function of a percentage of the Federal Poverty Level (FPL), retrieved
from the Kaiser Family Foundation (KFF). These will be merged into the primary data
source via each states Federal Information Processing Standard (FIPS) code identifiers,
which will serve as channels for cross matching state by year control data.
Associated Terms: β0 = Constant term; β1-7 = Beta coefficients specifying the
marginal effect of their corresponding variable in regards to the outcome variable CIVU;
e = Error term.
Cross Sections Examined (Subscripts): t = year; i = individual; s = state; These
subscripts denote cross sections used in the aforementioned regression equation, and
subsequent auxiliary estimations.
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Primary Coefficient Measure: The chief quantitative value that was interpreted in
order to determine the impact of P relative to CIVU, is the beta coefficient (β1).
Covariate Coefficient Measures: Covariate coefficients were examined, and
subsequently interpreted, in order to assess if baseline disparities existed, and if further
disparities existed beyond those due to standard inherent heterogeneity for certain
covariates. This signified if the disparities and heterogeneity were attributable to the
event occurrences specifically, or if they were naturally occurring by default.
Interpretation of Coefficients: The interpretation of the beta coefficients are as
follows. If the marginal effect yielded is a positive value, this indicates that the event of
interest increased the predicted probability of the outcome occurring, which is child flu
vaccine uptake by parents. If the marginal effect yielded is a negative value, this indicates
that the event decreased the predicted probability of the outcome occurring. If the
marginal effect equals zero, or is nearly zero, this signifies the event had no impact, or
minimal impact respectively. The magnitude of the marginal effect regardless of
directionality and sign exemplifies the degree of impact of the event of interest on the
outcome, with greater measures corresponding to larger impacts, without exceeding the
limit of 1 as the maximum value.

3.2.

Sensitivity Analyses
Aim 1 Robustness: Since 2003, the CDC publishes weekly surveillance reports of

influenza activity, in the form of the National Notifiable Diseases Surveillance System
(NNDSS). The CDC also integrates surveillance data into FluView, which synthesizes
nationally representative reports for indicators and measures of disease, such as morbidity
rates, mortality rates, and population-adjusted ILI incidence and prevalence rates, for
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each state, on an annual basis. By replacing the binary variable P, symbolizing the event
of interest, with a continuous measure of influenza burden, labeled variable I, we
exploited the specific timing and intensity of the H1N1 outbreak across the United States.
This sensitivity analysis was accomplished by implementing a fixed effects model (FEM)
that controls for temporal and state fixed effects. These factors are elements that are
intrinsic to this studies FEM estimations, and are essential fixed effects control variables.
This procedure supplemented the primary ITS estimation and provided reaffirmation of
its results. This statistical method was applied previously in a study examining pertussis
infections nationally, and has been previously tested with success.19,89
Aim 2 Robustness: We estimated a difference-in-differences model using children
age 6 months to 23 months as an untreated comparison group, or control group, since
LAIV was previously recommended for children age 2 years and older, but never for
children below 2 years of age. Children greater than or equal to the 2 year age threshold
will serve as the treatment group for LAIV recommendation, and those below this
threshold age point are disqualified from treatment exposure, due to ACIP never
approving or recommending the LAIV formulation for usage among this age range.
Spillover effects of the ACIP LAIV policy shifts in relation to the LAIV ineligible
individuals (IIV eligible only individuals) were assessed and examined as a byproduct of
this sensitivity analysis and execution of the DID statistical procedure.

3.2.1. Difference in Differences (DID) Overview and Application
The difference in differences (DID) is a quasi-experimental design applied as an
alternative to costlier and less feasible RCTs in order to establish causal relationships and
produce causal inferences. The DID regression computation examines in its basic form 2
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subgroups and 2 time periods, those being the control and treatment subgroups, and the
pre and post event point time ranges respectively. The DID technique calculates the
difference between the computed difference between the treatment and control subgroups
outcome measures, pre and post time point of interest, and compares the outcome values
for the subgroups both within and across time phases.90
In this study, the treatment group is individuals who were eligible for LAIV
receipt (ages 2 years and greater), and who would theoretically be affected by LAIV
related policy shifts, and the control group is individuals who were ineligible for LAIV
receipt but eligible for IIV (ages 6 to 23 months of age), and who would theoretically be
unaffected directly by LAIV based policy recommendations, but may be indirectly
impacted by linked spillover effects.
The time periods are divided into pre and post LAIV preferential recommendation
rescindment, also called LAIV withdrawal. The pre policy point time range will serve as
the unaffected time phase, and the post policy point time range will serve as the affected
time phase. Measures for overall influenza vaccine completion will be examined for both
LAIV eligible and non-eligible subgroups respectively, and compared for fluctuations
before and after the 2015 ACIP LAIV revocations. The outcome variable CIVU (child
influenza vaccine uptake) will be examined for both treatment (symbolized by the
subscript T) and control (symbolized by the subscript C) during the pre-policy shift time
phase (designated by the numeral 0), and the post-policy shift time phase (designated by
the numeral 1), and subsequently compared for differences in order to yield the DID
value (Table C.6).
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The DID estimation expression will possess a treatment (LAIV-eligible) versus
control (LAIV-ineligible) cohort assignment variable, LAIV Eligible, that will perform
this segregation predicated on the individuals age. The expression will also consist of a
DID variable that compares the LAIV eligible versus ineligibles vaccine completion rates
pre and post policy implementation. The empirical estimation equation is listed below.
Difference in Differences Regression Equation (DID): Logit (CIVUtis) = β0 + [β1
(H1N1ts)] + [β2 (LAIV 2014ts)] + [β3 (LAIV 2015ts)] + [β4 (LAIV 2016ts)] + [β5 (LAIV
Eligibletis)] + [β6 (DIDtis)] + [β7 (RSEts)] + [β8 (Xtis)] + [β9 (State Factorsts)] + etis
Similar to RCT’s, the DID approach has the advantages of possessing distinct
treatment and control subgroups, with established pre and post treatment, or exposure
time periods, allowing for profound comparisons to be attained. Furthermore the
population being examined and the criteria and conditions are well recognized when
designing the experiment. The dissimilarity with the DID technique, as contrasted with
RCT’s, is that it lacks direct randomized assignment of participants to treatment versus
control subgroupings, and hence must use other means in order to eliminate bias that may
arise at this stage due to confounding effects influencing both the outcome variable and
exposure to treatment. Instead, DID relies on assumptions in the form of constraints on
confounding factors that may exist.
These assumptions include the supposition that confounder variation due to
subgroup types, does not exhibit variation across time, and that confounder variation due
to time progression, does not exhibit variation across subgroups. These dual assumptions
on aggregate synthesize the greater common trend assumption, which is similar to the
true counterfactual assumption in ITS analyses.90
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The common trend assumption is at the core of the DID method, and violation of
this assumption could potentially negatively affect its application and results yielded. If
either of the primary assumption’s subcomponents are violated, then issues may arise.
Meaning that unmeasured factors involved with the DID estimation must be restricted to
group specific characteristics that are time invariant, or time specific characteristics that
are group invariant, otherwise the analysis may be flawed, and inferences made using the
DID technique are limited.90
Another assumption that the DID approach relies on in order for its estimation
mechanism to function properly is that the treatment exposure must be statistically
independent from the anticipated outcomes and their pattern of occurrence. That is,
overlapping effects of treatment exposure and other similarly timed events should be
avoided, and timing of other phenomenon that may affect the outcome should be
considered, with expected outcome fluctuations due to timing of parallel events being
compensated for. This concept is termed strict exogeneity, and if not adhered to can yield
validity issues with the DID estimation.90
Ultimately the DID method relies most on the parallel trends assumption in order
to ensure its validity, which states that in the absence of exposure to the treatment, the
treatment and control groups should possess constant variations in relation to the outcome
variable, with the progression of time, and should not deviate from this trend.
Additionally, the pre-treatment time period trends should ideally be identical, if not very
similar, for the subgroups being compared, since this trend is assumed to persist
consistently for the treatment subgroup past the treatment point, and into the post
treatment time period, where it is used to calculate the actual effects of the treatment.
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This serves as the basis for usage of the unobserved counterfactual in the post event time
phase portion of the DID analysis, which is responsible for establishing the baseline for
comparison, in order to compute the true impact of the event of interest on the outcome
for the treatment subgroup (refer to Figure 3.1 for graphical diagram of the DID
estimation).91
In order to protect the parallel trends assumption from violation, the pre 2015
policy phase trends for the LAIV eligible (2 years and up) and the LAIV ineligible (6 –
23 months) should be similar in relation to the outcome (overall flu vaccine completion).
The greater the amount of time, within the pre 2015 policy phase, that the LAIV eligible
(treatment) and LAIV ineligible (control) trajectories mimic and emulate each other’s
trends, the greater the degree of reinforcement for the DID estimations parallel trends
assumption, and its potential for violation is minimized. This is due to the concept that
the greater the amount of time of trend emulation, and degree of trend mimicry, prior to
treatment exposure point (2015 policy shift), the more probable it is that the assumed
unobservable counterfactuals trajectory (based on the LAIV ineligibles trend), post
treatment exposure, is an accurate depiction of the actual trajectory that the LAIV eligible
subgroup would have experienced in the absence of the 2015 policy shift.
Additional assumptions for the DID method include that the outcome variable
should not dictate the occurrence of the treatment in question, and outcome and treatment
application were initially unrelated. Also that for repeated cross sectional analyses, the
composition of the subgroupings should remain consistent and stable over time, with the
consistency of the treatment and control groups not varying substantially with subsequent
cross sections, and maintaining a sustained conformation.91
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Figure 3.1 - Difference in Differences (DID) Method Graphical Depiction

3.2.2. Fixed Effects Modelling Overview and Application
In attempts to confirm causal relationships associated between event exposures
and specific outcomes, estimations may suffer from bias attributable to selection,
confounding, and measurement of observations. Both observed (known), and unobserved
(unknown) factors lead to measured and unmeasured confounding respectively, which
diminish the estimations validity and potential for producing legitimate causal inferences
associated with exposure instigating outcome. Differences that occur with the progression
of time are composed of 2 primary subcomponents, those being intra-individual
alterations (time invariant modifications), not controlled for in this study, and interindividual alterations (time variant modifications). Fixed effects models generally control
for and regulate the time invariant changes inherent to the estimation, and hence limit the
effects of time invariant unmeasured confounding that may exist.
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They operate with the assumption of the aforementioned strict exogeneity
concept, which states that lagging effects of previous outcomes cannot influence current
covariates, and that current outcomes cannot influence future covariates. It also states that
previous covariate quantities cannot affect currently measured outcomes, and current
covariate values cannot affect future outcome values independently.85
This approach is limited in that in cannot regulate for bias resulting from time
variant unmeasured confounding, and reverse causation. Additionally, because the fixed
effects model is limited in controlling for these variations that are intrinsic to the
estimation, it fails to completely compensate for other sources of temporal variation, and
can yield declines in precision level. These characteristics of the fixed effects model are a
disadvantage, because they limit its precision level and efficiency, which mixed models
cope with better. This approach is limited also due to the fact that temporal parameters
that are time variant cannot be completely adjusted for, and there will be differences in
exposure levels due to temporal factors. This is critical to the fixed effects models
estimation, since it only incorporates observations where the exposure altered as part of
its computation of estimates.85
The FEM model for this study include temporal fixed effects in addition to state
fixed effects in the form of fixed effects for all study years. Although the incorporation of
the year fixed effects will adjust and control for a degree of unobserved time varying
factors, such as national level trends, it cannot completely achieve this, and hence is a
limitation of this approach.
Fixed effects models are optimal for application in situations like this study,
where exposure to a pandemic event is being assessed relative to the causation of changes
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in influenza vaccine uptake over time. This is achieved by the model by adjusting for
both measured and unmeasured time invariant confounding, and measured time variant
confounding, and usage of a data source with minimal attrition, sustained stability over
time of observations, with exhibited differences in exposures, and maintenance of the
strict exogeneity condition.85 The fixed effects model estimation was applied as a
sensitivity analysis and supplementary analysis that reaffirmed results yielded by the
primary ITS estimation.
The CDC’s National Notifiable Diseases Surveillance System (NNDSS), which
provides statewide counts of influenza cases annually, was merged with existing NIS
population data in order to produce influenza disease rates. The original logistic
regression estimation for the H1N1 pandemic had the binary event point variable of
interest P, replaced by the continuous influenza disease epidemic variable of interest I,
and temporal and state level fixed effects were incorporated into the equation, in order to
mitigate the potential for biased estimates. Once this level of regulation was achieved
using the fixed effects integration, and confounding factors were controlled for, the beta
coefficient associated with the influenza disease epidemic variable I, signified the
variations in CIVU rates that occurred with respective changes in the influenza disease
risk progression across states for different individuals. This exhibited how child flu
vaccine uptake rates were impacted as a function of H1N1 influenza disease incidence
and progression with time across states. Refer to regression equation below for the
mathematical expression of the aforementioned.
CIVU as a Function of Influenza Disease Outbreak: CIVUtis = β0 + [β1 (Its)] + [β2
(Xtis)] + [β3 (Zts)] + [β4 (Mts)] + [β5 (SFEs)] + [β6 (TFEt)] + etis
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CHAPTER 4

THE 2009 H1N1 PANDEMIC:
ASSESSING IMPACTS ON IMMUNIZATION1

1

A.H. Mehrabi, N.L. Hair, C.M. Andrews, S.E. Harrison, R.D. Horner. To be submitted
to American Journal of Public Health.
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Abstract
Introduction: The historical 2009 H1N1 Influenza pandemic, which had a CDC
estimated accrued disease burden of 100.5 million illnesses, 936,000 hospitalizations, and
75,000 deaths from 2009 to 2018, resulted in a declared state of emergency nationally,
with ensuing diminished vaccine confidence and amplified fears of infection, prompting
some to pursue flu vaccination, and others to forego. Although the Centers for Disease
Control and Prevention (CDC), and its Advisory Committee on Immunization Practices
(ACIP) recommend an annual flu vaccine for individuals 6 months of age and older as
the “first and best” defense against influenza, a low percentage of children are
vaccinated, and parental decisions are not fully understood. Examining previous
literature, a void exists in relation to parental perceptions and decisions for child
immunizations, particularly concerning the U.S. nationally, with most studies being
international. Furthermore, there is evidence of varied results with inadequate and
conflicting conclusions, specifically for children.
Methods: To assess impacts of the 2009 H1N1 pandemic on decisions to uptake
influenza vaccines for children age 6 months to 17 years of age, data from NIS was used
as a series of weighted consecutive annual surveys in order to synthesize a longitudinal
panel dataset spanning from 2003 to 2018. Population adjusted measures of influenza like
illness (ILI) by state and season procured from CDC’s FluView application and ILI Net
from 2008 to 2018 were used in order to supplement the primary NIS dataset. Quasiexperimental (QE) approaches in the form of segmented interrupted time series (ITS),
and fixed effects model (FEM) logistic estimations were executed on the integrated
dataset yielding logistic regression coefficients and post-estimation marginal effects
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signifying the impact of the pandemic on child influenza vaccine uptake (CIVU). ITS
regressions examined both level and trend changes due to pandemic occurrence via
binary and continuous pandemic incidence variables respectively. FEM regressions
examined fluctuations in CIVU as a function of influenza disease progression across
seasons and geographic jurisdictions.
Results: The segmented interrupted time series (ITS) regression for the NISChild sample yielded statistically significant coefficients. Post-estimation average
marginal effects (AMEs) were as follows. The H1N1 pandemics occurrence yielded a
12.57 percentage point (pp), 95% CI [10.28, 14.32], immediate level change increase in
the probability of a child being immunized, on average. It also yielded a 3.77 pp, 95% CI
[-4.32, -2.55], sustained slope change decrease in the probability of a child being
immunized annually, on average. Pre-pandemic, a 1.64 pp, 95% CI [1.47, 1.81],
sustained increase in the probability of a child being immunized annually, on average,
was evident. Restricted scale epidemic (RSE) occurrences of the influenza virus yielded
post-estimation AMEs that were statistically significant for RSEs on 2012, 2013, and
2014. These coefficients were a 1.79 pp, 95% CI [-2.22, 0.38], 5.23 pp, 95% CI [-6.27, 4.77], and 1.92 pp, 95% CI [2.74 1.10], decrease in the probability of a child being
immunized, on average, respectively. The respective trend change increases post RSE
occurrences were 0.85 pp, 95% CI [0.74, 0.96], 0.34 pp, 95% CI [0.28, 0.40], and 1.24
pp, 95% CI [1.12 1.35], on average, in the probability of the same outcome.
Sensitivity analysis fixed effects model (FEM) regressions yielded logit and AME
coefficients that were statistically insignificant with the exception of a single variable in
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subgroup 5, which indicated a decrease of 2.29 pp, on average, in immunization rates
during peak season weeks registering at a ILI intensity magnitude of 9 or greater.
FEM regressions for the NIS-Teen sample yielded logit and AME coefficients
that were statistically insignificant with the exception of three variables in subgroup 5.
The initial variable indicated a 1.31 pp increase, and the subsequent variables indicated a
0.135 pp, and a 0.212 pp decrease, on average, in immunization rates respectively.
Conclusion: Preliminary escalations in the probability of child immunization
uptake are evident following the pandemic. This is possibly linked to immediate
vaccination promoting factors connected to the pandemics occurrence, but cannot be
ascertained. These factors are possibly paramount in the initial post-pandemic phase, and
gradually diminish with the progression of time, theoretically yielding reductions in
uptake rates in the long term. Public health immunization professionals should expect
preliminary increases in uptake behavior, followed by gradual decreases in the same
outcome for influenza pandemics such as H1N1. They should anticipate decreases in
uptake behavior following smaller scale epidemics. For pandemic intensity ILI seasons,
uptake behavior is not sensitive to weekly fluctuations in ILI severity for children, but
slightly sensitive for teens during peak and late phases of the influenza season, with
fluctuating uptake behavior associated with peak season phases, and consistent increases
for late season phases. This study contributes to the existing literature by enhancing the
understanding of how vaccine uptake rates change following pandemic and epidemic
events. However it is limited in determining why these changes occur, and due to what
factors and mechanisms specifically, which future studies should attempt to discern and
ascertain.
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4.1.

Introduction
Each year millions of children in the U.S. experience influenza-related illness.

Although most children infected with influenza viruses recover within a week, serious
complications can result in hospitalization or death.1 Currently, the Centers for Disease
Control and Prevention (CDC), and its Advisory Committee on Immunization Practices
(ACIP) recommend an annual flu vaccine for individuals 6 months of age and older as
the “first and best” defense against influenza.2,3 Nevertheless, only 45.6% of children 6
months to 17 years of age received the vaccine in 2018 – 2019, and even less at 38.8% in
2017-2018.4 Understanding parental attitudes and barriers associated with uptake of
childhood immunization is a crucial national public health priority. This process is
complex, as numerous socioeconomic, psychological, demographic, and contextual
factors influence vaccine uptake rates.5–9 Doubts regarding vaccine benefits,10 concerns
regarding side-effects and safety,5,11–17 perceived disease seriousness and risk
assessment,11,15,16,18,19 uncertainties about vaccine effectiveness,8,11,12,20,21 and healthcare
access and costs,7,8,14,22,23 are prime influencers and factors affecting immunization
uptake.
The effects of epidemic and pandemic occurrences on parental perceptions and
decisions to uptake immunizations in the U.S. are not completely understood, with
conflicting, and inconsistent conclusions, 5,11,19,23–26 specifically for child flu vaccines.
This study overcame these shortcomings and contributes to a better understanding of how
parental perceptions and decisions are affected by these aforementioned factors by
examining the historical 2009 H1N1 pandemic. The pandemic served as a point of
analysis to determine how parental decision-making and perceptions regarding child flu
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vaccines may have shifted through mechanisms such as perceived disease risk and
erosion of vaccine confidence. This study has parallels to past research that has examined
the controversies regarding other diseases, health conditions, and vaccine formulation
elements. These include the measles, mumps, rubella and Autism dilemma, and
thimerosal presence in vaccines debate, where child vaccination rates shifted due to false
scares, ensuing spillover effects, incorrect conclusions, and parental inability to critically
analyze and decipher vaccine information.5,13,24,27
The occurrence of the historical 2009 H1N1 Influenza pandemic, which had a
CDC estimated accrued disease burden of 100.5 million illnesses, 936,000
hospitalizations, and 75,000 deaths from 2009 to 2018,28 resulted in a declared state of
emergency nationally. For the U.S. in 2009 alone, the pandemic resulted in
approximately 270,000 hospitalizations and 12,270 mortalities, with 1,270 of those
deaths being under age 18.29 Examining previous literature, a void exists in relation to
parental perceptions and decisions for their children, particularly concerning influenza for
the U.S. nationally, with most studies having been completed internationally.
Furthermore, there is evidence of varied results with inadequate and conflicting
conclusions, specifically for children. In certain studies, flu vaccine rates decreased
following the pandemic,11,16,30 while in others it increased,31,32 with the measured
magnitude of change being vastly different, with certain publications reporting
substantial fluctuations,11,31,32 and others stating milder effects, regardless of
directionality. A study examining the relationship between influenza season severity and
vaccine effectiveness, with influenza immunization rates, concluded that no statistically
significant association was evident,84 with minimal decreases in uptake observed for
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seasons following low vaccine effectiveness years.84 There also exists a lack of a
comprehensive nationwide study that is representative and all encompassing.
Given the aforementioned, the question arises as to what was the impact of the
historical 2009 H1N1 pandemic on overall child influenza vaccination uptake rates in the
U.S.? It is postulated that the 2009 H1N1 pandemic increased overall child Influenza
vaccine uptake rates due to stimulation of parental fears, and the perceived disease risk
being greater. The shock and awe of the pandemic and heightened sense of hazard would
supersede and overwhelm the erosion in vaccine confidence that ensued.
This study is novel and innovative in that it is the first nationally representative
and comprehensive study that will examine the impacts of the 2009 H1N1 pandemic on
overall child flu vaccine rates over a significant time span using an extensive vaccinefocused data source in the form of the National Immunization Survey (NIS). It is the first
to assess how parental uptake of child influenza immunizations is affected nationally
across diverse segments of the population, while yielding improved results with public
health implications. This is significant, as it allows for a better understanding of parental
cognitive and behavioral responses to pandemics in relation to decision making for
uptake of child flu vaccines within the United States. This is significant, as it ultimately
allows for U.S. public health policymakers to increase future child flu vaccine uptake by
understanding how parental uptake rates alter following a pandemic. By possessing
insight regarding the pandemic and epidemic associated trend alterations for
immunization, public health professionals and authorities can adapt better to the evolving
disease contagions progression and influences it has on vaccination. Vaccine campaigns
can then be designed and implemented accordingly based on forecasted patterns.
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4.2.

Description of Project Design and Methodological Approach
The primary purpose of this project is to advance understanding of how influenza

epidemics and pandemics affect parental perspectives and decisions regarding child flu
vaccine uptake. By examining marginal effects for completion of child flu vaccines
following the occurrence of the 2009 H1N1 pandemic we evaluated these impacts.
Analysis was achieved by executing logistic regression models, specifically by
implementing an interrupted time-series (ITS) empirical approach, with a quasiexperimental design strategy for the estimations, using STATA 16 statistical software.
Provider-verified immunization histories from a state and nationally representative
dataset served as the basis for performing these statistical estimations.
The 15-year time span from 2003 to 2018 was examined for this study,
encompassing the 2009 H1N1 pandemic completely and sufficiently. The time period of
analysis commenced in 2003, since that is the preliminary year where the IIV
formulation’s universal recommendation and application would be realized following the
ACIP’s decision. It is also the year the LAIV formulation of the immunization was
accepted and authorized for usage by the ACIP. The time period of analysis terminates in
2018 as that is the most recent year available for analysis. The data was aggregated, and
compiled for analysis by merging separate annual surveys consecutively into a single
dataset. The final version of the data was a series of repeated cross-sections based on
annually completed NIS surveys. This generated dataset emulated longitudinal and panel
data sources, and allowed for minimization of bias, while reinforcing estimation of a
correlation relationship that was representative of a larger scale heterogeneous
population.85 Sensitivity analysis in the form of auxiliary estimations using fixed effects
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models were performed in order to corroborate and validate results yielded by the
primary ITS logistic regressions.
Specific Aim 1: To ascertain the effects of the 2009 H1N1 pandemic on overall
child influenza vaccination uptake rates in the U.S. by assessing changes in the likelihood
that a child is vaccinated for influenza following the pandemic event.
H1: The 2009 H1N1 pandemic is expected to increase the likelihood of overall
child influenza vaccine uptake. In accordance with the previous literature, and this studies
conceptual model, vaccine uptake stimulating factors related to disease severity and
susceptibility to infection will drive the expected increases in flu immunization uptake.

4.2.1. Data Sources
The data source used for this study was the National Immunization Survey (NIS),
which is conducted by the CDC’s National Center for Immunization and Respiratory
Diseases (NCIRD) in order to monitor immunization coverage. It is nationally
representative and comprehensive including flu vaccination data for children 6 months –
17 years of age for all 50 states and additional U.S. territories.86 NIS consists of a
combination of NIS-Child (ages 19-35 months), and NIS-Teen (ages 13-17 years).86 NIS
offers national, state, and local level data, provided directly from the child’s providers
(NIS-Child and NIS-Teen consist of provider-verified immunization measures),
bolstering its accuracy and validity.86 It contains information regarding the types of
vaccines administered to children, their dates and dosages, demographic, socioeconomic,
geographic, and insurance data, as well as administrative data related to providers and
facilities where the procedures were performed.86
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The CDC published surveillance reports of influenza disease activity, in the form
of the National Notifiable Diseases Surveillance System (NNDSS), was the data source
used in conjunction with the aforementioned NIS population data, in order to execute
sensitivity analysis estimations for the H1N1 pandemic.92 CDC’s FluView and generated
report data from ILI Net, were used as well in order to achieve this sensitivity analysis.93
This was accomplished by examining measures related to intensity levels for populationadjusted ILI incidence and prevalence rates, for each state, on an annual basis.92

4.2.2. NIS Sampling Procedures, Weighting, and Response Rates
NIS-Child and NIS-Teen conduct sampling in a two phased and tiered approach.
In phase one, the data collection procedure is to attain immunization information for a
national probability sample of children, by performing random digit dialing (RDD)
within each of the statistical sampling strata in order to identify eligible subjects.86 The
interviewers request permission to contact the vaccination provider of the qualified child,
and subsequently, a mailed survey is sent to the designated clinician. In phase two, the
provider record check (PRC) survey is completed, and allows for confirmation and
verification of the phase one questionnaire responses.86 Overall this allows for
vaccination statistics that are comparable across geographic territories, with the progress
of time, and promotes minimization of bias that may exist.86
NIS-Child and NIS-Teen possess weighting processes and procedures that adjust
for variation in sampling rates, differences and discrepancies in response rates, and
variations in representation in the sample relative to the overall population being
assessed.86 This allows for improved accuracy of estimates at various sampling levels.
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The estimates and variance approximations are generated for separate areas, states, and
sampling subdivisions. Weight imputations are performed for the survey as necessary.86
The anticipated NIS-Child sample size for completed interviews is approximately
25,000 addresses, on average.86 The annual response rate of NIS-Child is approximately
65 percent of eligible subjects within the sample, on average, for the parent response
segment.86 The rate of children with adequate provider data available is approximately 70
percent, on average.86
The anticipated NIS-Teen sample size for completed interviews is approximately
35,000 addresses, on average.86 The annual response rate of NIS-Teen is approximately
60 percent of eligible subjects within the sample, on average, for the parent response
segment.86 The rate of children with adequate provider data available is approximately 70
percent, on average.86

4.2.3. General Regression Model Components and Estimation Elements
Outcome (Dependent) Variable: CIVU (Child Influenza Vaccine Uptake) denotes
whether the child was administered and received the influenza vaccine. This is a binary
“Yes” or “No” outcome measure represented by 1 or 0 respectively.
Primary Variables of Interest: H1N1, denotes the initial occurrence of the
pandemic, with its coefficient demonstrating the immediate level change with respect to
CIVU. This is binary and symbolizes the incidence of the H1N1 pandemic. The H1N1
slope change factor, is a continuous variable arising from the interaction between the
normalized time variable (T) and the pandemic indicator variable H1N1. It denotes the
ensuing trend occurrence in the post pandemic phase, with its coefficient demonstrating
the subsequent slope change with respect to CIVU.
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Predictive (Independent) Variables: Child sex, age, birth order, race/ethnicity,
relocation/mobility comparing state of birth and current location, maternal age, education
level, marital status, insurance type, family income level, and provider/clinician facility
type. These covariates are in concordance with previously applied conventions among
predecessor studies, and are standard across previously completed studies published in
the literature.
Additional Control Factors: State fixed effects (SFE), time fixed effects (TFE),
state level characteristics that vary with time, state level policy and mandate differences,
restricted scale epidemic occurrences of the influenza virus (RSEs), and CDC ACIP
influenza vaccine policy shifts. Time-variant state level attributes specifically include:
Unemployment rates, retrieved from the Bureau of Labor Statistics (BLS); Poverty rates,
retrieved from the U.S. Census; Health insurance coverage rates subdivided between
percentage private, public, and uninsured, retrieved from the U.S. Census; Medicaid
income eligibility thresholds as a function of a percentage of the Federal Poverty Level
(FPL), retrieved from the Kaiser Family Foundation (KFF). These will be merged into
the primary data source via each states Federal Information Processing Standard (FIPS)
code identifiers, which will serve as channels for cross matching state by year control
data.
Associated Terms: Beta coefficients specify the impact, or marginal effect, of
their corresponding variable in regards to the outcome variable CIVU.
Cross Sections Examined: Individuals are examined in conjunction with time
progression in years for different states.
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Covariate Coefficient Measures: Coefficients were examined, and subsequently
interpreted, in order to assess if baseline disparities existed, and if further disparities
existed beyond those due to standard inherent heterogeneity for certain covariates. This
signified if the disparities and heterogeneity were attributable to the event occurrence
specifically, or if they were naturally occurring by default.
Interpretation of Coefficients: The interpretation of the beta coefficients are as
follows. If the marginal effect yielded is a positive value, this indicates that the event of
interest increased the predicted probability of the outcome occurring, which is child flu
vaccine uptake by parents. If the marginal effect yielded is a negative value, this indicates
that the event decreased the predicted probability of the outcome occurring. If the
marginal effect equals zero, or is nearly zero, this signifies the event had no impact, or
minimal impact respectively. The magnitude of the marginal effect regardless of
directionality and sign exemplifies the degree of impact of the event of interest on the
outcome, with greater measures corresponding to larger impacts, without exceeding the
limit of 1 as the maximum value.

4.2.4. Regression Model Structures, Designations, and Specifications
The interrupted time series and fixed effects models are the two primary
methodological designations that were implemented in order to execute the logistic
regressions on the immunization data. Following the logistic regression estimations, post
estimation commands for predicted probability and marginal effect computations were
executed.
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4.2.4.a. Segmented Interrupted Time Series Estimation: NIS - Child
The segmented interrupted time series estimation was executed on NIS-Child data
for individuals across the entire age range (19-35 months) for consecutive years initiating
in 2003 and terminating in 2018. Due to the difficulty in isolating the effects of the 2009
pandemic individually, it was necessary to account for the three restricted scale
epidemics (RSE 1, RSE 2, RSE 3) corresponding to the 2012-2013, 2013-2014, and
2017-2018 influenza seasons respectively. In order to accomplish this, the ITS estimation
was executed as a segmented or piecewise regression as opposed to a regular ITS
estimation. The segmented ITS regression incorporates multiple temporal periods (pre2009, 2009 to 2012, 2012 to 2013, 2013 to 2017, and post-2017) in order to compute the
estimates for both level and slope changes for individual pandemic and epidemic severity
seasons. This model allows for slope as well as intercept changes to be calculated for
each of the three RSE points, as well as the main pandemic point, while controlling for
concomitant factors.
The regression equation included concomitant event control indicators for the
three CDC ACIP vaccine policy advisements (LAIV 2014, LAIV 2015, LAIV 2016)
corresponding to the LAIV 2014 preferential recommendation, LAIV 2015 revocation of
preferential recommendations, and LAIV 2016 complete rescindment of
recommendations. All contemporaneous influenza vaccination influencing events are
coded as categorical variables corresponding to the initial year of the contemporaneous
events season of occurrence.
This is due to the NIS survey design being such that it is conducted from the
January of the initial year to the February of the subsequent year, hence the year variable
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represents the interview year, or the year survey conduction commenced.86,94 This is the
initial year of the influenza season, which is of interest, since the vast majority of
vaccination happens during the months of September to February of each influenza
season.95,96 This allows for capturing of influenza vaccine uptake behavior during the
major vaccine completion portion of the year, spanning this intra-season time period.
Specifically for the H1N1 pandemic, the first monovalent vaccine formulation became
available to be administered October 2009,97 hence the 2009-2010 season, designated by
interview year 2009, would capture this occurrence. This also allows the post policy
period effects of the contemporaneous policy shifts to be captured effectively since the
ACIP policy decisions are completed in the preceding summer months, and regulations
and protocols are subsequently disseminated to clinicians and providers for the upcoming
season, permitting ample time for the effects of the policy shift to be realized.70,98
Predecessor vaccine studies have implemented this convention for analysis purposes, as it
is established in the literature.
The outcome variable representing CIVU is defined as an child who is completely
vaccinated and immunized based on CDC ACIP guidelines and regulations. Meaning that
completion of required dosages and injection sequences are incorporated into formulation
of this outcome measure as described in the CDC NIS user guide protocols and
definitions based on vaccine season recommendations from ACIP. An individual is
reported by providers as immunized when they are up-to-date for their vaccinations. This
is denoted in the NIS-Child data by a series of provider verified up-to-date (UTD)
variables specifically related to the influenza vaccine. To reflect CDC ACIP decisions
and adjustments in advisements, the final immunization variable used in this estimation is
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comprised of different up-to-date variables recorded in NIS-Child. From the time period
between 2003 to 2006, one variable is used, followed by another from 2007 to 2013, in
order to reflect the revised definition of vaccinated by ACIP, followed by a final variable
from 2014 to 2018, which was synthesized based on ACIP chart guidelines defining
complete immunization. This was achieved by using the intermediate variable denoting
the provider reported measure for total number of vaccinations completed per cycle to
date.
The alternative outcome variable that was implemented in supplementary ITS
estimations used the provider verified immunization measure for the total number of
shots completed. The outcome in the alternative regressions was coded as a binary
variable with 0 corresponding to no dosages received, and 1 corresponding to greater than
or equal to 1 dosage received.
The additional covariates used in the regression were selected based on ubiquity
and frequency of previous usage among predecessor literary works and publications, as
well as pertinence predicated on CDC NIS user guide definitions and recommendations.
Covariates representing child characteristics include age group of the child, gender,
race/ethnicity, birth order status, and translocation from a different state. Covariates
linked to maternal attributes include marriage status, age group, and education level.
Family characteristics included total number of children present, income level category as
a function of a percentage of the federal poverty line. Provider characteristics included
the providers facility classification type. State attributes included percentage poverty rate,
percentage unemployment rate, percentage uninsured below 65 years of age, percentage
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with public health insurance below 65 years of age, and Medicaid eligibility thresholds
for parents, and infants 0 to 1 and 1 to 5 years of age respectively.
Interrupted Time Series Regression Equation (ITS): Logit (CIVUtis) = β0 + [β1
(Tts)] + [β2 (H1N1 Levelts)] + [β3 (H1N1 Slopets)] + [β4 (RSE 1ts)] + [β5 (RSE 2ts)] + [β6
(RSE 3ts)] + [β7 (Policy Shiftsts)] + [β8 (Xtis)] + [β9 (State Factorsts)] + etis

4.2.4.b. Fixed Effects Model Estimation: NIS - Child
The fixed effects model for NIS-Child examined the same age range as the ITS
model for NIS-Child using a different time period that spans from 2008 to 2018 instead.
This is due to fixed effects models not requiring a substantial pre event time phase to
serve as the baseline trend for comparison, whereas their ITS counterparts necessitate this
time period to be sufficient. Also due to the fact that the influenza like iIlness (ILI) data
from CDC’s FluView application not going past 2008.
By accessing the CDC Weekly U.S. Influenza Surveillance Report data through
the FluView interactive application’s ILI Activity Indicator Map and ILI Net, it is
possible to obtain information regarding the weekly ILI activity level intensity by state
for each influenza season.92,93 The ILI activity levels are calculated using the proportion
of outpatient clinician and provider visits for ILI, and assigning an ILI intensity level for
different measures. The data is population adjusted for each jurisdiction.92
ILI intensity levels are predicated on the percentage of ambulatory visits for ILI
for different jurisdictions, compared to the average percentage for weeks that are minimal
or nonexistent for influenza circulation for those same jurisdictions.92 ILI activity levels
compare the mean percent of visits for ILI’s for a week in question to a non-circulation
influenza weeks value.92 ILI intensity levels are computed based on the number of
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standard deviations for the current mean value as compared to the non-circulation mean
value.92 ILI activity levels are classified as four categories, those being minimal (intensity
levels 1-3), low (intensity levels 4-5), moderate (intensity levels 6-7), and high (intensity
levels 8-10).92
Data for all states spanning from the 2008-2009 to 2017-2018 influenza season
were obtained, with each season possessing the total number of annual weeks. The
aggregated population adjusted data was coded in order to identify the maximum ILI
activity level for each state per season. This intermediary variable was then used to
generate a variable to determine whether the maximum ILI activity level was classified at
an epidemic or pandemic intensity based on CDC, WHO, and predecessor literary works
and publications.92,99 ILI intensity levels that are considered severe for an influenza
season, and at epidemic or pandemic magnitudes, exceed a threshold ILI activity level of
5 or greater,92,99 hence variables were generated to measure these. Following this
procedure, a time dimension was integrated by generating variables that measures the
number of weeks the ILI activity level exceeded a certain magnitude, which was used as
an intermediary to synthesize variables representing the aggregate number of influenza
weeks that an ILI intensity level was achieved for each state by season. These variables
serve as the measure for ILI progression with time across geographic jurisdictions across
the nation. A further variable designating intra-season time phases was generated to
indicate early, late, and peak time periods of the season and interacted with the previous
variable. This final variable serves as the primary variable of interest for the pandemic
fixed effect model (FEM) regression equations. The ILI analysis data following
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processing, augmentation, and refinement was merged with the primary NIS data via
state identifier codes and year markers for statistical estimation computations.
The FEM estimations possess two fixed effect control variables, those being for
states, and for seasons. The FEM regression equations possess identical covariates as
compared to the ITS regression equations. The difference is the substitution of the
influenza disease progression variables individually for the binary variable denoting the
H1N1 pandemic’s occurrence, and the insertion of the state and time fixed effects, and
the deletion of the normalized time progression variable, and H1N1 trend fluctuation
variable.
To perform the sensitivity analysis segment of this study, the experimental
measures of influenza season severity, using various ILI intensity level variables, were
developed and tested by conducting separate fixed effects model regressions for
individual ILI severity variables. The experimental variables were generated for ILI
intensity levels ranging from 5 to 10, as these magnitudes correspond to greater severity
seasons,92,99 with variations in threshold limit calculation and time period designation.
Threshold limit types were classified as singular limit thresholds exhibiting whether the
intensity level was surpassed or not. Total number of weeks threshold limit being
surpassed or not, by individual weekly increments for different segments of the season,
divided as early season, weeks initiating in September and terminating in November,95,96
late season, weeks initiating in March and terminating in May,95,96 and peak season,
weeks initiating in December and terminating in February,95,96 These variables were
generated by interacting intra-season time phases with previously defined variables for
total number of week ILI intensity level variables. Selection of the final ILI intensity
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level variable, representing influenza season severity as a progression of time across
geographical regions, is predicated on logistic regression coefficient and marginal effect
statistical significance levels, as determined by minimum standard error and p-value
computations, and confidence interval tests.
Fixed Effects Model Regression Equation (FEM): Logit (CIVUtis) = β0 + [β1 (ILI
Intensity Variablets)] + [β2 (SFEs)] + [β3 (TFEt)] + [β4 (Xtis)] + [β5 (State Factorsts)] + etis

4.2.4.c. Fixed Effects Model Estimation: NIS - Teen
The fixed effects model for NIS-Teen was executed on data for individuals across
the entire age range (13-17) for consecutive years initiating in 2008 and terminating in
2018. The outcome variable representing CIVU is defined as a teen who is completely
vaccinated and immunized based on CDC ACIP guidelines and regulations. Meaning that
completion of required dosages and injection sequences are incorporated into formulation
of this outcome measure as described in the CDC NIS user guide protocols and
definitions based on vaccine season recommendations from ACIP. An individual is
reported by providers as immunized when they are up-to-date for their vaccinations. This
is denoted in the NIS-Teen data by a series of UTD variables specifically related to the
influenza vaccine for each season. For individuals with adequate provider vaccination
information available, the seasonal variables were combined and integrated annually,
using each year systematically from 2008 to 2018, to generate a final measure of
complete vaccination. This variable symbolizes CIVU in the regression equation.
The FEM estimations possess two fixed effect control variables, those being for
states, and for seasons. The primary variable of interest will be as previously explained
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for NIS-Child, and will be the influenza disease progression variable. The sensitivity
analysis will be achieved using the exact systematic approach described for NIS-Child.
The additional covariates used in the regression were selected based on ubiquity,
pertinence, and frequency of previous usage among predecessor literary works and
publications, as well as pertinence predicated on CDC NIS user guide definitions and
recommendations. Covariates representing teen characteristics include age of the teen,
gender, race/ethnicity, insurance type, and translocation from a different state. Covariates
linked to maternal attributes include marriage status, age group, and education level.
Family characteristics included total number of children present, income level category as
a function of a percentage of the federal poverty line. Provider characteristics included
the providers facility classification type. State attributes included percentage poverty rate,
percentage unemployment rate, percentage uninsured below 65 years of age, percentage
with public health insurance below 65 years of age, and Medicaid eligibility thresholds
for parents, and infants 0 to 1 and 1 to 5 years of age respectively.
Fixed Effects Model Regression Equation (FEM): Logit (CIVUtis) = β0 + [β1 (ILI
Intensity Variablets)] + [β2 (SFEs)] + [β3 (TFEt)] + [β4 (Xtis)] + [β5 (State Factorsts)] + etis
Rational and decisions for regression variable and factor usage, formulation,
application, and incorporation were enhanced based on information and explanations
acquired regarding NIS data from electronic correspondence and consultation with data
experts and analysts at NORC. The empirical approach was enhanced based on similar
procedures performed in the previous literature, and predecessor studies which
implemented expressions similar to this studies estimation equations.
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4.3. Results
4.3.1. Descriptive and Summary Analysis
4.3.1.a. NIS-Child
The data sample for individuals ages 19 - 35 months consisted of 698,157 total
observations, with 29.34 % (204,855) between 19 - 23 months, 33.78 % (235,812)
between 24 - 29 months, and 36.88 % (257,490) between 30 - 35 months. Among the
sample, 26.35 % (183,982) received the influenza vaccine and possessed complete and
adequate provider records. Among this subsample, 32.77 % (60,294) were considered
immunized against the influenza virus as defined by ACIP regulations and protocols for
vaccine dosage sequence and administration. The division in frequency of observations
for the age ranges (19 - 23 months, 24 - 29 months, and 30 - 35 months) among this
subsample was 31.30% (18,870), 37.37 % (22,534), and 31.33 % (18,890) respectively.
Among immunized children with adequate provider verified vaccine records,
48.86 % (29,457) were female and 51.14 % (30,837) were male. Among the same
sample, 16.13 % (9,728) were Hispanic, 65.32 % (39,385) were Caucasian, 5.89 %
(3,553) were African American, and 12.65 % (7,628) were of another ethnicity. With
regard to first born status, 45.78 % (27,602) were the first child, and 54.22 % (32,692)
were not. With regard to relocation and mobility, 8.26 % (4,979) had relocated from
another state, and 91.74 % (55,312) had not.
With regard to marriage status of the mother and age, 81.25 %, (48,988) were
children of married mothers, and 18.75 % (11,306) were not, with 74.01 % (44,624) of
those mothers being over 30 years of age, and 25.99 % (15,670) being under 30 years of
age. Mothers education level was divided at 7.32 % (4,411) for less than high school
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achievement, 13.10 % (7,899) for high school graduate achievement, 20.12 % (12,132)
for some degree of university achievement, and 59.46 % (35,852) for university graduate
achievement.
With regards to the number of total children within the family unit, 29.87 %
(18,012) were single child families, 61.01% (36,786) were families with 2 to 3 children,
and 9.12 % (5,496) were families with 4 or more children. With regard to income to FPL
ratio status, 14.67 % (8,371) were below 100% of the FPL, 13.99 % (7,982) were
between 100 % to 199 % of the FPL, 13.50 % (7,706) were between 200 % to 299 % of
the FPL, and 57.84 % (33,005) were at or above 300 % of the FPL.
The provider facility type the child was administered the vaccine at was divided
such that 7.26 % (4,380) were at a public facility, 13.66 % (8,235) were at a hospital
facility, 62.08 % (37, 429) were at a private practice, 4.56 % (2,752) were at a military or
other type of facility, and 12.44 % (7,498) were at a hybrid or mixed facility.

4.3.1.b. NIS-Teen
The data sample for individuals ages 13 - 17 years consisted of 414,708 total
observations, with 19.52 % (80,956) at 13 years of age, 20.38 % (84,531) at 14 years of
age, 20.24 % (83,918) at 15 years of age, 20.58 % (85,359) at 16 years of age, and 19.28
% (79,944) at 17 years of age. Among the sample, 49.57 % (205,576) received the
influenza vaccine and possessed complete and adequate provider records. Among this
subsample, 21.35 % (43,895) were considered immunized against the influenza virus as
defined by ACIP regulations and protocols for vaccine dosage sequence and
administration. The frequency of observations based on ages (13 to 17 years) among this
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subsample was 23.95% (10,511), 22.21 % (9,750), 19.77 % (8,679), 18.60 % (8,163), and
15.47 % (6,792) respectively.
Among immunized children with adequate provider verified vaccine records,
48.23 % (21,171) were female and 51.77 % (22,724) were male. Among the same
sample, 15.01 % (6,587) were Hispanic, 65.53 % (28,765) were Caucasian, 8.53 %
(3,746) were African American, and 10.93 % (4,797) were of another ethnicity. With
regard to relocation and mobility, 22.42 % (9,840) had relocated from another state, and
77.58 % (34,055) had not.
With regard to marriage status of the mother and age, 75.20 %, (33,010) were
children of married mothers, and 24.80 % (10,885) were not, with 7.28 % (3,197) of
those mothers being at or under 34 years of age, and 39.26 % (17,233) being between 35
and 44 years of age inclusive, and 53.46 % (23,465) being at or above 45 years of age.
Mothers education level was divided at 10.14 % (4,449) for less than high school
achievement, 15.22 % (6,682) for high school graduate achievement, 24.18 % (10,616)
for some degree of university achievement, and 50.46 % (22,148) for university graduate
achievement.
With regards to the number of total children within the family unit, 35.29 %
(15,490) were single child families, 55.00 % (24,143) were families with 2 to 3 children,
and 9.71 % (4,262) were families with 4 or more children. With regard to income to FPL
ratio status, 15.61 % (6,459) were below 100% of the FPL, 15.12 % (6,254) were
between 100 % to 199 % of the FPL, 13.10 % (5,419) were between 200 % to 299 % of
the FPL, and 56.17 % (23,240) were at or above 300 % of the FPL.
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The provider facility type the child was administered the vaccine at was divided
such that 10.38 % (4,555) were at a public facility, 10.52 % (4,617) were at a hospital
facility, 48.17 % (21,143) were at a private practice, 8.11 % (3,561) were at a military or
other type of facility, and 22.82 % (10,019) were at a hybrid or mixed facility.

4.3.2. NIS-Child: Logistic Regression Analysis
4.3.2.a. Primary Analysis: Interrupted Time Series
The interrupted time series (ITS) regression targeting the H1N1 pandemic of 2009
yielded statistically significant coefficients for the primary variables of interest.
Execution of the delta-method margins procedure yielded post-estimation average
marginal effects (AMEs) for the primary variables of interest associated with the
pandemics occurrence. The H1N1 pandemics occurrence yielded a 12.57 percentage
point, 95% CI [10.28, 14.32], immediate level change increase in the probability of a
child being immunized, on average. It also yielded a 3.77 percentage point, 95% CI [4.32, -2.55], sustained slope change decrease in the probability of a child being
immunized annually, on average. Prior to the H1N1 pandemics occurrence, a 1.64
percentage point, 95% CI [1.47, 1.81], sustained increase in the probability of a child
being immunized annually, on average, was evident.
Restricted scale epidemic occurrences of the influenza virus yielded postestimation AMEs that were statistically significant. Occurrence of RSE 1 in 2012 yielded
a 1.79 percentage point, 95% CI [-2.22, 0.38], decrease in the probability of a child being
immunized, on average, followed by a 0.85 pp slope increase. Occurrence of RSE 2 in
2013 yielded a 5.23 percentage point, 95% CI [-6.27, -4.77], decrease in the probability
of a child being immunized, on average, followed by a 0.34 pp slope increase.
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Occurrence of RSE 3 in 2017 yielded a 1.92 percentage point, 95% CI [-2.74, -1.10],
decrease in the probability of a child being immunized, on average, followed by a 1.24 pp
slope increase. Refer to table 4.1 for ITS regression results pertaining to chief variables of
interest.
Table 4.1 – NIS Child H1N1 Pandemic ITS Regression: Variables of Interest

Pandemic Variables
Pre-H1N1 2009 Trend
H1N1 2009 Level
Post-H1N1 2009 Trend
RSE 1 2012 Level
Post-RSE 1 2012 Trend
RSE 2 2013 Level
Post-RSE 2 2013 Trend
RSE 3 2017 Level
Post-RSE 3 2017 Trend

AME
0.0164
0.1257
-0.0377
-0.0179
0.0085
-0.0523
0.0034
-0.0192
0.0124

SE
0.0009
0.0234
0.0030
0.0071
0.0005
0.0092
0.0003
0.0073
0.0006

z
18.83
7.53
-8.42
-1.46
15.58
-3.99
11.3
-3.68
21.45

P>z
0.0000
0.0000
0.0000
0.1500
0.0000
0.0000
0.0000
0.0000
0.0000

[95%
0.0147
0.1028
-0.0432
-0.0222
0.0074
-0.0627
0.0028
-0.0274
0.0112

CI]
0.0181
0.1432
-0.0255
0.0038
0.0096
-0.0477
0.0040
-0.0110
0.0135

The AME coefficients for the pre and post pandemic and epidemic trends and
their respective level changes are summarized above. The graphical depiction of the
segmented ITS estimation is illustrated in Figure 4.1. The dashed lines indicate
immediate level or intercept shifts, and solid lines signify trend or slope changes that
occurred respectively for each event point.
Execution of the segmented ITS estimation using the alternative flu vaccination
outcome (provider verified immunizations for the number of shots completed) yielded
statistically significant AME coefficients that corroborated the up-to-date outcome
regressions. The magnitude and direction of the AMEs for all pandemic and epidemic
variables were in agreement for both level and trend values, with the AME values slightly
greater in magnitude as compared to their counterparts (Table B.1).
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Figure 4.1 – Pandemic Piecewise ITS Regression Graphical Illustration

4.3.2.b. Sociodemographic Characteristics and Disparities (ITS):
The following segment is examining baseline differences relative to
sociodemographic factors, with positive differences indicating greater likelihoods of
immunization, and negative differences indicating lesser likelihoods of immunization, on
average (Table 4.2). Comparing average marginal effects (AMEs) between age subgroups
with 19-23 months as the reference category, ages 24-29 months experienced a 3.41%
point greater likelihood of immunization on average, 95% CI [2.93, 3.89], and ages 30-35
months experienced a 6.63% point greater likelihood of immunization on average, 95%
CI [6.05, 7.22]. With regards to gender differences, the AME was statistically
insignificant and no discernable disparities existed.
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With regards to ethnicity and race category, with Hispanic as the reference
subgroup, Caucasians experienced a 1.40% point greater likelihood of immunization on
average, 95% CI [0.75, 2.04], African Americans experienced a 5.59% point lesser
likelihood of immunization on average, 95% CI [-6.48, -4.69], other non-Hispanic
ethnicities possessed statistically insignificant differences.
Individuals who were the first born experienced a 4.00% point greater likelihood
of immunization on average compared to non-first born individuals, 95% CI [3.37, 4.62].
Individuals who had relocated from another state experienced a 6.00% point lesser
likelihood of immunization on average, 95% CI [-6.31, -4.89].
Mothers marital status being married was associated with a greater likelihood of
immunization by 2.24% points, on average, 95% [1.63, 2.85], as did a mothers age being
30 years of age or greater, at 5.33% points on average, 95% CI [4.81, 5.85]. For mothers
education level, with uneducated being the reference category, university graduates
experienced a 5.27% point greater likelihood of immunization on average, 95% CI [4.31,
6.23], and high school graduation and some degree of university achievement
experienced statistically insignificant differences.
For the number of children in the family unit, with one as the reference category,
families with two to three children experienced statistically insignificant differences, and
families with four or more experienced a 5.25% point on average lesser likelihood of
immunization, 95% CI [-6.21, -4.29]. For income to FPL ratio category, with less than
100% as the reference category, 100% to 199% of the FPL experienced statistically
insignificant differences, 200% to 299% of the FPL experienced a 1.93% point on
average greater likelihood of immunization, 95% CI [1.10, 2.76], and 300% of the FPL or
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greater experienced a 6.71% point on average greater likelihood of immunization, 95%
CI [5.91, 7.51].
Table 4.2 – NIS Child H1N1 Pandemic ITS Regression: Covariates
Covariates
Age (Ref: 19-23 months)
24-29 months
30-35 months
Gender (Ref: Male)
Female
Ethnicity (Ref: Hispanic)
Non-Hispanic Caucasian
Non-Hispanic AA
Non-Hispanic Other
Birth Order (Ref: No)
First Born
Mobility (Ref: No)
Relocated
Marital Status (Ref: No)
Married
Mother's Age (Ref: < 30)
30 years or over
Mother's Educ (Ref: < HS)
High School
Some College
College Graduate
Num of Children (Ref: 1)
2-3 Children
4+ Children
Inc to FPL (Ref: < 100%)
100 to 199% FPL
200 to 299% FPL
300% FPL or greater
Facility Type (Ref: Public)
Hospital Facility
Private Practice
Military/Other
Hybrid/Mixed

AME

SE

z

P>z

[95% CI]

0.0341 0.0024 13.9400 0.0000 0.0293 0.0389
0.0663 0.0030 22.2800 0.0000 0.0605 0.0722
0.0001 0.0021

0.0600

0.9510 -0.0041 0.0043

0.0140 0.0033 4.2500 0.0000 0.0075 0.0204
-0.0559 0.0046 -12.2300 0.0000 -0.0648 -0.0469
0.0049 0.0042 1.1700 0.2440 -0.0034 0.0132
0.0400 0.0032 12.5300 0.0000 0.0337 0.0462
-0.0560 0.0036 -15.4400 0.0000 -0.0631 -0.0489
0.0224 0.0031

7.1600

0.0000 0.0163 0.0285

0.0533 0.0026 20.1700 0.0000 0.0481 0.0585
-0.0059 0.0046 -1.2800 0.2000 -0.0150 0.0031
0.0008 0.0046 0.1700 0.8630 -0.0083 0.0098
0.0527 0.0049 10.7600 0.0000 0.0431 0.0623
-0.0043 0.0035 -1.2400 0.2160 -0.0111 0.0025
-0.0525 0.0049 -10.7500 0.0000 -0.0621 -0.0429
-0.0007 0.0037 -0.1800 0.8550 -0.0080 0.0066
0.0193 0.0042 4.5600 0.0000 0.0110 0.0276
0.0671 0.0041 16.3700 0.0000 0.0591 0.0751
0.0491
0.0523
0.0154
0.0427

0.0047 10.4000 0.0000 0.0398 0.0583
0.0039 13.3900 0.0000 0.0447 0.0600
0.0056 2.7700 0.0060 0.0045 0.0264
0.0047 9.0300 0.0000 0.0334 0.0519

97

With regards to the provider facility type the vaccine was administered at, public
facilities were the reference category, with hospital facilities experiencing a 4.91% point
greater likelihood of immunization, on average, 95% CI [3.99, 5.83]. Private practices
experienced a 5.23% point greater likelihood of immunization, on average, 95% CI [4.47,
6.00]. Military and other facility types experienced a 1.54% point greater likelihood of
immunization, on average, 95% CI [0.45, 2.64]. Hybrid and mixed facilities experienced
a 4.27% point greater likelihood of immunization, on average, 95% CI [3.34, 5.19]. Refer
to table 4.2 for ITS regression results pertaining to control variables. Differences
observed with regards to estimation covariates was consistent with expected and
predicted coefficients, and adhered to anticipated trends.
The heterogeneity for the sample was computed by subdividing the sample for
specific subgroups and executing logistic estimations for different subgroups separately.
This was achieved by applying commands to segregate the sample based on income to
FPL thresholds and ethnicity type (Table B.2). For ethnicity categories, with Hispanic as
the reference subgroup, Caucasian children were more likely to experience immunization
uptake, as were other ethnicities, and African Americans were less likely, on average.
This is consistent with expectations for ethnicity based variations, with African
Americans experiencing the least likelihood. For income to FPL ratio categories, with
less than 100% being the reference subgroup, if the income to FPL percent was greater
than 300%, the likelihood of experiencing immunization for a child increased
substantially, with the remaining categories experiencing greater likelihoods as compared
to the reference category, on average.
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4.3.2.c. Sensitivity Analysis: Fixed Effects Model Estimation
Fixed effects estimations were completed using fixed effect indicators for seasons
and states in addition to previously implemented covariates, and by substituting different
experimental ILI disease intensity and progression variables. The five subclasses
included activity levels greater than a certain threshold magnitude for disease intensity,
the total number of weeks the threshold limit was surpassed, and variations in intraseason time periods divided as early, peak, and late respectively, and interacted with the
other experimental variable subgroups. This was achieved for ILI intensity levels of 5 and
greater, specifically symbolizing epidemic and pandemic magnitude levels.
Executing regressions by systematically inserting individual experimental
variables measuring ILI intensity level and disease progression by state and season
yielded logit and average marginal effect coefficient values that were statistically
insignificant with the exception of a single variable in subgroup 5, which indicated a
decrease of 2.29% points, on average, in immunization rates during peak season weeks
registering at a ILI intensity magnitude of 9 or greater. Refer to Appendix A for
sensitivity analysis FEM regression results.

4.3.3. NIS-Teen: Logistic Regression Analysis
4.3.3.a. Primary Analysis: Fixed Effects Model Estimation
Fixed effects regressions were performed for the teen age group by executing and
implementing the same procedures and conventions. After executing regressions by
systematically inserting individual experimental variables measuring ILI intensity level
and disease progression by state and season yielded logit and average marginal effect
coefficient values that were statistically insignificant with the exception of three variables
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in subgroup 5. The first variable indicated a 1.31% point increase, on average, in
immunization rates during peak season weeks registering at a ILI intensity magnitude of
9 or greater. The second and third variables indicated a 0.135% point, and a 0.212% point
decrease, on average, in immunization rates during peak season weeks registering at a ILI
intensity magnitude of 8 and greater, or 10 and greater respectively. Refer to Appendix B
for primary analysis FEM regression results.

4.3.3.b. Sensitivity Analysis: Fixed Effects Model Estimation
Auxiliary fixed effects estimations were performed as an extension of primary
fixed effects regressions in order to isolate and ascertain intra-season variations and
effects of pandemic magnitude ILI intensity thresholds. This was achieved by
systematically interacting intra-season time phases with ILI threshold variables. AMEs
yielded following regressions for the maximum activity level, activity levels exceeding a
magnitude of 8, and activity levels exceeding a magnitude of 9, were statistically
significant during late segments of the influenza season. Respectively, AMEs were
0.2092% point, 95% CI [0.0038, 0.4145], 2.1965% point, 95% CI [0.0664, 4.3265], and
2.5850% point, 95% CI [0.2541, 4.9158], increases on average in immunization rates.
The reference category were influenza seasons that were below the pandemic ILI
intensity limit, and additionally did not surpass their specific maximum ILI intensity
thresholds during early (E), peak (P), or late (L) segments of the influenza season. AMEs
yielded following the remaining regressions were statistically insignificant and exhibited
no statistically discernable differences. Refer to table 4.3 for sensitivity analysis FEM
regression results.
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Table 4.3 – NIS Teen H1N1 Pandemic Sensitivity Analysis: FEM Regression

Period activitylevel_max activitylevel_8plus activitylevel_9plus activitylevel_10plus
E
0.000177
0.001233
0.001984
0.000417
P
0.000352
0.002662
0.003367
-0.006183
L
0.0020919*
0.0219645*
0.0258495*
0.020051
E*P
0.000555
0.007595
0.006216
-0.000043
P*L
-0.000759
-0.002945
-0.004138
-0.004690
E*L
-0.000548
-0.004513
-0.003350
-0.003787
E*P*L
0.000560
0.004346
0.001812
0.003227
* p < 0.05 ** p < 0.01 *** p < 0.001

4.4. Discussion
4.4.1. Recapitulation and Interpretation
Based on statistically significant AME coefficients computed following the ITS
regressions for the child sample, it is evident that the 2009 H1N1 pandemic was
associated with an initial increase in the probability of overall influenza immunization
uptake by parents, and subsequently followed by incremental annual decreases in the
same immunization outcome. The AME magnitude for the level change increase was
12.57 percentage points, on average, in the probability of immunization uptake for
children. The AME magnitude for the slope change decrease was 3.77 percentage points,
on average, in the probability of immunization uptake for children. The baseline trend
prior to the 2009 pandemic was a 1.64 percentage point, on average, increase in the
probability of immunization uptake by parents, on an annual basis.
It is also evident by the statistically significant AME coefficients for the 20122013, 2013-2014, and 2017-2018 restricted scale epidemics, that influenza seasons of
constrained epidemic scales yield level decreases in the probability of overall influenza
immunization uptake by parents. As demonstrated by the AME coefficients for RSE 1 in
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2012, RSE 2 in 2013, and RSE 3 in 2014, which demonstrate a 1.79 percentage point,
5.23 percentage point, and 1.92 percentage point, on average, decrease in the probability
of immunization uptake for children, respectively. The ensuing trend change increases
are 0.85 pp, 0.34 pp, and 1.24 pp, on average, respectively for each RSE.
Predicated on AME coefficients generated by the ITS estimation, it can be stated
that the 2009 H1N1 pandemic initially increased the probability of influenza
immunization uptake through psychological mechanisms of escalating fears of disease
contraction, and concerns regarding viral infection.18,30–32,83 It is also likely that shock
and awe impacts of the pandemics occurrence heightened parents perceptions regarding
the importance of the influenza vaccine and motivated them to pursue completion of
influenza vaccinations for their children.18 Uncertainties regarding potential clinical sideeffects, and possible ineffectiveness of vaccine formulations was most probably of lesser
concern as compared to the benefits of protection from infection from the influenza virus,
and prevention of disease contraction and mortality.100 It can additionally be speculated
that following the subsiding of initial pandemic linked concerns and fears about disease
contraction and ensuing morbidity, decision factors linked to assessment of influenza
vaccine effectiveness, efficiency, and risk of clinical side-effects, among others, became
incorporated in the immunization uptake decision process.11,45,100 Subsequently, erosions
in vaccine confidence and perceptions of effectiveness, diminished concerns regarding
risks of viral infection, and desensitization to pandemic progression and public health
warnings lead to incremental decreases in immunization uptake behavior.11,45,100
Evaluating the costs versus benefits of the influenza vaccine became less influenced by
initial pandemic trauma and distress.11,45,100 The degree of doubt and hesitancy regarding
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the vaccine likely escalated as well with the progression of time as individuals who were
immunized might have still contracted the virus, and this information propagated
throughout diffusion channels.11,45,50,100
For the RSE occurrences, the limited epidemics exhibit a converse relationship as
compared to the pandemic, with anti-immunization factors prominent initially, followed
by vaccination uptake promoting factors subsequently. The immediate intercept shifts are
notable, and the trend changes pre and post RSE occurrences are minimal. The RSE
occurrences relative to their vaccine uptake influences are in correspondence regardless
of temporal distance, with the consecutive RSEs (2012 and 2013) exemplifying the same
impact directionality as compared to the RSE of 2017.
Examining the sensitivity analysis FEM estimations for the child sample, it is
evident that the AME coefficients were statistically insignificant for the vast majority of
experimental variables for ILI intensity and disease progression by state and season. The
single highly statistically significant experimental indicator is among the pandemic
magnitude (high category ILI intensity level) variables during the peak intra-season phase
of the flu year. Evaluating the regressions in totality, it can be surmised that for the child
sample specifically, parental decisions to uptake influenza immunizations are not directly
influenced by influenza disease severity and progression by season and state. It is more
likely that vaccine uptake decisions and perceptions are influenced minimally by disease
severity on a weekly basis, in different states and geographical regions, and more so on a
national scale and larger scope basis. It is possible pandemics, with regards to parental
vaccination decisions, are viewed as a periodic occurrence as opposed to a disrupted and
dispersed occurrence.
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Examining the FEM estimation for the teen sample, it is evident that the AME
coefficients were statistically insignificant for the vast majority of experimental variables
for ILI intensity and disease progression by state and season. The statistically significant
experimental indicators are among the pandemic magnitude (high category ILI intensity
level) variables during the peak intra-season phase of the flu year. The peak flu season
segment, in conjunction with influenza weeks at pandemic ILI intensity levels of 8, 9,
and 10, yield statistically significant AME coefficients with fluctuating direction,
proceeding from decreasing to increasing to decreasing respectively. This demonstrates
that peak portions of the pandemic severity seasons, may experience oscillating changes
in vaccine uptake behavior for teens, and at minimum, that peak segments of pandemic
seasons are associated with a degree of effects on immunization uptake by parents for
their teens.
After evaluating the sensitivity analysis FEM estimations for the teen sample, it is
evident that they are statistically significant, with consistent increases in the probability
of immunization uptake occurring for pandemic severity seasons, specifically for their
late intra-season phases. For a pandemic severity season, the maximum activity level
week occurring during the late segment of the intra-season time phase yields a 0.21
percentage point increase, on average, in the probability of a teen being immunized. For a
pandemic severity season in its late phase, the ILI activity level exceeding an 8 or 9
threshold is associated with a 2.20 percentage point, and a 2.59 percentage point, increase
in the probability of a teen being immunized, on average. It can be surmised that for the
teen sample specifically, parental decisions to uptake influenza immunizations are
influenced by influenza disease severity and progression, by season and state, during
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peak and late segments of pandemic severity seasons only. With regards to the intraseason timing aspects, peak season uptake behavior is sporadic, while late season uptake
behavior is more consistent with minimal increases in the probability of a teen being
immunized.
The previous literature evaluating pertussis disease outbreaks by different states
attempted to exploit localized variations, and demonstrated escalating infection rates
were linked to uptake increases.23,89 This study determines that during severe influenza
seasons, very small increases in influenza vaccine uptake rates for different states are
evident, only for adolescents, with variations existing predominantly during later phases
of high intensity ILI seasons. This study also determines that for children, no statistically
significant effect is evident. This is different than the previous literature regarding
pertussis.23,89 As stated in the literature regarding pertussis outbreaks, perceptions of the
disease risk being greater are associated with increases in immunization completion.23,89
This association is not as evident for influenza pandemics, with escalating infection rates
being correlated with very small increases in immunization uptake, by state and season,
for adolescents only, and not for children.
The differences and discrepancies observed when comparing this study with the
pertussis study may be attributable to the infectious diseases being examined, and it may
be that pertussis affects vaccination uptake differently than influenza due to how the
infectious disease is perceived or how it progresses. The discrepancies may also be due to
the targeted age groups that were examined being different for the studies, with this study
examining young children and teens. The discrepancies may additionally be due to this
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study examining statewide measures of disease incidence as opposed to local instances
which is how the pertussis study performed its analysis.23,89
In the pertussis literature, access and costs were said to be involved in
determining vaccine uptake for severe seasons, and this may be the case for influenza as
well.23,89 In accordance with the previous literature regarding vaccine access and
availability as well as provider facility types, factors such as facility classification,
clinician-patient interactions, and vaccine availability may have influenced vaccine
uptake, and likely played a role during pandemic severity influenza seasons.50
Possibilities of vaccine shortages may have existed as well during these time periods, as
has been observed in the previous literature.53 These relationships however are postulated
for this study and cannot be ascertained.

4.4.2. Limitations
Limitations inherently associated with this study provide challenges in generating
definitive conclusions. The adjacent proximity of the consecutive LAIV advisements and
recommendations spanning from 2014 to 2016 produce complexities in delineating the
exact trend changes that exist pre and post policy implementation. Specifically for the
2014 post-policy phase, 2015 pre and post policy phases, and for the 2016 pre-policy
phase, the trend time periods intersect and are difficult to isolate for the ITS estimations.
This is a susceptibility of the ITS regression specification, and the ITS is vulnerable in
this respect. Implementing a segmented or piecewise ITS approach minimizes this
limitations effects and optimizes estimation results.
The study is limited by the absence of primary and secondary data measuring
perceptions of vaccine specific elements such as clinical safety, side effect risks,
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effectiveness, disease infection prevention capabilities, and disease susceptibility and
severity. The absence of psychologic data measuring aspects such as vaccine confidence
level, hesitancy, doubt, intent to vaccinate, concerns regarding infection by the virus, and
amplified anxiety and fears induced by the pandemics and epidemics are also a limitation.
Measurements for provider characteristics such as immunization availability and
accessibility, clinician and patient relationships, and clinician diffusion and dissemination
of vaccine information also limit this study. External factors such as societal norms and
beliefs are also difficult to integrate into this study due to lack of data measurements for
these aspects. The majority of these factors require qualitative study data that allow for in
depth analysis of these aspects.
Limitations pertaining to specific vaccine version supply and availability data
based on provider facility type and geographic region also reduce the ability to determine
if supply and access shortages existed for particular interview survey years. Limitations
pertaining to data source design aspects also generate complexities, such as interview
years not being subdivided into incremental time periods allowing for a greater number
of time points between consecutive annual time spans. This would permit for intra and
inter year trends to be examined with a greater degree of scrutiny.

4.5. Conclusion
The 2009 H1N1 influenza pandemic was associated with statistically significant
effects on parental decisions to uptake influenza immunizations for their children
(ages19-35 months). The pandemic was associated with an initial level change increase in
the probability of influenza immunization uptake, on average, for children. Subsequently,
annual declines in vaccination uptake ensued, as exhibited by the decreasing trend post
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pandemic. The baseline trend prior to the pandemic was a sustained annual increase, on
average, in the probability of immunization uptake by parents for children.
Restricted scale epidemic occurrences in 2012-2013, 2013-2014, and 2017-2018,
where the influenza season was constrained to epidemic scales, yielded decreases in the
probability of immunization uptake for children initially, followed by minimal increases
annually. Assessing the pandemic for children based on ILI intensity levels and disease
progression, while controlling for fixed effects for states and seasons, yielded minimal to
no effects on uptake behavior, with the exception of a single peak pandemic season
indicator.
Assessing the pandemic for teens based on ILI intensity levels and disease
progression, while controlling for fixed effects for states and seasons, yielded fluctuating
effects on uptake behavior for peak segments of pandemic magnitude seasons (intensity
levels 8, 9, and 10). Further sensitivity analysis examining intra-season phases in
conjunction with seasonal disease severity yielded consistent increasing effects on uptake
behavior for late segments of pandemic magnitude seasons.
The 2009 H1N1 influenza pandemic is linked to preliminary escalations in the
probability of child immunization uptake likely due to immediate fears of disease
contraction, concerns of viral infection, and trauma connected to shock and awe impacts
of the pandemics occurrence. These factors likely are paramount in the initial postpandemic decision phase, and supersede anti-uptake drivers such as uncertainties
regarding potential clinical side-effects, possible ineffectiveness of vaccine formulations,
and associated erosions in vaccine confidence, and ensuing hesitancy, and doubt.
Heightened parental perceptions regarding the importance of the vaccine likely motivates
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uptake initially, with the benefits of protection from infection from the influenza virus,
and prevention of disease contraction and mortality of chief importance.
Subsequently, initial pandemic linked concerns and fears about disease
contraction and ensuing morbidity subside, and decision factors linked to assessment of
influenza vaccine effectiveness, efficiency, and risk of clinical side-effects, become
integrated more prominently in the immunization uptake decision process, leading to
erosions in vaccine confidence and perceptions of effectiveness, and increasing hesitancy
and doubt regarding the vaccines advantages. Furthermore, it is speculated that
evaluation of the costs versus benefits of the influenza vaccine become less influenced by
initial pandemic trauma and distresses. This in conjunction with reduced concerns of viral
infection, and desensitization to the pandemics progression lead to gradual declines in
uptake behavior. Additionally, it is possible the degree of vaccine confidence declined
with the progression of time as individuals who were immunized still contracted the virus
and became infected.
Restricted scale epidemics are consistently associated with declines in
immunization uptake behavior for children initially, followed by nominal increases
annually. It is likely that RSEs do not generate the degree of initial trauma and shock that
pandemics such as the H1N1 generate, hence assessments of vaccination merits are
considered in the absence of pandemic linked distresses and fears. This possibly permits
factors such as vaccine effectiveness, risk of clinical side-effects, and immunization
hazards to supersede, in terms of importance, vaccine protection benefits from viral
infection, and prevention of morbidity. This altered perception may produce the observed
post RSE declines in uptake behavior for children.
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Immunization uptake behavior for children is likely not sensitive to ILI severity
and disease progression with respect to geography and time specifically, and may be
perceived as a grander scale occurrence disconnected from individual state and season
occurrences on a weekly basis. Immunization uptake behavior for teens is likely sensitive
to ILI severity and disease progression with respect to geography and time specifically,
with oscillating effects on uptake behavior exhibited for peak segments of pandemic
magnitude seasons, and consistent positive effects on uptake behavior exhibited for late
segments of pandemic magnitude seasons.
Public health immunization professionals and personnel should expect
preliminary increases in child immunization uptake behavior, followed by gradual
decreases in the same outcome for influenza pandemics such as H1N1. They should
anticipate decreases in child immunization uptake behavior following smaller scale
influenza epidemics. For pandemic intensity ILI seasons, immunization uptake behavior
is not sensitive to weekly fluctuations in ILI severity for children, but sensitive for teens
during peak and late phases of the influenza season, with fluctuating uptake behavior
associated with peak season phases, and consistent increases in uptake behavior
associated with late season phases.
This study contributes to the existing literature by enhancing the understanding of
how vaccine uptake rates change following pandemic and epidemic events. However it is
limited in determining why these changes occur, and due to what factors and mechanisms
specifically, which future studies should attempt to discern and ascertain.
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CHAPTER 5

THE 2015 LAIV POLICY SHIFT:
ASSESSING IMPACTS ON IMMUNIZATION1

1

A.H. Mehrabi, N.L. Hair, C.M. Andrews, S.E. Harrison, R.D. Horner. To be submitted
to American Journal of Public Health.
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Abstract
Introduction: The 2015 Centers for Disease Control and Prevention’s (CDC)
Advisory Committee on Immunization Practices (ACIP) retraction of its original
preferential recommendations for usage of the live attenuated influenza vaccine (LAIV),
which is the intra-nasal version of the vaccine, has resulted in varied responses, with
fluctuations in ensuing CDC vaccine advisements affecting its implementation and
uptake among children. Although the CDC’s ACIP recommend an annual flu vaccine for
individuals 6 months of age and older as the “first and best” defense against influenza, a
low percentage of children are vaccinated, and parental decisions are not completely
comprehended, particularly in regards to the LAIV formulation. Reviewing the literature,
in certain studies a decline in flu vaccine uptake was concluded, whereas in other
instances, it conversely increased, or remained static, yielding inconsistent outcomes.
Furthermore, there exists a void in the number, scale, and scope of studies published,
with none being nationally representative, and examining parental perspectives,
decisions, and responses in regard to child flu vaccine uptake following the 2015 ACIP
LAIV policy shift.
Methods: To assess impacts of the 2015 ACIP LAIV preferential
recommendation revocation on decisions to uptake influenza vaccines for children age 6
months to 17 years of age, data from NIS was used as a series of weighted consecutive
annual surveys in order to synthesize a longitudinal panel dataset spanning from 2003 to
2018. Quasi-experimental (QE) approaches in the form of segmented interrupted time
series (ITS), and difference in differences (DID) logistic estimations were executed on
the integrated dataset yielding logistic regression coefficients and post-estimation
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marginal effects signifying the impact of the 2015 ACIP LAIV policy shift on child
influenza vaccine uptake (CIVU). ITS regressions examined both level and trend changes
due to policy shift occurrence via binary and continuous policy shift incidence variables
respectively. DID regressions incorporated LAIV eligibility indicators to ascertain the
level and trend differences in CIVU between LAIV eligible (age 2 years and greater), and
LAIV ineligible (age 6 to 23 months) individuals, pre and post policy shift. This
additionally allowed for ascertainment of spillover effects and impacts of the policy shift
on individuals who were only eligible for the injected influenza vaccine (IIV)
formulation. Vaccine specific ITS estimations for individual formulations were executed
applying previous procedures, in addition to regressions assessing heterogeneity effects.
Results: The segmented interrupted time series (ITS) regression for the NISChild sample yielded statistically significant coefficients. Post-estimation average
marginal effects (AMEs) were as follows. The LAIV preferential recommendation
revocation yielded a 3.01 percentage point (pp), 95% CI [2.54, 4.74], immediate level
change increase in the probability of a child being immunized, on average. It also yielded
a 2.41 pp, 95% CI [-2.62, -2.11], sustained slope change decrease in the probability of a
child being immunized annually, on average. Pre-policy shifts, a 2.06 pp, 95% CI [1.91,
2.22], sustained increase in the probability of a child being immunized annually, on
average, was evident. The LAIV preferential recommendation of 2014, and the
subsequent LAIV recommendation rescindment of 2016, respectively yielded a 5.25 pp
decrease, 95% CI [-7.05, -3.25], and a 1.02 pp increase, 95% CI [0.55, 1.12], in the
probability of a child being immunized, on average. The respective trend changes post-
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policy shifts were a 1.21 pp increase, 95% CI [1.11, 1.31], and a 5.30 pp decrease, 95%
CI [-6.22, -4.38], on average.
The sensitivity analysis difference in differences (DID) estimation yielded
statistically significant coefficients. Comparing the differences between LAIV-eligible
and LAIV-ineligible individuals, pre and post 2015 policy shift, yielded a DID of 20.70
pp, 95% CI [19.52, 21.88], indicating an increase occurred in the probability of a LAIVeligible child being immunized as compared to an LAIV-ineligible child, on average,
following the 2015 policy shift. Examining the LAIV-eligibility indicator’s AME, it is
evident that an LAIV-eligible child experiences a 1.34 pp, 95% CI [0.64, 2.03], increase
in the probability of being immunized, on average, as compared to an LAIV-ineligible
child.
The segmented interrupted time series (ITS) regression for the NIS-Teen sample
yielded statistically significant coefficients. Post-estimation AMEs are as follows. The
LAIV preferential recommendation revocation yielded a 4.25 pp, 95% CI [2.31, 6.22],
immediate level change increase in the probability of a teen being immunized, on
average. It also yielded a 3.02 pp, 95% CI [-4.77, -2.33], sustained slope change decrease
in the probability of a teen being immunized annually, on average. Pre-policy shifts, a
2.70 pp, 95% CI [2.12, 3.16], sustained increase in the probability of a teen being
immunized annually, on average, was evident. The LAIV preferential recommendation of
2014, and the subsequent LAIV recommendation rescindment of 2016, respectively
yielded a 8.41 pp decrease, 95% CI [-10.35, -6.41], and a 6.52 pp decrease, 95% CI [8.21, -4.42], in the probability of a teen being immunized, on average. The respective

114

trend changes post-policy shifts were a 7.17 pp increase, 95% CI [6.11, 8.58], and a 2.84
pp increase, 95% CI [1.96, 3.71], on average.
Conclusion: The 2015 policy shift was associated with preliminary increases in
vaccine uptake, followed by annual declines, for both children and teens. Reductions in
overall immunization uptake following the preceding 2014 policy shift, and subsequent
2016 policy shift were evident, for both samples for 2014, and teens for 2016. Public
health policies concerning influenza immunization for children and adolescents should
concentrate on refraining from issuing preferential advisements for either vaccine
formulation if possible. Immunization policies should focus on consistent and stable
annual advisements, which may promote greater trust in immunization policies. This
study contributes to the existing literature by enhancing the understanding of how vaccine
uptake rates change following policy shifts. However it is limited in determining why
these changes occur, and due to what factors and mechanisms specifically, which future
studies should attempt to discern and ascertain.

5.1.

Introduction
Each year millions of children in the U.S. experience influenza-related illness.

Although most children infected with influenza viruses recover within a week, serious
complications can result in hospitalization or death.1 Currently, the Centers for Disease
Control and Prevention (CDC), and its Advisory Committee on Immunization Practices
(ACIP) recommend an annual flu vaccine for individuals 6 months of age and older as
the “first and best” defense against influenza.2,3 Nevertheless, only 45.6% of children 6
months to 17 years of age received the vaccine in 2018 – 2019, and even less at 38.8% in
2017-2018.4 Understanding parental attitudes and barriers associated with uptake of
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childhood immunization is a crucial national public health priority. This process is
complex, as numerous socioeconomic, psychological, demographic, and contextual
factors influence vaccine uptake rates.5–9 Doubts regarding vaccine benefits,10 concerns
regarding side-effects and safety,5,11–17 perceived disease seriousness and risk
assessment,11,15,16,18,19 uncertainties about vaccine effectiveness,8,11,12,20,21 and healthcare
access and costs,7,8,14,22,23 are prime influencers and factors affecting immunization
uptake.
The effects of policy shifts on parental perceptions and decisions to uptake
immunizations in the U.S. are not completely understood, with conflicting, and
inconsistent conclusions, 5,11,19,23–26 specifically for child flu vaccines. This study
overcame these shortcomings and contributes to a better understanding of how parental
uptake is affected by these aforementioned factors by examining the 2015 ACIP live
attenuated influenza vaccine (LAIV) preferential advisement revocation. The policy shift
served as a point of analysis to determine how parental uptake for child flu vaccines may
have shifted through different mechanisms. This study has parallels to past research that
has examined the controversies regarding other diseases, health conditions, and vaccine
formulation elements. These include the measles, mumps, rubella and Autism dilemma,
and thimerosal presence in vaccines debate, where child vaccination rates shifted due to
false scares, ensuing spillover effects, incorrect conclusions, and parental inability to
critically analyze and decipher vaccine information.5,13,24,27
The 2015 CDC ACIP retraction of its original preferential recommendations for
usage of the LAIV, which is the intra-nasal version of the vaccine for children, 21,25,26,33–37
has resulted in varied responses, with fluctuations in ensuing CDC vaccine advisements

116

affecting its implementation and uptake among children.25,33,38,39 Reviewing the literature,
in certain studies a decline in flu vaccine uptake was concluded,33 whereas in other
instances, it conversely increased,26 or remained static,25 yielding inconsistent outcomes.
There is a void in the number, scale, and scope of studies published with none being
nationally representative and examining parental perspectives, decisions, and responses
in regard to child flu vaccine uptake following the ACIP LAIV withdrawal.
Given the aforementioned, the question arises as to what was the policy impact of
the 2015 ACIP LAIV withdrawal on overall child influenza vaccination uptake rates in
the U.S.? It is postulated that the 2015 ACIP LAIV withdrawal increased overall child
influenza vaccine uptake rates.
This study is novel and innovative as it is the first nationally extensive study
assessing the potential impacts of the 2015 LAIV withdrawal on overall child flu vaccine
rates over a substantial time range using the National Immunization Survey (NIS)
focusing specifically on children. It is the first to evaluate parental decisions to vaccinate
their children against the flu by considering changes in parental uptake of child influenza
immunizations, following consecutive and evolving ACIP recommendations and
advisements. This study is significant, as it is an improved assessment of the LAIV
withdrawals, and assists in addressing the shortcomings of predecessor publications. It is
significant, as it provides a preliminary understanding of how CDC policy shifts may
impact decision making for uptake of child flu vaccines within the U.S., permitting public
health policymakers to increase future child flu vaccine uptake by anticipating how
parental perspectives and decisions may alter following future ACIP advisements and
recommendations.
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5.2.

Description of Project Design and Methodological Approach
The primary purpose of this project is to advance understanding of how influenza

immunization policy shifts affect parental perspectives and decisions regarding child flu
vaccine uptake. By examining marginal effects for completion of child flu vaccines
following the occurrence of the 2015 LAIV policy shift we evaluated these impacts.
Analysis was achieved by executing logistic regression models, specifically by
implementing an interrupted time-series (ITS) empirical approach, with a quasiexperimental design strategy for the estimations, using STATA 16 statistical software.
Provider-verified immunization histories from a state and nationally representative
dataset served as the basis for performing these statistical estimations.
The 15-year time span from 2003 to 2018 was examined for this study,
encompassing the 2015 ACIP LAIV preferential recommendation revocation completely
and sufficiently. The time period of analysis commences in 2003, since that is the
preliminary year where the IIV formulation’s universal recommendation and application
would be realized following the ACIP’s decision.
It is also the year where the LAIV formulation of the immunization was accepted
and authorized for usage by the ACIP. The time period of analysis terminates in 2018 as
that is the most recent year available for analysis. The data was aggregated, and compiled
for analysis by merging separate annual surveys consecutively into a single dataset. The
final version of the data was a series of repeated cross-sections based on annually
completed NIS surveys. This generated dataset emulated longitudinal and panel data
sources, and allowed for minimization of bias, while reinforcing estimation of a
correlation relationship that is representative of a larger scale heterogeneous population.85
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Sensitivity analyses in the form of auxiliary ITS estimations, implementing a difference
in differences (DID) designation, for the LAIV policy shift, were performed in order to
corroborate and validate results yielded by the primary logistic regressions.
Specific Aim 2: To ascertain the policy effects of the 2015 ACIP LAIV
preferential recommendation revocation on overall child influenza vaccination uptake
rates in the U.S. by assessing changes in the likelihood that a child is vaccinated for
influenza following the policy shift event.
H2: The 2015 ACIP LAIV preferential recommendation revocation is expected to
decrease the likelihood of overall child influenza vaccine uptake. In accordance with the
previous literature, and this studies conceptual model, provider dissemination of
immunization information, based on ACIP advisements, will likely reduce vaccine
uptake, since LAIV will not be recommended as the preferred option to parents by
providers.

5.2.1. Data Sources
The data source used for this study was the National Immunization Survey (NIS),
which is conducted by the CDC’s National Center for Immunization and Respiratory
Diseases (NCIRD) in order to monitor immunization coverage. It is nationally
representative and comprehensive including flu vaccination data for children 6 months –
17 years of age for all 50 states and additional U.S. territories.86 NIS consists of a
combination of NIS-Child (ages 19-35 months), and NIS-Teen (ages 13-17 years).86 NIS
offers national, state, and local level data, provided directly from the child’s providers
(NIS-Child and NIS-Teen consist of provider-verified immunization measures),
bolstering its accuracy and validity.86 It contains information regarding the types of
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vaccines administered to children, their dates and dosages, demographic, socioeconomic,
geographic, and insurance data, as well as administrative data related to providers and
facilities where the procedures were performed.86

5.2.2. NIS Sampling Procedures, Weighting, and Response Rates
NIS-Child and NIS-Teen conduct sampling in a two phased and tiered approach.
In phase one, the data collection procedure is to attain immunization information for a
national probability sample of children, by performing random digit dialing (RDD)
within each of the statistical sampling strata in order to identify eligible subjects.86 The
interviewers request permission to contact the vaccination provider of the qualified child,
and subsequently, a mailed survey is sent to the designated clinician. In phase two, the
provider record check (PRC) survey is completed, and allows for confirmation and
verification of the phase one questionnaire responses.86 Overall this allows for
vaccination statistics that are comparable across geographic territories, with the progress
of time, and promotes minimization of bias that may exist.86
NIS-Child and NIS-Teen possess weighting processes and procedures that adjust
for variation in sampling rates, differences and discrepancies in response rates, and
variations in representation in the sample relative to the overall population being
assessed.86 This allows for improved accuracy of estimates at various sampling levels.
The estimates and variance approximations are generated for separate areas, states, and
sampling subdivisions. Weight imputations are performed for the survey as necessary.86
The anticipated NIS-Child sample size for completed interviews is approximately
25,000 addresses, on average.86 The annual response rate of NIS-Child is approximately
65 percent of eligible subjects within the sample, on average, for the parent response

120

segment.86 The rate of children with adequate provider data available is approximately 70
percent, on average.86
The anticipated NIS-Teen sample size for completed interviews is approximately
35,000 addresses, on average.86 The annual response rate of NIS-Teen is approximately
60 percent of eligible subjects within the sample, on average, for the parent response
segment.86 The rate of children with adequate provider data available is approximately 70
percent, on average.86

5.2.3. General Regression Model Components and Estimation Elements
Outcome (Dependent) Variable: CIVU (Child Influenza Vaccine Uptake) denotes
whether the child was administered and received the influenza vaccine. This is a binary
“Yes” or “No” outcome measure represented by 1 or 0 respectively.
Primary Variables of Interest: The LAIV 2015 level change variable denotes the
initial occurrence of the policy shift, with its coefficient demonstrating the immediate
level change with respect to CIVU. This is binary and symbolizes the incidence of the
policy shift. The LAIV 2015 slope change variable is a continuous variable arising from
the interaction between the normalized time variable (T) and the policy point indicator
variable. It denotes the ensuing trend occurrence in the post policy phase, with its
coefficient demonstrating the subsequent slope change with respect to CIVU.
Predictive (Independent) Variables: Child sex, age, birth order, race/ethnicity,
relocation/mobility comparing state of birth and current location, maternal age, education
level, marital status, insurance type, family income level, and provider/clinician facility
type. These covariates are in concordance with previously applied conventions among
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predecessor studies, and are standard across previously completed studies published in
the literature.
Additional Control Factors: State level characteristics that vary with time, state
level policy and mandate differences, occurrence of the H1N1 influenza pandemic,
restricted scale epidemic occurrences of the influenza virus (RSEs), and CDC ACIP
influenza vaccine policy shifts. Time-variant state level attributes specifically include:
Unemployment rates, retrieved from the Bureau of Labor Statistics (BLS); Poverty rates,
retrieved from the U.S. Census; Health insurance coverage rates subdivided between
percentage private, public, and uninsured, retrieved from the U.S. Census; Medicaid
income eligibility thresholds as a function of a percentage of the Federal Poverty Level
(FPL), retrieved from the Kaiser Family Foundation (KFF). These will be merged into
the primary data source via each states Federal Information Processing Standard (FIPS)
code identifiers, which will serve as channels for cross matching state by year control
data.
Associated Terms: Beta coefficients specify the impact, or marginal effect, of
their corresponding variable in regards to the outcome variable CIVU.
Cross Sections Examined: Individuals are examined in conjunction with time
progression in years for different states.
Covariate Coefficient Measures: Coefficients were examined, and subsequently
interpreted, in order to assess if baseline disparities existed, and if further disparities
existed beyond those due to standard inherent heterogeneity, for certain covariates. This
signified if the disparities and heterogeneity were attributable to the event occurrence
specifically, or if they were naturally occurring by default.
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Interpretation of Coefficients: The interpretation of the beta coefficients are as
follows. If the marginal effect yielded is a positive value, this indicates that the event of
interest increased the predicted probability of the outcome occurring, which is child flu
vaccine uptake by parents. If the marginal effect yielded is a negative value, this indicates
that the event decreased the predicted probability of the outcome occurring. If the
marginal effect equals zero, or is nearly zero, this signifies the event had no impact, or
minimal impact respectively. The magnitude of the marginal effect regardless of
directionality and sign exemplifies the degree of impact of the event of interest on the
outcome, with greater measures corresponding to larger impacts, without exceeding the
limit of 1 as the maximum value.

5.2.4. Regression Model Structures, Designations, and Specifications
The interrupted time series and difference in difference models are the two
primary methodological designations that were implemented in order to execute the
logistic regressions on the immunization data. Following the logistic regression
estimations, post estimation commands for predicted probability and marginal effect
computations will be executed.

5.2.4.a. Segmented Interrupted Time Series Estimation: NIS - Child
The segmented interrupted time series estimation was executed on NIS-Child data
for individuals across the entire age range (19-35 months) for consecutive years initiating
in 2003 and terminating in 2018. Due to the difficulty in isolating the effects of the 2015
policy point individually, it is necessary to account for the 2014 and 2016 policy shifts as
well. In order to accomplish this, the ITS estimation was executed as a segmented or
piecewise regression as opposed to a regular ITS estimation. The segmented ITS
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regression incorporates multiple temporal periods (pre-2014, 2014 to 2015, 2015 to 2016,
and post-2016) in order to compute the estimates for both level and slope changes for
individual policy shifts. This model allows for slope as well as intercept changes to be
calculated for each of the three policy points, while controlling for concomitant factors.
The regression equation included concomitant event control indicators for the
H1N1 influenza pandemic of 2009, and the three restricted scale epidemics (RSE 1, RSE
2, RSE 3) corresponding to the 2012-2013, 2013-2014, and 2017-2018 influenza seasons
respectively. All contemporaneous influenza vaccination influencing events are coded as
categorical variables corresponding to the initial year of the contemporaneous events
season of occurrence.
This is due to the NIS survey design being such that it is conducted from the
January of the initial year to the February of the subsequent year, hence the year variable
represents the interview year, or the year survey conduction commenced.86,94 This is the
initial year of the influenza season, which is of interest, since the vast majority of
vaccination happens during the months of September to February of each influenza
season.95,96 This allows for capturing of influenza vaccine uptake behavior during the
major vaccine completion portion of the year, spanning this intra-season time period.
This also allows the post policy period effects of the contemporaneous policy shifts to be
captured effectively since the ACIP policy decisions are completed in the preceding
summer months, and regulations and protocols are subsequently disseminated to
clinicians and providers for the upcoming season, permitting ample time for the effects of
the policy shift to be realized.70,98 Predecessor vaccine studies have implemented this
convention for analysis purposes, as it is established in the literature.
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The outcome variable representing CIVU is defined as an child who is completely
vaccinated and immunized based on CDC ACIP guidelines and regulations. Meaning that
completion of required dosages and injection sequences are incorporated into formulation
of this outcome measure as described in the CDC NIS user guide protocols and
definitions based on vaccine season recommendations from ACIP. An individual is
reported by providers as immunized when they are up-to-date for their vaccinations. This
is denoted in the NIS-Child data by a series of provider up-to-date (UTD) variables
specifically related to the influenza vaccine. To reflect CDC ACIP decisions and
adjustments in advisements, the final up-to-date variable used in this estimation is
comprised of different immunization variables recorded in NIS-Child. From the time
period between 2003 to 2006, one variable is used, followed by another from 2007 to
2013, in order to reflect the revised definition of vaccinated by ACIP, followed by a final
variable from 2014 to 2018, which was synthesized based on ACIP chart guidelines
defining complete immunization. This was achieved using the intermediate variable
denoting the provider reported measure for total number of vaccinations completed per
cycle to date.
The alternative outcome variable that was implemented in supplementary ITS
estimations used the provider verified immunization measure for the total number of
shots completed. The outcome in the alternative regressions was coded as a binary
variable with 0 corresponding to no dosages received, and 1 corresponding to greater than
or equal to 1 dosage received.
The additional covariates used in the regression were selected based on ubiquity,
appositeness, and frequency of previous usage among predecessor literary works and
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publications, as well as pertinence predicated on CDC NIS user guide definitions and
recommendations. Covariates representing child characteristics include age group of the
child, gender, race/ethnicity, birth order status, and translocation from a different state.
Covariates linked to maternal attributes include marriage status, age group, and education
level. Family characteristics included total number of children present, income level
category as a function of a percentage of the federal poverty line. Provider characteristics
included the providers facility classification type. State attributes included percentage
poverty rate, percentage unemployment rate, percentage uninsured below 65 years of age,
percentage with public health insurance below 65 years of age, and Medicaid eligibility
thresholds for parents, and infants 0 to 1 and 1 to 5 years of age respectively.
Interrupted Time Series Regression Equation (ITS): Logit (CIVUtis) = β0 + [β1
(Tts)] + [β2 (H1N1ts)] + [β3 (LAIV 2014ts)] + [β4 (LAIV 2015 Levelts)] + [β5 (LAIV 2015
Slopets)] + [β6 (LAIV 2016ts)] + [β7 (RSEts)] + [β8 (Xtis)] + [β9 (State Factorsts)] + etis

5.2.4.b. Difference in Differences Estimation: NIS - Child
The difference in differences (DID) estimation function executed on NIS-Child
was identical to the ITS estimation function executed on NIS-Child except the DID
regression equation integrated additional treatment versus control subgrouping variables
in conjunction with the pre-existing ITS time phase variables. The treatment cohort is
designated as those individuals who are eligible to receive the LAIV formulation in
addition to the standard IIV version (infants greater than 2 years or 24 months of age).
The control cohort is designated as those individuals who are candidates to receive the
IIV formulation only (infants 6 to 23 months of age).
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To establish these cohort divisions necessary for the DID estimation, a binary
categorical treatment (LAIV eligible) vs control (LAIV non-eligible) cohort assignment
variable is generated, with a value of 0 corresponding to individuals in the age range
between 19 to 23 months, and a value of 1 corresponding to individuals in the age range
between 24 to 35 months. The intermediary variable for age subgroup was used to
achieve this segregation. The treatment versus control subgroup assignment variable’s
beta coefficient symbolizes the baseline difference comparing LAIV eligible to noneligible individuals, with respect to the outcome variable CIVU.
The variable DID is generated to compute the trend difference between LAIV
eligible versus non-eligible individuals, pre and post policy point, also termed the
difference between differences comparing treatment versus control subgroups, across the
time phases. The DID variable is synthesized by interacting the policy point time phase
variable, with the LAIV eligibility variable. The beta coefficient for the DID variable
symbolizes the difference in trends comparing LAIV eligible to non-eligible individuals,
pre and post 2015 policy shift, with respect to the outcome variable CIVU. The calculated
beta coefficient value signifies the degree of impact of the policy on vaccination rates for
LAIV eligible individuals, and also ascertain whether spillover effects were experienced
by LAIV non-eligible individuals with respect to CIVU, as an unintended consequence of
the 2015 LAIV advisement.
Difference in Differences Regression Equation (DID): Logit (CIVUtis) = β0 + [β1
(H1N1ts)] + [β2 (LAIV 2014ts)] + [β3 (LAIV 2015ts)] + [β4 (LAIV 2016ts)] + [β5 (LAIV
Eligibletis)] + [β6 (DIDtis)] + [β7 (RSEts)] + [β8 (Xtis)] + [β9 (State Factorsts)] + etis

127

5.2.4.c. Segmented Interrupted Time Series Estimation: NIS - Teen
The segmented interrupted time series estimation for teens was executed on NISTeen data for individuals across the entire age range (13 to 17 years) for consecutive
years initiating in 2008 and terminating in 2018. Due to the difficulty in isolating the
effects of the 2015 policy point individually, it was necessary to account for the 2014 and
2016 policy shifts as well. In order to accomplish this, the ITS estimation was executed
as a segmented or piecewise regression as opposed to a regular ITS estimation. The
segmented ITS regression incorporates multiple temporal periods (pre-2014, 2014 to
2015, 2015 to 2016, and post-2016) in order to compute the estimates for both level and
slope changes for individual policy shifts. This model allows for slope as well as
intercept changes to be calculated for each of the three policy points, while controlling
for concomitant factors.
The regression equation included concomitant event control indicators for the
H1N1 influenza pandemic of 2009, and the three restricted scale epidemics (RSE 1, RSE
2, RSE 3) corresponding to the 2012-2013, 2013-2014, and 2017-2018 influenza seasons
respectively. All contemporaneous influenza vaccination influencing events are coded as
categorical variables corresponding to the initial year of the contemporaneous events
season of occurrence.
This is due to the NIS survey design being such that it is conducted from the
January of the initial year to the February of the subsequent year, hence the year variable
represents the interview year, or the year survey conduction commenced.86,94 This is the
initial year of the influenza season, which is of interest, since the vast majority of
vaccination happens during the months of September to February of each influenza
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season.95,96 This allows for capturing of influenza vaccine uptake behavior during the
major vaccine completion portion of the year, spanning this intra-season time period.
This also allows the post policy period effects of the contemporaneous policy shifts to be
captured effectively since the ACIP policy decisions are completed in the preceding
summer months, and regulations and protocols are subsequently disseminated to
clinicians and providers for the upcoming season, permitting ample time for the effects of
the policy shift to be realized.70,98 Predecessor vaccine studies have implemented this
convention for analysis purposes, as it is established in the literature.
The outcome variable representing CIVU is defined as a teen who is completely
vaccinated and immunized based on CDC ACIP guidelines and regulations. Meaning that
completion of required dosages and injection sequences are incorporated into formulation
of this outcome measure as described in the CDC NIS user guide protocols and
definitions based on vaccine season recommendations from ACIP. An individual is
reported by providers as immunized when they are up-to-date for their vaccinations. This
is denoted in the NIS-Teen data by a series of provider verified up-to-date variables
specifically related to the influenza vaccine for each season. For individuals with
adequate provider vaccination information available, the seasonal up-to-date variables
were combined and integrated annually, using each year systematically from 2008 to
2018, to generate a final measure of complete vaccination. This variable symbolizes
CIVU in the regression equation.
The alternative outcome variable that was implemented in supplementary ITS
estimations used the provider verified immunization measure for the total number of
shots completed. The outcome in the alternative regressions was coded as a binary
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variable with 0 corresponding to no dosages received, and 1 corresponding to greater than
or equal to 1 dosage received.
The additional covariates used in the regression were selected based on ubiquity,
appositeness, and frequency of previous usage among predecessor literary works and
publications, as well as pertinence predicated on CDC NIS user guide definitions and
recommendations. Covariates representing teen characteristics include age of the teen,
gender, race/ethnicity, insurance type, and translocation from a different state. Covariates
linked to maternal attributes include marriage status, age group, and education level.
Family characteristics included total number of children present, income level category as
a function of a percentage of the federal poverty line. Provider characteristics included
the providers facility classification type. State attributes included percentage poverty rate,
percentage unemployment rate, percentage uninsured below 65 years of age, percentage
with public health insurance below 65 years of age, and Medicaid eligibility thresholds
for parents, and infants 0 to 1 and 1 to 5 years of age respectively.
Interrupted Time Series Regression Equation (ITS): Logit (CIVUtis) = β0 + [β1
(Tts)] + [β2 (H1N1ts)] + [β3 (LAIV 2014ts)] + [β4 (LAIV 2015 Levelts)] + [β5 (LAIV 2015
Slopets)] + [β6 (LAIV 2016ts)] + [β7 (RSEts)] + [β8 (Xtis)] + [β9 (State Factorsts)] + etis
Rational and decisions for regression variable and factor usage, formulation,
application, and incorporation were enhanced based on information and explanations
acquired regarding NIS data from electronic correspondence and consultation with data
experts and analysts at NORC. The empirical approach was enhanced by similar
procedures implemented by predecessor studies.
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5.3. Results
5.3.1. Descriptive and Summary Analysis
5.3.1.a. NIS-Child
The data sample for individuals ages 19 - 35 months consisted of 698,157 total
observations, with 29.34 % (204,855) between 19 - 23 months, 33.78 % (235,812)
between 24 - 29 months, and 36.88 % (257,490) between 30 - 35 months. Among the
sample, 26.35 % (183,982) received the influenza vaccine and possessed complete and
adequate provider records. Among this subsample, 32.77 % (60,294) were considered
immunized against the influenza virus as defined by ACIP regulations and protocols for
vaccine dosage sequence and administration. The division in frequency of observations
for the age ranges (19 - 23 months, 24 - 29 months, and 30 - 35 months) among this
subsample was 31.30% (18,870), 37.37 % (22,534), and 31.33 % (18,890) respectively.
Among immunized children with adequate provider verified vaccine records,
48.86 % (29,457) were female and 51.14 % (30,837) were male. Among the same
sample, 16.13 % (9,728) were Hispanic, 65.32 % (39,385) were Caucasian, 5.89 %
(3,553) were African American, and 12.65 % (7,628) were of another ethnicity. With
regard to first born status, 45.78 % (27,602) were the first child, and 54.22 % (32,692)
were not. With regard to relocation and mobility, 8.26 % (4,979) had relocated from
another state, and 91.74 % (55,312) had not.
With regard to marriage status of the mother and age, 81.25 %, (48,988) were
children of married mothers, and 18.75 % (11,306) were not, with 74.01 % (44,624) of
those mothers being over 30 years of age, and 25.99 % (15,670) being under 30 years of
age. Mothers education level was divided at 7.32 % (4,411) for less than high school
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achievement, 13.10 % (7,899) for high school graduate achievement, 20.12 % (12,132)
for some degree of university achievement, and 59.46 % (35,852) for university graduate
achievement.
With regards to the number of total children within the family unit, 29.87 %
(18,012) were single child families, 61.01% (36,786) were families with 2 to 3 children,
and 9.12 % (5,496) were families with 4 or more children. With regard to income to FPL
ratio status, 14.67 % (8,371) were below 100% of the FPL, 13.99 % (7,982) were
between 100 % to 199 % of the FPL, 13.50 % (7,706) were between 200 % to 299 % of
the FPL, and 57.84 % (33,005) were at or above 300 % of the FPL.
The provider facility type the child was administered the vaccine at was divided
such that 7.26 % (4,380) were at a public facility, 13.66 % (8,235) were at a hospital
facility, 62.08 % (37, 429) were at a private practice, 4.56 % (2,752) were at a military or
other type of facility, and 12.44 % (7,498) were at a hybrid or mixed facility.

5.3.1.b. NIS-Teen
The data sample for individuals ages 13 - 17 years consisted of 414,708 total
observations, with 19.52 % (80,956) at 13 years of age, 20.38 % (84,531) at 14 years of
age, 20.24 % (83,918) at 15 years of age, 20.58 % (85,359) at 16 years of age, and 19.28
% (79,944) at 17 years of age. Among the sample, 49.57 % (205,576) received the
influenza vaccine and possessed complete and adequate provider records. Among this
subsample, 21.35 % (43,895) were considered immunized against the influenza virus as
defined by ACIP regulations and protocols for vaccine dosage sequence and
administration. The frequency of observations based on ages (13 to 17 years) among this
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subsample was 23.95% (10,511), 22.21 % (9,750), 19.77 % (8,679), 18.60 % (8,163), and
15.47 % (6,792) respectively.
Among immunized children with adequate provider verified vaccine records,
48.23 % (21,171) were female and 51.77 % (22,724) were male. Among the same
sample, 15.01 % (6,587) were Hispanic, 65.53 % (28,765) were Caucasian, 8.53 %
(3,746) were African American, and 10.93 % (4,797) were of another ethnicity. With
regard to relocation and mobility, 22.42 % (9,840) had relocated from another state, and
77.58 % (34,055) had not.
With regard to marriage status of the mother and age, 75.20 %, (33,010) were
children of married mothers, and 24.80 % (10,885) were not, with 7.28 % (3,197) of
those mothers being at or under 34 years of age, and 39.26 % (17,233) being between 35
and 44 years of age inclusive, and 53.46 % (23,465) being at or above 45 years of age.
Mothers education level was divided at 10.14 % (4,449) for less than high school
achievement, 15.22 % (6,682) for high school graduate achievement, 24.18 % (10,616)
for some degree of university achievement, and 50.46 % (22,148) for university graduate
achievement.
With regards to the number of total children within the family unit, 35.29 %
(15,490) were single child families, 55.00 % (24,143) were families with 2 to 3 children,
and 9.71 % (4,262) were families with 4 or more children. With regard to income to FPL
ratio status, 15.61 % (6,459) were below 100% of the FPL, 15.12 % (6,254) were
between 100 % to 199 % of the FPL, 13.10 % (5,419) were between 200 % to 299 % of
the FPL, and 56.17 % (23,240) were at or above 300 % of the FPL.
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The provider facility type the child was administered the vaccine at was divided
such that 10.38 % (4,555) were at a public facility, 10.52 % (4,617) were at a hospital
facility, 48.17 % (21,143) were at a private practice, 8.11 % (3,561) were at a military or
other type of facility, and 22.82 % (10,019) were at a hybrid or mixed facility.

5.3.2. NIS-Child: Logistic Regression Analysis
5.3.2.a. Primary Analysis: Interrupted Time Series
The interrupted time series (ITS) regression targeting the LAIV preferential
recommendation revocation of 2015 yielded statistically significant coefficients for the
primary variables of interest. Execution of the delta-method margins procedure yielded
post-estimation average marginal effects (AMEs) for the primary variables of interest
associated with the policy shifts occurrence. The LAIV preferential recommendation
revocation yielded a 3.01 percentage point, 95% CI [2.54, 4.74], immediate level change
increase in the probability of a child being immunized, on average. It also yielded a 2.41
percentage point, 95% CI [-2.62, -2.11], sustained slope change decrease in the
probability of a child being immunized annually, on average. Prior to the policy shifts
occurrence, a 2.06 percentage point, 95% CI [1.91, 2.22], sustained increase in the
probability of a child being immunized annually, on average, was evident.
The LAIV preferential recommendation of 2014, and the subsequent LAIV
recommendation rescindment of 2016, yielded post-estimation AMEs that were
statistically significant. Occurrence of the 2014 policy shift yielded a 5.25 percentage
point, 95% CI [-7.05, -3.25], decrease in the probability of a child being immunized, on
average, followed by a 1.21 pp sustained slope increase. Occurrence of the 2016 policy
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shift yielded a 1.02 percentage point, 95% CI [0.55, 1.12], increase in the probability of a
child being immunized, on average, followed by a 5.30 pp sustained slope decrease.
Refer to table 5.1 for ITS regression results pertaining to chief variables of interest.
Table 5.1 – NIS Child LAIV Policy Shift ITS Regression: Variables of Interest

Policy Variables
Pre-LAIV 2014 Trend
LAIV 2014 Level
Post-LAIV 2014 Trend
LAIV 2015 Level
Post-LAIV 2015 Trend
LAIV 2016 Level
Post-LAIV 2016 Trend

AME
0.0206
-0.0525
0.0121
0.0301
-0.0241
0.0102
-0.0530

SE
0.0079
0.0056
0.0052
0.0052
0.0006
0.0052
0.0047

z
26.08
-14.73
23.49
7.47
-25.78
2.46
-11.30

P>z
0.0000
0.0000
0.0000
0.0000
0.0000
0.0140
0.0000

[95%
0.0191
-0.0705
0.0111
0.0254
-0.0262
0.0055
-0.0622

CI]
0.0222
-0.0325
0.0131
0.0474
-0.0211
0.0112
-0.0438

Examining the policy variables specifically with regards to their temporal aspects
pertaining to intercept and trend shifts yields statistically significant AME values
following execution of a segmented ITS regression for NIS-Child. The AME coefficients
for the pre and post policy trends as well as their respective level changes are
summarized above. The graphical depiction of the segmented ITS estimation is illustrated
in Figure 5.1. The pre and post policy shift trends are indicated by solid graph lines, and
the policy shift intercept changes are exhibited by dashed graph lines. The trend changes
are demonstrated by percentage point fluctuations annually with respect to the outcome,
and the level changes are demonstrated by immediate percentage point intercept shifts.
Execution of the segmented ITS estimation using the alternative flu vaccination
outcome (provider verified immunizations for the number of dosages completed) yielded
statistically significant AME coefficients that corroborated the up-to-date outcome
regressions. The magnitude and direction of the AMEs for all policy shift variables were
in agreement for both level and trend values (Table C.5).
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Figure 5.1 – NIS Child Policy Specific Piecewise ITS Regression Graph

5.3.2.b. Sociodemographic Characteristics and Disparities (ITS)
The following segment is examining baseline differences relative to
sociodemographic factors, with positive differences indicating greater likelihoods of
immunization, and negative differences indicating lesser likelihoods of immunization, on
average (Table 5.2). Comparing average marginal effects (AMEs) between age
subgroups with 19-23 months as the reference category, ages 24-29 months experienced a
3.40% point greater likelihood of immunization on average, 95% CI [2.92, 3.88], and
ages 30-35 months experienced a 6.60% point greater likelihood of immunization on
average, 95% CI [6.01, 7.18]. With regards to gender differences, the AME was
statistically insignificant and no discernable disparities existed.
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With regards to ethnicity and race category, with Hispanic as the reference
subgroup, Caucasians experienced a 1.38% point greater likelihood of immunization on
average, 95% CI [0.74, 2.03], African Americans experienced a 5.55% point lesser
likelihood of immunization on average, 95% CI [-6.44, -4.65], other non-Hispanic
ethnicities possessed statistically insignificant differences.
Individuals who were the first born experienced a 4.22% point greater likelihood
of immunization on average compared to non-first born individuals, 95% CI [3.60, 4.85].
Individuals who had relocated from another state experienced a 5.60% point, on average,
lesser likelihood of immunization, 95% CI [-6.31, -4.89].
Mothers marital status being married was associated with a greater likelihood of
immunization by 2.24% points, on average, 95% [1.63, 2.85], as did a mothers age being
30 years of age or greater, at 5.37% points on average, 95% CI [4.85, 5.89]. For mothers
education level, with uneducated being the reference category, university graduates
experienced a 5.21% point greater likelihood of immunization, 95% CI [4.25, 6.17], and
high school graduation and some degree of university achievement experienced
statistically insignificant differences.
For the number of children in the family unit, with one as the reference category,
families with two to three children experienced statistically insignificant differences, and
families with four or more experienced a 5.06 % point, on average, lesser likelihood of
immunization, 95% CI [-6.01, -4.10]. For income to FPL ratio category, with less than
100% as the reference category, 100% to 199% of the FPL experienced statistically
insignificant differences, 200% to 299% of the FPL experienced a 1.94% point on
average greater likelihood of immunization, 95% CI [1.11, 2.77] and 300% of the FPL or
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greater experienced a 6.75% point on average greater likelihood of immunization, 95%
CI [5.94, 7.55].
Table 5.2 – NIS Child LAIV Policy Shift ITS Regression: Covariates
Covariates
Age (Ref: 19-23 months)
24-29 months
30-35 months
Gender (Ref: Male)
Female
Ethnicity (Ref: Hispanic)
Non-Hispanic Caucasian
Non-Hispanic AA
Non-Hispanic Other
Birth Order (Ref: No)
First Born
Mobility (Ref: No)
Relocated
Marital Status (Ref: No)
Married
Mother's Age (Ref: < 30)
30 years or over
Mother's Educ (Ref: < HS)
High School
Some College
College Graduate
Num of Children (Ref: 1)
2-3 Children
4+ Children
Inc to FPL (Ref: < 100%)
100 to 199% FPL
200 to 299% FPL
300% FPL or greater
Facility Type (Ref: Public)
Hospital Facility
Private Practice
Military/Other
Hybrid/Mixed

AME

SE

z

P>z

[95% CI]

0.0340 0.0024 13.8700 0.0000 0.0292 0.0387
0.0660 0.0030 22.1600 0.0000 0.0601 0.0718
0.0001 0.0021

0.0600 0.9520 -0.0041 0.0043

0.0138 0.0033 4.2100 0.0000 0.0074 0.0203
-0.0555 0.0046 -12.1400 0.0000 -0.0644 -0.0465
0.0048 0.0042 1.1400 0.2550 -0.0035 0.0131
0.0422 0.0032 13.2800 0.0000 0.0360 0.0485
-0.0560 0.0036 -15.4500 0.0000 -0.0631 -0.0489
0.0224 0.0031

7.1500 0.0000 0.0163 0.0285

0.0537 0.0026 20.3400 0.0000 0.0485 0.0589
-0.0063 0.0046 -1.3600 0.1750 -0.0154 0.0028
0.0008 0.0046 0.1700 0.8620 -0.0082 0.0099
0.0521 0.0049 10.6300 0.0000 0.0425 0.0617
-0.0025 0.0035 -0.7100 0.4750 -0.0092 0.0043
-0.0506 0.0049 -10.3700 0.0000 -0.0601 -0.0410
-0.0006 0.0037 -0.1700 0.8660 -0.0079 0.0066
0.0194 0.0042 4.5800 0.0000 0.0111 0.0277
0.0675 0.0041 16.4600 0.0000 0.0594 0.0755
0.0488
0.0527
0.0159
0.0427

0.0047 10.3600 0.0000 0.0396 0.0581
0.0039 13.4900 0.0000 0.0450 0.0604
0.0056 2.8500 0.0040 0.0050 0.0268
0.0047 9.0300 0.0000 0.0334 0.0519

138

With regards to the provider facility type the vaccine was administered at, public
facilities were the reference category, with hospital facilities experiencing a 4.89% point
greater likelihood of immunization, on average, 95% CI [3.96, 5.81]. Private practices
experienced a 5.27% point greater likelihood of immunization, on average, 95% CI [4.51,
6.04]. Military and other facility types experienced a 1.59% point greater likelihood of
immunization, on average, 95% CI [0.50, 2.68]. Hybrid and mixed facilities experienced
a 4.27% point greater likelihood of immunization, on average, 95% CI [3.34, 5.19]. Refer
to table 5.2 for ITS regression results pertaining to control variables.
The heterogeneity for the sample was computed by subdividing the sample for
specific subgroups and executing logistic estimations for different subgroups separately.
This was achieved by applying commands to segregate the sample based on income to
FPL thresholds and ethnicity type (Table C.3). For ethnicity categories, with Hispanic as
the reference subgroup, Caucasian children were more likely to experience immunization
uptake, as were other ethnicities, and African Americans were less likely, on average.
This is consistent with expectations for ethnicity based variations, with African
Americans experiencing the least likelihood. For income to FPL ratio categories, with
less than 100% being the reference subgroup, as the income to FPL percent increased, the
likelihood of experiencing immunization for a child increased, on average, and is
consistent with expectation.

5.3.2.c. Sensitivity Analysis: Difference in Differences Estimation
Examination of child observations for the sample (289,712) yielded 71.24 %
(206,381) eligible to be administered the LAIV formulation, and 28.76 % (83,331)
ineligible to receive the LAIV formulation. Among the LAIV eligible individuals

139

(77,348), 46.24 % (35,769) were specified as immunized with adequate provider verified
vaccination records, and 53.76 % (41,579) were specified as not completely immunized,
and had adequate provider verified vaccination records.
Among the LAIV ineligible individuals (42,798), 65.48 % (14,775) were
specified as immunized with adequate provider verified vaccination records, and 34.52 %
(28,023) were specified as not completely immunized, and had adequate provider verified
vaccination records.
The difference in differences (DID) estimation targeting the effects of the LAIV
preferential recommendation revocation of 2015 for LAIV-eligible children (treatment)
versus LAIV-ineligible children (control) yielded statistically significant coefficients.
Execution of the delta-method margins procedure yielded post-estimation average
marginal effects (AMEs) for the DID primary variable of interest and associated LAIVeligibility indicator. Comparing the differences between LAIV-eligible and LAIVineligible individuals, pre and post 2015 LAIV preferential recommendation revocation,
yielded a difference in differences of 20.70 percentage points, 95% CI [19.52, 21.88].
This indicates that a 20.70 percentage point increase occurred in the probability of a
LAIV-eligible child being immunized as compared to an LAIV-ineligible child, on
average, following the 2015 policy shift. Examining the LAIV-eligibility indicator’s
AME, it is evident that an LAIV-eligible child experiences a 1.34 percentage point, 95%
CI [0.64, 2.03], increase in the probability of being immunized, on average, as compared
to an LAIV-ineligible child. Refer to table 5.3 for sensitivity analysis DID regression
results.

140

Table 5.3 – NIS Child LAIV Policy Shift: Difference in Differences Regression
Sensitivity Analysis
LAIV Eligible
Difference in Differences

AME
SE
z
P>z
[95% CI]
0.0134 0.0036
3.7600 0.0000 0.0064 0.0203
0.2070 0.0060 34.4300 0.0000 0.1952 0.2188

5.3.2.d. Sensitivity Analysis: Formulation Specific ITS Estimations
Auxiliary ITS estimations specifically aiming at assessing the influences of the
2015 policy point with respect to vaccine formulation type were executed. This was
performed by alternating the dependent variable measuring overall uptake, and instead
substituting the provider verified measures for immunization completion for each version
of the vaccine individually (IIV and LAIV). Following regression procedures, the
preliminary logit coefficients and post-estimation average marginal effect (AME)
coefficients were statistically significant (Table C.1). Examining the IIV formulation
singularly yielded a 4.43 pp sustained annual increase, on average, in the probability of a
child being immunized, pre-policy implementation. For the 2015 policy immediate level
change, a 4.17 pp increase, on average, was evident in the probability of the outcome,
followed by a 1.98 pp sustained annual decrease, on average, in the probability of the
outcome, post-policy implementation.
For the 2014 policy point, a 13.31 pp decrease, on average, in the probability of
the outcome was evident, and for the 2016 policy point, the AME was statistically
insignificant. The H1N1 pandemic yielded a 1.51 pp increase, on average, in the
probability of the outcome, with RSE 1 and RSE 2 yielding a 4.76 pp and a 8.45 pp
decrease, on average, in the probability of the outcome, respectively.
Examining the LAIV formulation singularly yielded a 2.02 pp sustained annual
increase, on average, in the probability of a child being immunized, pre-policy
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implementation. For the 2015 policy immediate level change, a 23.43 pp increase, on
average, was evident in the probability of the outcome, followed by a 1.42 pp sustained
annual decrease, on average, in the probability of the outcome, post-policy
implementation.
For the 2014 policy point, a 4.00 pp decrease, on average, in the probability of the
outcome was evident, and for the 2016 policy point, a 13.01 pp increase, on average, in
the probability of the outcome was evident. The H1N1 pandemic yielded a 2.09 pp
increase, on average, in the probability of the outcome, with RSE 1 and RSE 2 yielding a
1.89 pp and a 3.08 pp decrease, on average, in the probability of the outcome,
respectively.
Evaluating LAIV uptake with respect to segregated provider facility types, public
establishments experienced a 17.17 pp level increase, on average, in the probability of the
outcome, followed by a 4.20 pp sustained annual decrease, on average, after inception of
the 2015 policy shift. Private practices experienced a 24.06 pp level increase, on average,
in the probability of the outcome, followed by a 7.05 pp sustained annual decrease, on
average, after inception of the 2015 policy shift (Table C.1).

5.3.3. NIS-Teen: Logistic Regression Analysis
5.3.3.a. Primary Analysis: Interrupted Time Series
The interrupted time series (ITS) regression targeting the LAIV preferential
recommendation revocation of 2015 yielded statistically significant coefficients for the
primary variables of interest. Execution of the delta-method margins procedure yielded
post-estimation average marginal effects (AMEs) for the primary variables of interest
associated with the policy shifts occurrence. The LAIV preferential recommendation
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revocation yielded a 4.25 percentage point, 95% CI [2.31, 6.22], immediate level change
increase in the probability of a teen being immunized, on average. It also yielded a 3.02
percentage point, 95% CI [-4.77, -2.33], sustained slope change decrease in the
probability of a teen being immunized annually, on average. Prior to the policy shifts
occurrence, a 2.70 percentage point, 95% CI [2.12, 3.16], sustained increase in the
probability of a teen being immunized annually, on average, was evident.
The LAIV preferential recommendation of 2014, and the subsequent LAIV
recommendation rescindment of 2016, yielded post-estimation AMEs that were
statistically significant. Occurrence of the 2014 policy shift yielded a 8.41 percentage
point, 95% CI [-10.35, -6.41], decrease in the probability of a teen being immunized, on
average, followed by a sustained slope increase of 7.17 pp. Occurrence of the 2016 policy
shift yielded a 6.52 percentage point, 95% CI [-8.21, -4.42], decrease in the probability of
a teen being immunized, on average, followed by a sustained slope increase of 2.84 pp.
Refer to table 5.4 for ITS regression results pertaining to chief variables of interest.
Table 5.4 – NIS Teen LAIV Policy Shift ITS Regression: Variables of Interest

Policy Variables
Pre-LAIV 2014 Trend
LAIV 2014 Level
Post-LAIV 2014 Trend
LAIV 2015 Level
Post-LAIV 2015 Trend
LAIV 2016 Level
Post-LAIV 2016 Trend

AME
0.0270
-0.0841
0.0717
0.0425
-0.0302
-0.0652
0.0284

SE
0.0018
0.0084
0.0047
0.0047
0.0018
0.0122
0.0044

z
14.63
-11.96
15.21
5.62
-14.53
-7.06
6.38

P>z
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000

[95%
0.0212
-0.1035
0.0611
0.0231
-0.0477
-0.0821
0.0196

CI]
0.0316
-0.0641
0.0858
0.0622
-0.0233
-0.0442
0.0371

The graphical depiction of the segmented ITS estimation is illustrated in Figure 5.2, with
dashed lines signifying level or intercept shifts, and solid lines indicating trend or slope
shifts.
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Figure 5.2 – NIS Teen Policy Specific Piecewise ITS Regression Graph
Execution of the segmented ITS estimation using the alternative flu vaccination
outcome (provider verified immunizations for the number of dosages completed) yielded
statistically significant AME coefficients that corroborated the up-to-date outcome
regressions. The magnitude and direction of the AMEs for all policy shift variables were
in agreement for both level and trend values (Table C.5).

5.3.3.b. Sociodemographic Characteristics and Disparities (ITS)
The following is examining baseline differences relative to sociodemographic
factors (Table 5.5). Comparing average marginal effects (AMEs) between age subgroups
with 13 years of age as the reference category, 14 years of age experienced a 2.41% point
lesser likelihood of immunization on average, 95% CI [-3.23, -1.60], 15 years of age
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experienced a 4.32% point lesser likelihood of immunization on average, 95% CI [-5.14,
-3.50], 16 years of age experienced a 5.59% point lesser likelihood of immunization on
average, 95% CI [-6.41, -4.77], 17 years of age experienced a 7.15% point lesser
likelihood of immunization on average, 95% CI [-7.99, -6.32]. With regards to gender
differences, the AME was statistically insignificant and no discernable disparities existed.
With regards to ethnicity and race category, with Hispanic as the reference
subgroup, Caucasians experienced a 2.86% point greater likelihood of immunization on
average, 95% CI [1.99, 3.73], African Americans experienced a 2.53% point lesser
likelihood of immunization on average, 95% CI [-3.70, -1.36], other non-Hispanic
ethnicities possessed statistically insignificant differences.
For insurance type, private insurance was the reference category, individuals with
only Medicaid experienced a 2.52% point greater likelihood of immunization on
average, 95% CI [1.59, 3.45], uninsured individuals experienced a 7.92% lesser
likelihood of immunization on average, 95% CI [-10.63, -5.22], individuals covered by SChip or alternative plans possessed statistically insignificant differences. Individuals who
had relocated from another state experienced a 1.18% point, on average, lesser likelihood
of immunization, 95% CI [-1.78, -0.59].
Mothers marital status being married was associated with a greater likelihood of
immunization by 0.83% points, on average, 95% [0.18, 1.48]. For mothers age, with 34
years of age or younger being the reference category, mother between 35 to 44 years of
age experienced statistically insignificant differences, and mothers 45 years of age or
greater experienced a 3.15% point, on average, greater likelihood of immunization, 95%
CI [2.10, 4.21]. For mothers education level, with uneducated being the reference
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category, children of mothers who were university graduates experienced statistically
insignificant differences, children of mothers who were high school graduates
experienced a 2.22% point, on average, lesser likelihood of immunization, 95% CI [-3.32,
-1.12], children of mothers with some degree of university achievement experienced a
2.38% point, on average, lesser likelihood of immunization, 95% CI [-3.45, -1.31].
For the number of children in the family unit, with one as the reference category,
families with two to three children experienced a 2.72% point, on average, greater
likelihood of immunization, 95% CI [2.15, 3.29], and families with four or more
experienced a 2.03 % point, on average, greater likelihood of immunization, 95% CI
[1.04, 3.01]. For income to FPL ratio category, with less than 100% as the reference
category, 100% to 199% of the FPL experienced a 1.53% point, on average, lesser
likelihood of immunization, 95% CI [-2.47, -0.58], 200% to 299% of the FPL
experienced a 1.56% point, on average, lesser likelihood of immunization, 95% CI [-2.67,
-0.46], and 300% of the FPL or greater experienced a 2.69% point, on average, greater
likelihood of immunization, 95% CI [1.57, 3.80].
For provider facility type, public facilities were the reference category, with
hospital facilities experiencing a 6.60% point greater likelihood of immunization, on
average, 95% CI [5.53, 7.68]. Private practices experienced a 4.94% point greater
likelihood of immunization, on average, 95% CI [4.18, 5.70]. Military and other facility
types experienced a 4.84% point greater likelihood of immunization, on average, 95% CI
[3.73, 5.95]. Hybrid and mixed facilities experienced a 9.10% point greater likelihood of
immunization, on average, 95% CI [8.22, 9.98].
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Table 5.5 – NIS Teen LAIV Policy Shift ITS Regression: Covariates
Covariates
Age (Ref: 13)
14
15
16
17
Gender (Ref: Male)
Female
Ethnicity (Ref: Hispanic)
Non-Hispanic Caucasian
Non-Hispanic AA
Non-Hispanic Other
Mobility (Ref: No)
Relocated
Insurance (Ref: Private)
Medicaid Only
S-Chip or Other Plan
Uninsured
Mother's Age (Ref: <= 34)
35 to 44 years
>= 45 years
Marital Status (Ref: No)
Married
Mother's Educ (Ref: < HS)
High School
Some College
College Graduate
Inc to FPL (Ref: < 100%)
100 to 199% FPL
200 to 299% FPL
300% FPL or greater
Num of Children (Ref: 1)
2-3 Children
4+ Children
Facility Type (Ref: Public)
Hospital Facility
Private Practice
Military/Other
Hybrid/Mixed

AME
-0.0241
-0.0432
-0.0559
-0.0715

SE

z

P>z

[95% CI]

0.0042 -5.8000 0.0000 -0.0323
0.0042 -10.3400 0.0000 -0.0514
0.0042 -13.4100 0.0000 -0.0641
0.0042 -16.8800 0.0000 -0.0798

-0.0160
-0.0350
-0.0477
-0.0632

0.0045 0.0026

1.7500 0.0810 -0.0005 0.0095

0.0286 0.0044
-0.0253 0.0060
0.0077 0.0061

-6.4300 0.0000 0.0199 0.0373
-4.2500 0.0000 -0.0370 -0.0136
1.2700 0.2040 -0.0042 0.0197

-0.0118 0.0030

-3.9100 0.0000 -0.0178 -0.0059

0.0252 0.0047
0.0058 0.0050
-0.0792 0.0138

5.3100 0.0000 0.0159 0.0345
1.1700 0.2400 -0.0039 0.0155
-5.7500 0.0000 -0.1062 -0.0522

0.0088 0.0051
0.0315 0.0054

1.7400 0.0830 -0.0011 0.0187
5.8500 0.0000 0.0210 0.0421

0.0083 0.0033

2.4900 0.0130 0.0018 0.0148

-0.0222 0.0056
-0.0238 0.0055
0.0112 0.0058

-3.9500 0.0000 -0.0331 -0.0112
-4.3500 0.0000 -0.0345 -0.0131
1.9400 0.0530 -0.0001 0.0225

-0.0152 0.0048
-0.0156 0.0056
0.0269 0.0057

-3.1500 0.0020 -0.0247 -0.0058
-2.7800 0.0060 -0.0267 -0.0046
4.7200 0.0000 0.0157 0.0380

0.0272 0.0029
0.0203 0.0050

9.3800 0.0000 0.0215 0.0329
4.0300 0.0000 0.0104 0.0301

0.0660
0.0494
0.0484
0.0910

0.0055 12.0500 0.0000 0.0553 0.0768
0.0039 12.7900 0.0000 0.0418 0.0570
0.0057 8.5600 0.0000 0.0373 0.0595
0.0045 20.2600 0.0000 0.0822 0.0998
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The heterogeneity for the sample was computed by subdividing the sample for
specific subgroups and executing logistic estimations for different subgroups separately.
This was achieved by applying commands to segregate the sample based on income to
FPL thresholds and ethnicity type (Table C.4). For ethnicity categories, with Hispanic as
the reference subgroup, Caucasian children were more likely to experience immunization
uptake, as were other ethnicities, and African Americans were less likely, on average.
This is consistent with expectations for ethnicity based variations, with African
Americans experiencing the least likelihood. For income to FPL ratio categories, with
less than 100% being the reference subgroup, as the income to FPL percent increased, the
likelihood of experiencing immunization for a child increased, on average, and is
consistent with expectation.

5.3.3.c. Sensitivity Analysis: Formulation Specific ITS Estimations
Auxiliary ITS estimations specifically aiming at assessing the influences of the
2015 policy point with respect to vaccine formulation type were executed. This was
performed by alternating the dependent variable measuring overall uptake, and instead
substituting the provider verified measures for immunization completion for the LAIV
version of the vaccine separately. Following regression procedures, the preliminary logit
coefficients and post-estimation average marginal effect (AME) coefficients were
statistically significant (Table C.2).
Examining the LAIV formulation singularly yielded a 6.39 pp sustained annual
increase, on average, in the probability of a child being immunized, pre-policy
implementation. For the 2015 policy immediate level change, a 4.53 pp increase, on
average, was evident in the probability of the outcome, followed by a 3.04 pp sustained
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annual decrease, on average, in the probability of the outcome, post-policy
implementation.
For the 2014 policy point, a 10.67 pp decrease, on average, in the probability of
the outcome was evident, and for the 2016 policy point, a 7.75 pp decrease, on average,
in the probability of the outcome was evident. The H1N1 pandemic yielded a statistically
insignificant AME coefficient, while RSE 1 and RSE 2 yielding a 5.02 pp and a 8.55 pp
decrease, on average, in the probability of the outcome, respectively.
Evaluating LAIV uptake with respect to segregated provider facility types, public
establishments experienced a 2.98 pp level increase, on average, in the probability of the
outcome, followed by a 2.33 pp sustained annual decrease, on average, after inception of
the 2015 policy shift. Private practices experienced a 4.05 pp level increase, on average,
in the probability of the outcome, followed by a 3.03 pp sustained annual decrease, on
average, after inception of the 2015 policy shift (Table C.2).

5.4. Discussion
5.4.1. Recapitulation and Interpretation
Based on statistically significant AME coefficients computed following the ITS
regressions for the child and teen samples, it is evident that in both samples, that the 2015
preferential advisement rescindment was associated with an initial increase in the
probability of overall influenza immunization uptake by parents, and subsequently
followed by incremental annual decreases in the same immunization outcome. The AME
magnitudes for the level change increases for both samples were similar at 3.01
percentage points on average for children, and 4.25 percentage points on average for
teens. The AME magnitudes for the slope change decreases were also in agreement with
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2.41 percentage points on average for children, and 3.02 percentage points on average for
teens. Baseline trends pre-2014 policy point were in accordance as well with a 2.06
percentage point, and a 2.70 percentage point on average increase in the probability of
immunization uptake by parents on an annual basis.
With regard to the juxtaposed LAIV policy points, the AME magnitudes and
direction for the 2014 preferential advisement were in accordance with decreases of 5.25
percentage points and 8.41 percentage points for children and teens respectively. The
post-2014 trend changes were in agreement at 1.21 pp and 7.17 pp respectively. The
AME magnitudes and direction however were opposites with regards to the 2016 nonrecommendation of LAIV with a 1.02 percentage point increase on average for children,
and a 6.52 percentage point decrease for teens. The post-2016 trend changes were
different directionally at a 5.30 pp decrease for children, and a 2.84 pp increase for teens.
The trends and fluctuations exhibited in influenza immunization uptake by parents
following the policy points can be rationalized in various hypothetical and theoretical
ways. Theoretically, changes in a physician’s clinical practices, including alterations in
the information they discuss with parents, and their vaccine recommendations, could
influence changes in parental perceptions of the relative risks versus benefits of
immunizations, and their particular formulations.10,50 It is possible that vaccine
formulations are being recommended as options by providers and clinicians differently
following the occurrence of the ACIP policy decisions, due to clinicians and providers
altering suggestions for which formulation to pursue based on that years ACIP
advisement.10,50 This is due to providers being informed regarding recent adjustments to
immunization policies and protocols, hence providers adapt their recommendations
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appropriately, including what formulation options they present to the parent during
appointments or informational sessions.10,50 It is unlikely that parents are cognizant of
minor revisions to ACIP LAIV policies on an annual basis, and are likely uninformed
regarding such advisements or modifications of ACIP advisements, and instead are
dependent on clinician and provider recommendations. The providers dissemination of
vaccine related information is likely to be modified predicated on ACIP annual guidance
as well, hence this leads to differences in the providers vaccination practices following
each advisement, and the information they convey to parents.9,10,50
Preferential recommendation for LAIV over IIV in 2014 likely lead to the intranasal vaccine formulation being offered by providers as the optimal selection as
compared to the IIV formulation.26 The subsequent rescindment of the preferential
advisement in 2015 likely lead to reductions in prescription of LAIV as compared to IIV
by the child’s providers.10,26,50,101 The clinicians equally promoted both LAIV and IIV
formulations as recommended influenza vaccine versions, possibly stimulating greater
vaccination uptake in totality as a consequence.10,26,50,101 This possibly lead to the
increases in overall immunization uptake rates initially, since both formulations were
being favored as opposed to a single version.101 This rationalizes the initial increase in the
probability of immunization uptake exhibited by the immediate level change difference
following the 2015 policy shift, but cannot be ascertained.
It is possible that vacillating and fluctuating advisements by ACIP, and ultimately
clinician dissemination of vaccine information regarding recommendations, may have led
to decreased trust in health and medical authorities, inducing annual declines in influenza
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immunization uptake with the progression of time.9 This rationalizes the subsequent
incremental decreases in overall influenza immunization uptake rates annually.
With regards to LAIV eligibility, the baseline difference between LAIV eligible
and LAIV ineligible cohorts was minimal at 1.34 percentage points in favor of LAIV
eligible children experiencing a greater probability of immunization uptake on average.
Following the 2015 policy shift, the difference between LAIV eligible and ineligible
cohorts was more prominent as exemplified by a difference in differences AME
coefficient of 20.7 percentage points. Meaning that LAIV eligible individuals, as
compared to non-eligible individuals, experienced a substantially greater probability of
being immunized by their parents. This may be because the LAIV eligible individuals,
who are also IIV eligible, experienced greater adoption of influenza vaccines in general,
since both versions of the immunization were recommended to them by providers as
options, meaning both formulation channels (LAIV and IIV) were considered as
legitimate options by providers. This is demonstrated by the DID AME coefficient being
substantially greater in magnitude for LAIV eligible individuals following the 2015
policy point.
It is also possible that LAIV eligible children, being older, are more likely to
receive influenza vaccinations by predisposition, since a greater percentage of 24 month
and older children were up to date for their influenza immunizations, and parents might
be more likely to pursue immunizations for them, and be less sensitive about
uncertainties. This would also potentially explain the difference observed pre and post
between LAIV eligible and ineligible children, and the magnitude of the DID estimation
coefficient.
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Finally, it is possible that fluctuating recommendations and advisements by ACIP
on an annual basis diminished parental trust relative to immunization authorities.9 It is
possible that this also directed attention towards the influenza vaccine overall, hence
leading to more parents pursuing information regarding influenza immunizations from
providers and clinicians.9
Assessing the vaccine formulations singularly corroborated the primary analysis
results and rationalization of immunization uptake mechanisms. The IIV formulation
estimation validated the core estimation by exhibiting an increasing pre-policy trend,
followed by an immediate level change increase in the probability of the outcome for the
2015 policy point, followed by a sustained annual decrease, on average, during the postpolicy phase. The LAIV formulation estimations validated the principal regressions by
exemplifying a sustained increasing pre-policy trend, followed by an immediate level
change increase in the probability of the outcome for the 2015 policy point, followed by a
subsequent annual decrease, on average, during the post-policy phase. This trend
sequence was evident for both child and teen samples, with the pre and post 2015 policy
trends for both samples in agreement for magnitude and direction, as well as the intercept
increases. The level change increase for the child sample was prominent for the LAIV
specific estimation.
For the juxtaposed policy shifts of 2014 and 2016, the magnitude and
directionality of the LAIV specific estimations were in agreement with the primary
analysis regressions and corroborated the previous results. The formulation specific
estimations indicate that the preferential advisements for the LAIV induce declines in
uptake for both vaccine versions, particularly for IIV, and that subsequent rescindments
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of the preferential recommendations stimulate increases in uptake for both formulations,
specifically for IIV. This further corroborates the rationalizations and explanations for the
overall influenza vaccine uptake results.
The provider facility type specific estimations that were executed for both child
and teen samples exhibited immediate level change increases in the probability of the
outcome, on average, followed by sustained annual decreases in the post-policy phase.
This was evident for both child and teen samples and for both private and public facility
types. However, private practices exhibited a more prominent level increase in vaccine
uptake rates for both child and teen samples as compared to public facilities, with the
difference being most noticeable for children specifically.

5.4.2. Limitations
Limitations inherently associated with this study provide challenges in generating
definitive conclusions. The adjacent proximity of the consecutive LAIV advisements and
recommendations spanning from 2014 to 2016 produce complexities in delineating the
exact trend changes that exist pre and post policy implementation. Specifically for the
2014 post-policy phase, 2015 pre and post policy phases, and for the 2016 pre-policy
phase, the trend time periods intersect and are difficult to isolate for the ITS estimations.
This is a susceptibility of the ITS regression specification, and the ITS is vulnerable in
this respect. Implementing a segmented or piecewise ITS approach minimizes this
limitations effects and optimizes estimation results.
The study is limited by the absence of primary and secondary data measuring
perceptions of vaccine specific elements such as clinical safety, side effect risks,
effectiveness, disease infection prevention capabilities, and disease susceptibility and
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severity. The absence of psychologic data measuring aspects such as vaccine confidence
level, hesitancy, doubt, intent to vaccinate, concerns regarding infection by the virus, and
amplified anxiety and fears induced by the pandemics and epidemics are also a limitation.
Measurements for provider characteristics such as immunization availability and
accessibility, clinician and patient relationships, and clinician diffusion and dissemination
of vaccine information also limit this study. External factors such as societal norms and
beliefs are also difficult to integrate into this study due to lack of data measurements for
these aspects. The majority of these factors require qualitative study data that allow for in
depth analysis of these aspects.
Limitations pertaining to specific vaccine version supply and availability data
based on provider facility type and geographic region also reduce the ability to determine
if supply and access shortages existed for particular interview survey years. Limitations
pertaining to data source design aspects also generate complexities, such as interview
years not being subdivided into incremental time periods allowing for a greater number
of time points between consecutive annual time spans. This would permit for intra and
inter year trends to be examined with a greater degree of scrutiny.

5.5. Conclusion
The 2015 LAIV preferential recommendation revocation was associated with
statistically significant effects on parental decisions to uptake influenza immunizations
for their children (ages19-35 months) and adolescents (ages 13 to 17 years). The policy
shift was associated with an initial level change increase in the probability of influenza
immunization uptake, on average, for children and teens. Subsequently, annual declines
in vaccination uptake ensued, with slope change decreases in the probability of influenza
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immunization uptake, on average, for children and teens. Baseline trends prior to the
policy shift sequences exhibited a sustained annual increase, on average, in the
probability of immunization uptake by parents for children and teens.
LAIV eligibility was associated with a minimal baseline difference between
LAIV eligible and ineligible cohorts, with LAIV eligible children experiencing a 1.34
percentage point increase in the probability of immunization uptake, on average.
Following the 2015 policy shift, the difference between LAIV eligible and ineligible
cohorts was more prominent as exemplified by a difference in differences sensitivity
analysis that yielded a 20.7 percentage point increase, on average, in the probability of a
LAIV eligible child being immunized, as compared to a non-eligible child. This signifies
a substantially greater probability of an LAIV eligible child being immunized by their
parents following the policy shift as compared to their ineligible counterparts, who are
IIV eligible only. Spillover effects in the form of reductions in the probability of
immunization uptake for LAIV ineligible children is evident predicated on DID
estimation outcomes.
Provider and clinician recommendations for the LAIV and IIV versions of the
influenza immunization, based on ACIP advisements, including preferential
recommendations, may have stimulated reductions in overall immunization uptake rates
following the 2014 policy shift, which were counteracted by the 2015 policy shift
initially, when both formulations were equally recommended by providers due to the
elimination of the preferential statement. This possibly led to the increases in
immunization uptake rates that were exhibited initially. Subsequently erosion in vaccine
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uptake due to fluctuating annual LAIV advisements, and provider recommendations, may
have induced the declining slope change trend post 2015 policy shift.
Public health policies concerning influenza immunization for children and
adolescents should concentrate on refraining from issuing preferential advisements for
either vaccine version if possible. Immunization policies should focus on recommending
both formulations in order to maximize overall immunization uptake rates instead.
Consistent and stable annual advisements, and minimizing vacillation of
recommendations on an annual basis, may additionally increase parental trust in
immunization policies and provider suggestions, and promote increases in child influenza
vaccine uptake.
This study contributes to the existing literature by enhancing the understanding of
how vaccine uptake rates change following policy shifts. However it is limited in
determining why these changes occur, and due to what factors and mechanisms
specifically, which future studies should attempt to discern and ascertain.

157

CHAPTER 6
CONCLUSION
6.1. The 2009 H1N1 Pandemic
The 2009 H1N1 influenza pandemic was associated with statistically significant
effects on parental decisions to uptake influenza immunizations for their children
(ages19-35 months). The pandemic was associated with an initial level change increase in
the probability of influenza immunization uptake, on average, for children. Subsequently,
annual declines in vaccination uptake ensued, as exhibited by the decreasing trend post
pandemic. The baseline trend prior to the pandemic was a sustained annual increase, on
average, in the probability of immunization uptake by parents for children.
Restricted scale epidemic occurrences in 2012-2013, 2013-2014, and 2017-2018,
where the influenza season was constrained to epidemic scales, yielded decreases in the
probability of immunization uptake for children initially, followed by minimal increases
annually. Assessing the pandemic for children based on ILI intensity levels and disease
progression, while controlling for fixed effects for states and seasons, yielded minimal to
no effects on uptake behavior, with the exception of a single peak pandemic season
indicator.
Assessing the pandemic for teens based on ILI intensity levels and disease
progression, while controlling for fixed effects for states and seasons, yielded fluctuating
effects on uptake behavior for peak segments of pandemic magnitude seasons
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(intensity levels 8, 9, and 10). Further sensitivity analysis examining intra-season phases
in conjunction with seasonal disease severity yielded consistent increasing effects on
uptake behavior for late segments of pandemic magnitude seasons.
The 2009 H1N1 influenza pandemic is linked to preliminary escalations in the
probability of child immunization uptake likely due to immediate fears of disease
contraction, concerns of viral infection, and trauma connected to shock and awe impacts
of the pandemics occurrence. These factors likely are paramount in the initial postpandemic decision phase, and supersede anti-uptake drivers such as uncertainties
regarding potential clinical side-effects, possible ineffectiveness of vaccine formulations,
and associated erosions in vaccine confidence, and ensuing hesitancy, and doubt.
Heightened parental perceptions regarding the importance of the vaccine likely motivates
uptake initially, with the benefits of protection from infection from the influenza virus,
and prevention of disease contraction and mortality of chief importance.
Subsequently, initial pandemic linked concerns and fears about disease
contraction and ensuing morbidity subside, and decision factors linked to assessment of
influenza vaccine effectiveness, efficiency, and risk of clinical side-effects, become
integrated more prominently in the immunization uptake decision process, leading to
erosions in vaccine confidence and perceptions of effectiveness, and increasing hesitancy
and doubt regarding the vaccines advantages. Furthermore, it is speculated that
evaluation of the costs versus benefits of the influenza vaccine become less influenced by
initial pandemic trauma and distresses. This in conjunction with reduced concerns of viral
infection, and desensitization to the pandemics progression lead to gradual declines in
uptake behavior. Additionally, it is possible the degree of vaccine confidence declined
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with the progression of time as individuals who were immunized still contracted the virus
and became infected.
Restricted scale epidemics are consistently associated with declines in
immunization uptake behavior for children initially, followed by nominal increases
annually. It is likely that RSEs do not generate the degree of initial trauma and shock that
pandemics such as the H1N1 generate, hence assessments of vaccination merits are
considered in the absence of pandemic linked distresses and fears. This possibly permits
factors such as vaccine effectiveness, risk of clinical side-effects, and immunization
hazards to supersede, in terms of importance, vaccine protection benefits from viral
infection, and prevention of morbidity. This altered perception may produce the observed
post RSE declines in uptake behavior for children.
Immunization uptake behavior for children is likely not sensitive to ILI severity
and disease progression with respect to geography and time specifically, and may be
perceived as a grander scale occurrence disconnected from individual state and season
occurrences on a weekly basis. Immunization uptake behavior for teens is likely sensitive
to ILI severity and disease progression with respect to geography and time specifically,
with oscillating effects on uptake behavior exhibited for peak segments of pandemic
magnitude seasons, and consistent positive effects on uptake behavior exhibited for late
segments of pandemic magnitude seasons.
Public health immunization professionals and personnel should expect
preliminary increases in child immunization uptake behavior, followed by gradual
decreases in the same outcome for influenza pandemics such as H1N1. They should
anticipate decreases in child immunization uptake behavior following smaller scale
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influenza epidemics. For pandemic intensity ILI seasons, immunization uptake behavior
is not sensitive to weekly fluctuations in ILI severity for children, but sensitive for teens
during peak and late phases of the influenza season, with fluctuating uptake behavior
associated with peak season phases, and consistent increases in uptake behavior
associated with late season phases.
This study contributes to the existing literature by enhancing the understanding of
how vaccine uptake rates change following pandemic and epidemic events. However it is
limited in determining why these changes occur, and due to what factors and mechanisms
specifically, which future studies should attempt to discern and ascertain.

6.2. The 2015 LAIV Preferential Recommendation Revocation
The 2015 LAIV preferential recommendation revocation was associated with
statistically significant effects on parental decisions to uptake influenza immunizations
for their children (ages19-35 months) and adolescents (ages 13 to 17 years). The policy
shift was associated with an initial level change increase in the probability of influenza
immunization uptake, on average, for children and teens. Subsequently, annual declines
in vaccination uptake ensued, with slope change decreases in the probability of influenza
immunization uptake, on average, for children and teens. Baseline trends prior to the
policy shift sequences exhibited a sustained annual increase, on average, in the
probability of immunization uptake by parents for children and teens.
LAIV eligibility was associated with a minimal baseline difference between
LAIV eligible and ineligible cohorts, with LAIV eligible children experiencing a 1.34
percentage point increase in the probability of immunization uptake, on average.
Following the 2015 policy shift, the difference between LAIV eligible and ineligible
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cohorts was more prominent as exemplified by a difference in differences sensitivity
analysis that yielded a 20.7 percentage point increase, on average, in the probability of a
LAIV eligible child being immunized, as compared to a non-eligible child. This signifies
a substantially greater probability of an LAIV eligible child being immunized by their
parents following the policy shift as compared to their ineligible counterparts, who are
IIV eligible only. Spillover effects in the form of reductions in the probability of
immunization uptake for LAIV ineligible children is evident predicated on DID
estimation outcomes.
Provider and clinician recommendations for the LAIV and IIV versions of the
influenza immunization, based on ACIP advisements, including preferential
recommendations, may have stimulated reductions in overall immunization uptake rates
following the 2014 policy shift, which were counteracted by the 2015 policy shift
initially, when both formulations were equally recommended by providers due to the
elimination of the preferential statement. This possibly led to the increases in
immunization uptake rates that were exhibited initially. Subsequently erosion in vaccine
uptake due to fluctuating annual LAIV advisements, and provider recommendations, may
have induced the declining slope change trend post 2015 policy shift.
Public health policies concerning influenza immunization for children and
adolescents should concentrate on refraining from issuing preferential advisements for
either vaccine version if possible. Immunization policies should focus on recommending
both formulations in order to maximize overall immunization uptake rates instead.
Consistent and stable annual advisements, and minimizing vacillation of
recommendations on an annual basis, may additionally increase parental trust in
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immunization policies and provider suggestions, and promote increases in child influenza
vaccine uptake.
This study contributes to the existing literature by enhancing the understanding of
how vaccine uptake rates change following policy shifts. However it is limited in
determining why these changes occur, and due to what factors and mechanisms
specifically, which future studies should attempt to discern and ascertain.
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APPENDIX A
H1N1 PANDEMIC FEM ANALYSES
Table A.1 - NIS Child FEM Regressions
Experimental Variables Subgroup 1
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 2
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 3
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 4
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 5
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
* p < 0.05 ** p < 0.01 *** p < 0.001

activitylevel_5plus
-0.0345
-0.00731
totalweeks_5plus
-0.00245
-0.000519
early_totalweeks_5plus
-0.00184
-0.000389
late_totalweeks_5plus
0.00198
0.000419
peak_totalweeks_5plus
0.000664
0.000141
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activitylevel_6plus
-0.0143
-0.00304
totalweeks_6plus
-0.000756
-0.000160
early_totalweeks_6plus
-0.00145
-0.000308
late_totalweeks_6plus
0.00218
0.000461
peak_totalweeks_6plus
0.000718
0.000152

activitylevel_7plus
-0.0259
-0.00548
totalweeks_7plus
-0.000587
-0.000124
early_totalweeks_7plus
-0.00155
-0.000329
late_totalweeks_7plus
0.00260
0.000550
peak_totalweeks_7plus
0.00117
0.000248

Experimental Variables Subgroup 1
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 2
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 3
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 4
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 5
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
* p < 0.05 ** p < 0.01 *** p < 0.001

activitylevel_8plus
-0.0132
-0.00280
totalweeks_8plus
0.000289
0.0000612
early_totalweeks_8plus
-0.000557
-0.000118
late_totalweeks_8plus
0.00240
0.000509
peak_totalweeks_8plus
0.000372
0.0000789
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activitylevel_9plus
-0.0275
-0.00582
totalweeks_9plus
0.00201
0.000426
early_totalweeks_9plus
0.000855
0.000181
late_totalweeks_9plus
0.00174
0.000368
peak_totalweeks_9plus
-0.108***
-0.0229***

activitylevel_10plus
0.00464
0.000982
totalweeks_10plus
0.000466
0.0000986
early_totalweeks_10plus
0.000900
0.000191
late_totalweeks_10plus
0.00125
0.000265
peak_totalweeks_10plus
-0.000606
-0.000128

Table A.2 - NIS Teen FEM Regressions
Experimental Variables Subgroup 1
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 2
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 3
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 4
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 5
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
* p < 0.05 ** p < 0.01 *** p < 0.001

activitylevel_5plus
0.00564
0.000899
totalweeks_5plus
-0.00187
-0.000297
early_totalweeks_5plus
-0.00131
-0.000209
late_totalweeks_5plus
0.00223
0.000355
peak_totalweeks_5plus
-0.00367
-0.000584
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activitylevel_6plus
0.000518
0.0000826
totalweeks_6plus
-0.00151
-0.00024
early_totalweeks_6plus
-0.00209
-0.000333
late_totalweeks_6plus
0.00307
0.00049
peak_totalweeks_6plus
-0.00455
-0.000725

activitylevel_7plus
0.0218
0.00348
totalweeks_7plus
-0.000609
-0.000097
early_totalweeks_7plus
-0.00256
-0.000408
late_totalweeks_7plus
0.00401
0.000638
peak_totalweeks_7plus
-0.00575
-0.000916

Experimental Variables Subgroup 1
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 2
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 3
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 4
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
Experimental Variables Subgroup 5
ILI Intensity Level Logit Coefficient
ILI Intensity Level Marginal Effect
* p < 0.05 ** p < 0.01 *** p < 0.001

activitylevel_8plus
0.0341
0.00543
totalweeks_8plus
-0.00271
-0.000433
early_totalweeks_8plus
-0.00379
-0.000604
late_totalweeks_8plus
0.00356
0.000568
peak_totalweeks_8plus
-0.00845*
-0.00135*
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activitylevel_9plus
0.0196
0.00312
totalweeks_9plus
-0.00334
-0.000531
early_totalweeks_9plus
-0.00543
-0.000865
late_totalweeks_9plus
0.00392
0.000624
peak_totalweeks_9plus
0.0824*
0.0131*

activitylevel_10plus
-0.0195
-0.0031
totalweeks_10plus
-0.00549
-0.000874
early_totalweeks_10plus
-0.00800
-0.00127
late_totalweeks_10plus
0.00342
0.000546
peak_totalweeks_10plus
-0.0133**
-0.00212**

APPENDIX B
H1N1 PANDEMIC AUXILIARY ANALYSES
Table B.1 – NIS Child Alternative Outcome ITS Estimation
Pandemic Variables
Pre-H1N1 2009 Trend
H1N1 2009 Level
Post-H1N1 2009 Trend
RSE 1 2012 Level
Post-RSE 1 2012 Trend
RSE 2 2013 Level
Post-RSE 2 2013 Trend
RSE 3 2017 Level
Post-RSE 3 2017 Trend

AME
0.0464
0.1502
-0.0583
-0.0348
0.0196
-0.0474
0.0181
-0.0374
0.0207

P>z
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000

[95%
0.0255
0.1107
-0.0652
-0.0411
0.0105
-0.0701
0.0074
-0.0453
0.0102

CI]
0.0673
0.1921
-0.0502
-0.0289
0.0287
-0.0137
0.0273
-0.0297
0.0317
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Table B.2 – NIS Child Heterogeneity
Pandemic Variables
Pre-H1N1 2009 Trend
H1N1 2009 Level
Post-H1N1 2009 Trend
RSE 1 2012 Level
Post-RSE 1 2012 Trend
RSE 2 2013 Level
Post-RSE 2 2013 Trend
RSE 3 2017 Level
Post-RSE 3 2017 Trend

Hispanic
0.0275***
0.0103***
-0.0137**
0.0138***
-0.0139**
0.0140***
-0.0141**
0.0142***
-0.0143**

Caucasian
African American
0.0581***
0.0032***
0.0665***
-0.0635***
-0.0021***
-0.0397***
0.0571**
0.0012***
-0.0026***
-0.0455***
0.0671***
0.0152**
-0.0081**
-0.051**
0.0693***
0.0091**
-0.0031**
-0.0429***

Other
0.0294***
0.0334**
-0.0165***
0.0185***
-0.0219***
0.0311**
-0.0273**
0.0108***
-0.0201**

Pandemic Variables <100% FPL 100 to 199% FPL 200 to 299% FPL 300% FPL or greater
Pre-H1N1 2009 Trend
0.0379**
0.0463***
0.0477***
0.0714***
H1N1 2009 Level
0.0152***
0.0421***
0.0364**
0.1323***
Post-H1N1 2009 Trend -0.0252***
-0.0173***
-0.0403**
-0.0591***
RSE 1 2012 Level
0.0032***
0.0189***
0.0272***
0.0439**
Post-RSE 1 2012 Trend
-0.0292**
-0.0105***
-0.0128***
-0.0033***
RSE 2 2013 Level
0.0119***
0.0181***
0.0226**
0.0596**
Post-RSE 2 2013 Trend
-0.0381**
-0.0297***
-0.0306***
-0.0116***
RSE 3 2017 Level
0.0271***
0.0259***
0.0409***
0.0487***
Post-RSE 3 2017 Trend
-0.0481**
-0.0331***
-0.0292***
-0.0117***
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APPENDIX C
LAIV POLICY AUXILIARY ANALYSES
Table C.1 – NIS Child Vaccine Specific ITS Estimations
Policy Variables
LAIV
IIV
Overall
Public
Private
Pre-LAIV 2014 Trend 0.0202*** 0.0443*** 0.0206*** 0.0352*** 0.0178***
LAIV 2014 Level
-0.0401*** -0.1331*** -0.0525*** -0.0488*** -0.3471***
Post-LAIV 2014 Trend 0.0349*** 0.0251*** 0.0121*** 0.0259*** 0.0437***
LAIV 2015 Level
0.2343*** 0.0417*** 0.0301*** 0.1717*** 0.2406***
Post-LAIV 2015 Trend -0.0142*** -0.0198*** -0.0240*** -0.0421*** -0.0705***
LAIV 2016 Level
0.1301**
0.0502**
0.0101*
0.0197**
0.0262**
Post-LAIV 2016 Trend -0.0629*** -0.0307** -0.0530** -0.0733** -0.0622**
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Table C.2 – NIS Teen Vaccine Specific ITS Estimations
Policy Variables
LAIV
IIV
Overall
Public
Private
Pre-LAIV 2014 Trend 0.0639*** 0.0379*** 0.0269*** 0.0355*** 0.0194***
LAIV 2014 Level
-0.1067*** -0.0726*** -0.0841*** -0.0902*** -0.0758***
Post-LAIV 2014 Trend 0.0298*** 0.0391*** 0.0717*** 0.0478*** 0.0594***
LAIV 2015 Level
0.0453*** 0.0584*** 0.0425*** 0.0298*** 0.0405***
Post-LAIV 2015 Trend -0.0304*** -0.0229*** -0.0302*** -0.0233*** -0.0303***
LAIV 2016 Level
-0.0775** -0.0471*** -0.0652*** -0.0317*** -0.0253***
Post-LAIV 2016 Trend
0.0572**
0.0397** 0.0284*** 0.0152*** 0.0276***
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Table C.3 – NIS Child Heterogeneity
Policy Variables
Pre-LAIV 2014 Trend
LAIV 2014 Level
Post-LAIV 2014 Trend
LAIV 2015 Level
Post-LAIV 2015 Trend
LAIV 2016 Level
Post-LAIV 2016 Trend

Hispanic
0.0271***
-0.0112***
0.0241***
0.0151***
-0.0227***
0.0233***
-0.0228***

Caucasian
African American
0.0506***
0.0182***
-0.0025***
-0.0588***
0.0722***
0.0017***
0.0662***
-0.0017***
-0.0092***
-0.0581***
0.0509***
0.0106**
-0.0051***
-0.0422***

Other
0.0227***
-0.0179***
0.0154***
0.0393***
-0.0263**
0.0367***
-0.0197***

Policy Variables
<100% FPL 100 to 199% FPL 200 to 299% FPL 300% FPL or greater
Pre-LAIV 2014 Trend
0.0162**
0.0291***
0.0284***
0.0533***
LAIV 2014 Level
-0.0259***
-0.0305***
-0.0326***
-0.0186***
Post-LAIV 2014 Trend 0.0129***
0.0181***
0.0336***
0.0404***
LAIV 2015 Level
0.0101***
0.0270***
0.0644***
0.1238**
Post-LAIV 2015 Trend -0.0311***
-0.0378***
-0.0124***
-0.0102***
LAIV 2016 Level
0.0208***
0.0295***
0.0303**
0.0477***
Post-LAIV 2016 Trend -0.0135***
-0.0122***
-0.0274***
-0.0076***
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Table C.4 – NIS Teen Heterogeneity
Policy Variables
Pre-LAIV 2014 Trend
LAIV 2014 Level
Post-LAIV 2014 Trend
LAIV 2015 Level
Post-LAIV 2015 Trend
LAIV 2016 Level
Post-LAIV 2016 Trend

Hispanic
0.0307***
-0.0209***
0.0352***
0.0110***
-0.0184***
-0.0598***
0.0397***

Caucasian
African American
0.0482***
0.0104***
-0.0155***
-0.0322***
0.0606***
0.0177***
0.0305***
-0.0207***
-0.0071***
-0.0438***
-0.0177***
-0.0701***
0.0633***
0.0171***

Other
0.0372***
-0.0195***
0.0292***
0.0294***
-0.0299**
-0.0442***
0.0304***

Policy Variables
<100% FPL 100 to 199% FPL 200 to 299% FPL 300% FPL or greater
Pre-LAIV 2014 Trend
0.0211**
0.0257***
0.0293***
0.0461***
LAIV 2014 Level
-0.0137***
-0.0121***
-0.0208***
-0.0106***
Post-LAIV 2014 Trend 0.0407***
0.0493***
0.0583***
0.0596***
LAIV 2015 Level
0.0030***
0.0286***
0.0304***
0.0342***
Post-LAIV 2015 Trend -0.0479***
-0.0408***
-0.0238***
-0.0251***
LAIV 2016 Level
-0.0255***
-0.0261***
-0.0136***
-0.0109***
Post-LAIV 2016 Trend 0.0431***
0.0409***
0.0512***
0.0593***
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Table C.5 - NIS Child and Teen Alternative Outcome ITS Estimations

Policy Variables
Pre-LAIV 2014 Trend
LAIV 2014 Level
Post-LAIV 2014 Trend
LAIV 2015 Level
Post-LAIV 2015 Trend
LAIV 2016 Level
Post-LAIV 2016 Trend

Child
AME
0.0593
-0.0366
0.0337
0.0482
-0.0478
0.0273
-0.0104

P>z
0.0000
0.0000
0.0000
0.0000
0.0000
0.0203
0.0000

Teen
AME
0.0717
-0.0649
0.0558
0.0593
-0.0422
-0.0508
0.0381

P>z
0.0000
0.0000
0.0000
0.0000
0.0000
0.0001
0.0000
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Table C.6 - Difference in Differences (DID) Estimation Schematic
Treatment Versus
Control Subgroup
Designation

Pre ACIP LAIV
Revocations

Post ACIP LAIV
Revocations

LAIV Eligible
(Treatment)
LAIV Non-Eligible
(Control)
Intra Time-Period
Difference
(Treatment Versus
Control Comparison)

CIVUT0

CIVUT1

Inter Time-Period
Difference
(Pre Versus Post
Policy Comparison)
CIVUT1 - CIVUT0

CIVUC0

CIVUC1

CIVUC1 - CIVUC0

CIVUT0 - CIVUC0

CIVUT1 - CIVUC1

DID =
(CIVUT1 - CIVUT0) (CIVUC1 - CIVUC0)
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